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The widespread occurrence of drug resistant trypanosomes has constituted a
major hindrance to the control of animal trypanosomosis. The study described
here was an investigation into the mechanisms of acquisition of drug resistance
by Trypanosoma evansi. The main aim was to determine the biochemical basis
for the development of resistance to the melaminophenyl arsenical drugs, mel Cy
and mel B. Experiments were designed to compare the mode of development of
resistance in vitro with in v/'vo-derived resistance and to determine the effect of
host immunity on resistance development. Resistance to mel Cy was induced in
a sensitive stock of T. evansi by infection and treatment with sub-curative levels
of drug, in immunosuppressed and immunocompetent mice. Induction was also
carried out in vitro by cultivation of the culture-adapted T. evansi isolate in the
continuous presence of increasing subinhibitory concentrations of mel Cy.
Resistance was measured using in vivo drug sensitivity tests and, in vitro growth
inhibition assays.
High levels (up to 300-fold) of resistance were attained within 6 months of
induction in immunosuppressed mice and in vitro. It was not possible to
produce resistance in immunocompetent mice, even after 24 months. In vivo
drug resistant trypanosomes maintained their infectivity but virulence was
reduced. Resistance induced by mel Cy was characterised with respect to
stability of resistance and cross resistance to other trypanocides. The resistance
developed from either immunosuppressed mice or in vitro continued to be
expressed in immunocompetent mice treated with the trypanocidal drug. After
withdrawal of drug in vz'/ro-induced resistance remained stable whereas in vivo-
derived resistance was reduced by over 50%. Mel Cy-induced resistance
conferred cross resistance to other trypanocidal drugs, namely, mel B,
Berenil®and, to a limited extent, quinapyramine, but not suramin. Sub-
populations of trypanosomes tolerant to the selection dose (20 r|g/ml) of mel Cy
were not found in the unselected parent clone. Increased sensitivity to
Summary
quinapyramine and suramin was observed after adaptation of the drug sensitive
isolate to in vitro culture.
Uptake of melaminophenyl arsenicals into T. evansi was investigated using an in
vitro lysis assay. Mel Cy and mel B caused lysis of drug sensitive and drug
resistant trypanosomes in a dose-dependent and saturable manner. Mel B was
less effective in lysis of drug sensitive trypanosomes but very potent in lysis of
drug resistant parasites. The in vitro lysis assay differentiated between drug
sensitive and drug resistant trypanosomes. Mel Cy lysis was blocked by
adenosine, adenine and Berenil®, but not inosine. Mel B lysis was inhibited by
• (R)
Berenil but not adenosine, adenine or inosine. These results indicate that mel
Cy competes for an adenine/adenosine transporter whereas mel B does not.
Uptake of adenosine into drug sensitive and drug resistant trypanosomes was
investigated using competitive inhibition experiments. Adenine, inosine and
Berenil® all inhibited adenosine uptake in a concentration-dependent and
saturable manner. Percentage inhibitions in the drug sensitive parasites were
53.6, 23.2, and 33.2, respectively, for adenine, inosine and Berenil®.
Combinations of adenine and inosine resulted in total inhibition of uptake of
adenosine. These findings suggest that T. evansi possesses a bipartite P1/P2
adenosine transport system. Mel Cy was taken up by the P2 transporter. The P2
transporter was maintained in arsenical resistant T. evansi. However, uptake on
the P2 was reduced 3-10 times in different resistant lines. Reduction in uptake at
the P2 transporter resulted in reductions in total adenosine uptake by the resistant
parasites. Moderate reductions in PI were also observed. Berenil also
interacted with the P2 transporter in drug sensitive trypanosomes. Interaction of
Berenil® with the P2 transporter was greatly reduced in the resistant population.
Thus, the cross resistance that develops between melaminophenyl arsenicals and
diamidines is a result of their common mechanisms of uptake.
Kinetic studies on the PI and P2 adenosine transporters were carried out on both
the drug sensitive and the drug resistant T. evansi. Uptake rates including Amax
(maximum transport capacity), Rate constant (T), and initial rates of uptake,
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were determined. In the drug sensitive trypanosomes the P2 transporter was a
larger transport process. Amax for P2 was 2 times greater than Amax for PI
transporter. Rate constant and initial rates for PI and P2 were similar. The Amax
at the P2 was decreased 3.4 times in drug resistant trypanosomes. The Rate
constant at both the PI and P2 were increased. Initial rate at the P2 was
decreased 2-fold. Reduced Amax accounted for the reduced uptake at the P2
transporter. Michaelis-Menten kinetic parameters were also determined for the
PI and P2 transporters. In drug sensitive trypanosomes the Umax at the P2 (28.9
pmol/108cells/5min.) was 2-fold greater than the Umax (12.4 pmol/108cells/5min)
at the PI. The Km for the PI (0.07 pM) was 10-fold lower than the Km for P2
(0.74 pM). The Umax (3.3 pmol/108cells/5min.) for the P2 in drug resistant
trypanosomes was reduced 9-fold. The Km ( 0.1 pM) was decreased 7-fold.
Kinetic changes for total adenosine uptake in trypanosomes were also
determined. It was found that reduction in uptake capacity of P2 in arsenical
resistant T. evansi was not due to decreased affinity. Rather a decrease in
numbers of transporter molecules was responsible for the decrease in adenosine
uptake at the P2. The changes in kinetic parameters of adenosine transport
suggested that the P2 in drug resistant trypanosomes had greatly undergone
mutation (P2R), as such it interacted with Berenil® in a different way.
The kinetics of inhibition of adenosine uptake showed that inosine, adenine and
Berenil inhibited uptake on either the PI or P2 transporters with very low K;
values. In the drug sensitive trypanosomes K, for inosine or adenine alone were
0.002 pM or 0.28 pM, respectively. K, for Berenil® alone was 0.00 pM
indicating that there was little or no interaction. On the PI the K, for inosine was
(ft)
0.03 pM. There was no interaction with Berenil on the PI. The K, for adenine
and Berenil® on the P2 were 0.3 and 0.01 pM, respectively. In the drug resistant
line the Kj for inosine on PI (0.06 pM) was similar to that of the drug sensitive
line. However there was a 7-fold increase (1.94 pM) in K, for adenine on the P2.
Based on changes in all the kinetic parameters of what should be the P2 it was
concluded that a new transporter (P3) was present in the arsenical resistant
Summary
trypanosomes. This transporter may have been selected for during induction of
resistance to mel Cy, or may be an adaptation by the resistant trypanosomes
following gross reductions in activity of the P2 transporter.
Molecular studies involving isolation and characterisation of the P2 and P3
transporters may fully elucidate the specific mutations responsible for arsenical
resistance in trypanosomes. It will also be interesting to study the interaction of
the P3 transporter with other alternative substrates, including toxic adenosine
analogues. This may provide useful information for improved chemotherapy of
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Trypanosomes are flagellated protozoan parasites belonging to the Order
Kinetoplastida, Family Trypanosomatidae and Genus Trypanosoma. The parasites
are found in the peripheral blood of domestic and wild animals throughout the
World. Some species also infect man. Most members of the family
Trypanosomatidae are not pathogenic for their host. However a minority of
trypanosome species are responsible for causing diseases in animals and man in
tropical and sub-tropical areas of the world.
The genus Trypanosoma is subdivided into two main sections (the Stercoraria and
Salivaria) on the basis of their site of development in the insect vector which
transmits them. The stercorarian trypanosomes undergo cyclical development in the
hind gut of biting insects following ingestion of an infected blood meal. Infection is
transmitted to new hosts by infective metacyclic trypanosomes, via faecal
contamination. This section contains one important species, Trypanosoma cruzi. T.
cruzi causes Chagas disease in man and is transmitted by reduviid triatomine bugs.
Chagas disease has been rated as the most serious parasitic disease in South and
Central America. An estimated 16-18 million people are affected with around 100
million at risk of infection (Guhl and Schofield, 1996; Docampo and Schmunis,
1997). Young people are particularly likely to die in the acute febrile stage. Adults
tend to survive to the chronic phase in which the parasite causes damage to the heart
muscles and autonomous nervous tissue. Congestive heart failure and dilatation of
the oesophagus and colon are common features. There is yet no cure for Chagas'
disease. However, presently, the disease is on the decline as a result of vector control
(Guhl and Schofield, 1996; Schofield and Dujardin, 1997).
Trypanosomes belonging to the section Salivaria develop in the anterior station as
well as the gut of Glossina species (tsetse fly) and are transmitted from host to host
by infective bite. Several species of trypanosomes that cause important diseases in
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animals and man belong to this section. T. brucei, T. congolense and T. vivax
primarily infect cattle, sheep, goats and other domestic animals. They cause a disease
condition commonly called nagana in affected animals. These three species
constitute a major constraint to the development of the cattle industry in the sub-
Saharan Africa. Other minor species include T. simiae and T. suis which cause
infections in pigs. Two members of this section also cause diseases in humans: T.
gambiense is distributed in West and Central Africa and causes the Western African
sleeping sickness. T. rhodesiense in East and Southern Africa is the cause of Eastern
African sleeping sickness.
Some salivarian trypanosomes are capable of mechanical (non-developmental)
transmission, on the mouth parts of other biting Diptera. Important in this category is
T. evansi which causes a disease known as surra in affected animals, and T.
equiperdum the causative agent of dourine, a venereal infection in equines; and T.
vivax in South America.
T. evansi is a monomorphic (i.e. consisting of only one developmental stage)
trypanosome species morphologically similar to the long slender trypomastigote form
of the pleomorphic T. brucei species. Unlike other members of this genus T. evansi
is mechanically transmitted by Tabanidae and to a lesser extent other blood-sucking
insects. In view of its mechanical transmission T. evansi has the widest geographical
distribution among all the pathogenic trypanosome species. Its distribution is world¬
wide affecting domesticated livestock in many countries of Africa, Central and
Southern Asia as well as Central and South America.
Trypanosomosis caused by T. evansi is a problem of great economic importance in
affected areas. Important working animals such as camels, horses, buffaloes and
cattle are affected. Outbreaks of disease occur sporadically resulting in high levels of
morbidity and mortality in endemic areas. The productivity of farm animals such as
Friesian Holstein cattle, especially the bull calves, can be adversely affected by T.
evansi (Payne et al., 1994a).
The use of antitrypanosomal drugs has been the mainstay for controlling animal
trypanosomosis. Other control measures aimed at vector eradication such as use of
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insecticides or biological methods have been successful only to a limited extent.
Furthermore, antigenic variation by trypanosomes has constituted a major barrier to
the development of vaccines for the control of trypanosomosis (Overath et al, 1994).
Antigenic variation is the process by which a trypanosome changes its surface
glycoprotein coat thereby presenting the host with varying antigen types (Borst and
Rudenko, 1994; Barry, 1997). At infection the trypanosome presents a particular
antigen to the host against which antibodies are produced. However, by the time the
antibodies are produced a smaller number of trypanosomes have replaced their
surface coat with one comprising different VSGs (variant surface glycoprotein), and
thus are not recognised by these antibodies. A majority of the parasites are destroyed
resulting in rapid fall in parasitaemia. However, the few that escaped the antibodies
proliferate, presenting a different antigen type to the host. The host again produces
antibodies specific to this new type of antigen. This process continues, but the
parasite is at least one step ahead of the host each time. Because of the high numbers
of variable antigen types in each trypanosome species (Barry and Turner, 1991) it has
been impossible to develop a suitable vaccine that could protect animals against any
of the forms of trypanosomosis.
Despite the fact that chemotherapy is the major means of controlling trypanosomosis
few drugs are available for this purpose. Treatment and prophylaxis of
trypanosomosis in cattle, sheep and goats is currently dependent upon the use of three
drugs, namely, homidium, a phenanthridine compound, isometamidium, a
phenanthridine-aromatic amidine, and diminazene, an aromatic diamidine
(Williamson, 1970). Three other compounds are generally used for therapeutic or
prophylactic purposes in camels, equidae and buffaloes. These are suramin, a
sulphonated naphthylamine; quinapyramine, a quinoline pyrimidine (Williamson,
1970) and melarsomine (mel Cy), a melaminyl thioarsonite (Raynaud et al., 1989a).
Some of these compounds have been used for prolonged period of time. Suramin for
example, have been in use for over 70 years and, presently commercial production of
this drug has been stopped.
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There is urgent need for new compounds for the treatment of trypanosomosis.
However, development of new antitrypanosomal drugs has been static over the last
few decades. This lack of interest has been largely because animal trypanosomosis
occurs in developing countries most of which have poor, unsustainable market
economies. The resultant small and uncertain market for trypanocidal drugs
discourages the significant involvement of the pharmaceutical industry (Gutteridge,
1985). The present emphasis is on effective utilisation of the few existing drugs in
order to prolong their useful life. Towards achieving this goal a clear understanding
of aspects of drug disposition, mechanisms of action, toxicity and resistance is
essential.
Drug resistance was first recognised by Paul Ehrlich with the arsenicals he used to
treat trypanosome infections. Drug resistant organisms have been described as stable
genotypic variants, selected from a normally sensitive population by drug exposure,
that have the ability to survive and multiply in the presence of normally effective
drug concentrations (Geary et ai, 1986). Today, reports abound of the occurrence of
strains of trypanosomes resistant to different trypanocides in different parts of the
world. For example, ethidium-resistant T. congolense was reported in Nigeria
(Ilemobade et al., 1975) and Ethiopia (Scott and Pegram, 1974); isometamidium
resistant T. congolense is common in Central and West Africa (Pinder and Authie,
1984; Chitambo and Arakawa, 1992); diminazene aceturate resistant T. congolense in
Zambia (Chitambo and Arakawa, 1992), Tanzania (Mbwambo et al., 1988), and
Zimbabwe (Joshua et al., 1995); diminazene aceturate resistant T. evansi in China
(Zhang et al., 1990) and T. vivax in French Guyana (Desquesnes et al., 1995); and
suramin-resistant T. evansi in Indonesia (Payne et al., 1994a) and Sudan (Abebe et
al., 1983). Drug-resistant strains of trypanosomes that affect humans have also been
reported. Pentamidine-resistant T. gambiense has been reported in Zaire, and T.
rhodesiense resistant to melarsoprol has been reported in Uganda (Bacchi, 1993).
Also T. rhodesiense naturally resistant to difluoromethylornithine (DFMO) has been
reported from East Africa (Iten et al., 1995).
The problem of drug resistance in animal trypanosomosis has been exacerbated by
the frequent misuse of veterinary trypanocides such as irregular administration of
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drugs, including prophylactic drugs. This gives rise to the existence of low
subcurative concentrations of trypanocides which are suitable for selection of drug
resistant mutants. Furthermore, it has been found that strains of trypanosomes that
are made resistant to one trypanocidal drug are often cross-resistant to one or more
other trypanocides.
A detailed understanding of the mechanisms by which parasites develop resistance is
an important starting point towards optimisation of the few available trypanocides.
The development of drug resistance is thought to be multifactorial. As such
intormation on the pharmacology of the drug, its mode of action and its biochemical
pathways within the organism is required. Some of these vital information are
presently lacking for most of the few available veterinary trypanocides as well as the
different parasites they affect. The control of T. evansi is particularly at risk because
commercial production of suramin has ceased. It is anticipated that this situation
would lead to overdependence on the very few alternative drugs such as
quinapyramine and mel Cy.
Mel Cy is an injectable, trivalent arsenical compound that has been developed in the
last decade for treatment of infections with trypanosomes belonging to the brucei
group (Raynaud et al., 1989a). This drug has been shown to be very effective against
T. evansi infections in camels, buffaloes, goats and pigs, and in vitro. It is reported to
be effective against stocks of T. evansi resistant to quinapyramine and suramin, and
T. brucei stocks resistant to diminazene aceturate (Zweygarth and Kaminsky, 1990).
Mel Cy has been found useful as part of combination chemotherapies in mouse
models of secondary human trypanosomosis (Jennings, 1993). So far there has been
no reports of occurrence of field strains of trypanosomes resistant to mel Cy.
This study was essentially an investigation on the mechanisms of acquisition of
resistance to arsenical drugs by T. evansi, using mel Cy. The T. evansi used was a
field isolate from Indonesia. This was cloned and adapted to laboratory growth in
mice at the Centre for Tropical Veterinary Medicine (CTVM). The overall aim was
to elucidate the various adaptations which make it possible for drug-resistant
trypanosomes to evade the actions of drugs to which drug-sensitive organisms
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succumb. This may highlight possible ways by which such pathways can be by¬
passed, thereby circumventing resistance. Alternative pathways found may also be
explored in the chemotherapy of drug-resistant trypanosomes.
The experimental design was to compare the development of resistance using in vitro
systems to that in animal models. The ultimate goal was to determine if in vitro
systems would be useful substitutes for animals in the study of drug resistance.
The specific areas of investigations included the following:
1. Induction of resistance to mel Cy in T. evansi using different laboratory methods
in order to determine the range of sensitivities expressed by populations derived
from the parent clone.
2. Characterisation of the resistance induced by mel Cy in terms of the behaviour of
resistant parasites in the host, stability of resistance, and cross-resistance to other
trypanocides.
3. Experiments to ascertain whether mel Cy and mel B would cause lysis of T.
evansi similar to that observed with other arsenical drugs in related trypanosome
species.
4. Determine to what extent this in vitro lysis can be used to differentiate between
drug sensitive and drug resistant trypanosomes.
5. Identification of compounds which inhibit lysis of T. evansi by mel Cy and mel B
with a view to determining the mode of uptake of these arsenicals drugs.
6. Determination of the mechanisms of resistance in mel Cy through a detailed
study of the purine transport pathways of the drug-resistant clones in comparison
with the drug-sensitive isolate.
7. Investigation of the influence of the host environment on the mechanisms of
resistance development.
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It is believed that the first observations on trypanosomes were made by Valentin in
1841 who described findings in the blood of trout (Salmo fario) of motile elongated
organisms which he likened to Amoeba. However, the true nature of these
haemoflagellates was recognised by Gruby in 1843 who created the generic name
Trypanosoma (Hoare, 1972). Trypanosoma evansi was the first trypanosome to be
described and identified as the causative agent of mammalian trypanosomosis.
Earliest reports on the trypanosome were published by Evans (1880, 1881- 1882)
who associated the parasite with an endemic disease in equines and camels, known as
"surra" in the Dera Ismail Khan in Punjab in India. Steel (1885) made similar
observations during an outbreak of a disease in transport mules in Burma and he
named the parasite Spirochete evansi. Its true nature was recognised by Crookshank
(1886), and Steel's name was amended to Trypanosoma evansi by Balbiani (1888)
(Hoare, 1970). Trypanosomosis due to T. evansi (= T. ninaekolyakimovi, Hoare,
1972) was also later described by Yakinoff, 1921-1923, in Russian camels in
Turkestan. In his report Yakinoff stated that trypanosomosis in Russian camels was
first detected by Feinschmidt in 1912 in Astrakhan and Saratov (reviewed in
Mahmoud and Gray 1980 ). Rogers (1901) proved experimentally that surra in India
was transmitted mechanically by tabanid flies (Hoare 1972).
Following these early reports more discoveries were made of diseases caused by
trypanosomes indistinguishable from T. evansi in different mammalian hosts in
different parts of the world. Thirty three different names have been associated with
these trypanosomes but T. evansi is accepted as the valid name for the parasite of
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surra. The name, T. evansi now applies to the trypanosomes causing "murrina" (I
hippicum), "Mai de Caderas" (T. equinum) , "Derrengadera" (T. venezuelensis) in
Central and South America and "Su-auru" (T. ninaekolyakimovi) in Russia (Hoare,
1972; Mahmoud and Gray, 1980).
2.1.2. Geographical distribution
T. evansi is widely distributed in countries with hot and warm-temperate climates.
Details of its geographical distribution is given by Hoare (1970, 1972). In North
Africa T. evansi occurs along the Atlantic and Mediterranean regions. It is prevalent
in Morocco, Algeria, Tunisia, Libya and Egypt. In the West it extends across the
Sahara into Senegal, Mali, Chad and other parts of West Africa, north of the tsetse
belt varying between latitudes 13°N in Nigeria to 15-16° N elsewhere. In the East
the disease spreads southwards to about 13° N in Sudan and almost up to the equator
in northern Kenya and Somalia.
In the Eurasian continent distribution of T. evansi is uneven and patchy. In the Near
and Middle East surra has been reported from Israel, Lebanon and Syria, the northern
half of the Arabian Peninsula, Asia Minor, Iraq and Iran. In Europe Turkey and
Bulgaria are affected, but the trans Volga region of the Soviet Union is mostly
affected. The prevalence extends to the Soviet Middle East, Iran, India, Burma,
Malaysia, Indo-China and parts of southern China. The parasite also occurs in
islands of the Indian Ocean (Mauritius, Reunion), Indonesia and Philippines.
In the new world T. evansi (Murrina, syn: T. hippicum) is found in Mexico, all of
Central America, Venezuela and Colombia while Mai de Caderas (syn: T. equinum)
is present in a greater part of South America, especially Brazil with Derrengadera
(syn: T. venezuelensis) occupying an intermediate position (Hoare, 1972; Lun and
Desser, 1995).
2.1.3. Host range
T. evansi occurs in a number of domestic and wild animals. Its principal hosts are
camels, equines and dogs, but it is common in bovines and it has been found in the
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Indian elephant (Hoare, 1972). Although T. evansi is pathogenic to all domestic
animals its effect upon the host depends upon both the virulence of the strain of
parasite and the susceptibility of the host (Hoare, 1956, 1970). Camels are highly
susceptible to infection and the disease in this species usually runs an acute or
chronic course, terminating fatally in untreated cases. Horses are similarly affected
in North Africa whereas in Sudan and Somalia they are refractory to infection. The
disease in cattle and pigs is mild and often asymptomatic while in dogs the course of
infection is acute (Hoare, 1970).
T. evansi epidemics often involve different animal hosts in different parts of the
world. In Indochina horses are mainly affected, followed by bovines and buffaloes,
whereas in the Soviet Middle Asia the main hosts are camels, and to a lesser extent
horses. In Africa camels are mostly affected while in Central and south America
horses are the main hosts followed by cattle (Mahmoud and Gray, 1980). Natural
infections have also been reported in mules and donkeys (Mahmoud and Gray, 1980).
Evidence from experimental infections confirm that donkeys, cattle sheep and goats
undergo protracted course of disease that results in a "carrier state" and may act as
reservoir hosts (Ilemobade, 1971; Mahmoud and Gray, 1980).
Healthy Capybaras (Hydrochoerus hydrochaeris) have been shown to harbour T.
evansi and can constitute a reservoir of infection for horses and dogs in Colombia
(Morales et al., 1976). Similarly, Ocelot (Felis pardalis) in the lower Amazon
Region and Orangutan (Pongo pygmaeus) in Sumatra. Experimental infections have
been established in monkeys (Family Cercopithecidae) with sub-clinical symptoms.
T. evansi is pathogenic to all laboratory mammals which rapidly succumb to the
infection (Hoare, 1970). The parasite has been shown to be susceptible to human
plasma, hence is of no zoonotic importance (Hawking, 1978).
2.1.4. Morphology
Detailed investigation into the morphological characteristics of various strains of T.
evansi from different parts of the world was carried out by Hoare (1956). A detailed
description of the morphology of the parasite is given in Hoare (1972).
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T. evansi is generally regarded as monomorphic. It is represented almost exclusively
by thin trypomastigotes comprising the slender and intermediate forms identical to
those of T. brucei. The slender forms have a long free flagellum, and a drawn out
narrow posterior extremity which may be rounded or truncated, with the kinetoplast
situated at some distance from the tip. The intermediate forms have a shorter free
flagellum and a short, frequently pointed posterior extremity, with the kinetoplast
lying near this end. The kinetoplast of T. evansi is small, usually rod-shaped and
typically sub-terminal or marginal in position (Hoare, 1972) (see Plate 2.1).
Plate 2.1: Micrograph showing T. evansi in peripheral blood. Giemsa stain, x400
magnification.
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2.1.5. Transmission
Unlike most other species of Trypanosoma, T. evansi does not undergo any cycle of
development in an intermediate host but is transmitted mechanically from one host to
another by blood-sucking Diptera belonging to the family Tabanidae. In this case
trypanosomes are merely transferred from an infected to a susceptible host by the
interrupted feeding of the biting fly. The trypanosomes in or on the contaminated
proboscis of the fly do not multiply and die quickly so cross transmission is only
possible for a few hours (Urquhart et al., 1996). It has been shown that
transmissibility is highest when the interval between the feeding on the donor and
recipient did not exceed 15 minutes, and no infection was produced when the interval
exceeded 8 hours (Hoare, 1972).
Various species of Tabanus (Horse fly) and Stomoxys (Stable fly) have been shown
to transmit T. evansi, Tabanus species being the most efficient transmitters (Luckins,
1988). Tabanus species are important in transmission under field conditions, while
transmission in stables is effected mainly by Stomoxys species (Hoare, 1970, 1972).
It has been demonstrated experimentally that T. evansi is incapable of undergoing
cyclical development either in tabanids or other flies, including Glossina spp (Hoare,
1972).
In Central and South America, in addition to tabanid flies, T. evansi has also been
proven (both experimentally and under natural conditions) to be transmitted by the
bites of sanguinivorous vampire bat (Desmodus rotundus). These bats which are
widespread in Latin America (extending from northern Mexico to Southern
Argentina) become infected when feeding on infected horses or cattle. The disease
which usually lasts for about one month may terminate fatally or the bat may survive
and recover spontaneously. Trypanosomes gain access into the bloodstream of the
bat through penetration of the mucous membranes of the buccal cavity. The parasites
multiply in the blood however, without undergoing any morphological
transformation. They then migrate back into the buccal cavity where they are
inoculated into a new host while the animal takes its blood meal. In effect the bat
plays a dual role of being both the vector and the host for T. evansi and thus is
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capable of transmitting the parasites for a relatively long period of time. This
particularly makes them very important in the spread of T. evansi in those regions.
Carnivores, especially dogs and wild Carnidae become infected with T. evansi by
ingestion of infected carcass.
2.1.6. Classification
A detailed classification of T. evansi is given in Table 2.1.
T. evansi can be distinguished from other members of the subgenus Trypanozoon
using essentially three criteria: absence of tsetse flies in the area where the parasite
was isolated; absence or rarity of pleomorphism in the bloodstream forms; and, the
inability of the trypanosome to develop in Glossina (Hoare, 1970).
Hoare (1970) suggested that T. evansi descended from T. brucei when the latter was
carried outside the tsetse belt by camels. Subsequent repeated transmission over
many years from host to host by biting flies such as tabanids may have transformed
the parasite into the T. evansi known today, and the replacement of Glossina by
mechanical inoculations such as Tabanidae. This enabled the disease surra to spread
to outside the tsetse belts to the north of Africa and beyond the continent to Europe,
Asia and the Americas.
2.1.7. Diseases caused by Trypanosoma evansi
The clinical course of T. evansi infections depend on the susceptibility of the host
and the strain of the parasite. Generally the symptoms closely resemble those caused
by T. brucei.
In horses the acute disease may be as short as 2-3 weeks, chronic phase lasting up to
four months. Clinical signs include pyrexia, progressive anaemia, ascites and oedema
of the ventral abdomen and genitalia. There is a characteristic transient appearance
of small urticarial plaques which coincides with peak parasitaemia, and petechiation
of mucous membranes. Camels are readily infected by T. evansi. The first clinical
sign is pyrexia followed by anaemia. The course of the disease varies with the strain
of the parasite and the physical condition of the animal which is related to the
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nutritional status and the amount of work which it is required to do. The disease in
horses in South America, known as mal de caderas (meaning disease of the hip) and
murrina, is characterised by signs of a gradual development of central nervous
system involvement, and progressive paralysis of the hind quarters is common. As
the disease advances there is increasing weakness, oedema of dependent parts and
marked loss of condition.
Cattle and Asiatic buffalo are readily infected with T. evansi but they seldom show
clinical signs. The disease may, however, flare up in acute or peracute form. Cattle
are important reservoir hosts in Asia from where more susceptible species such as
horses and camels may become infected. African cattle on the other hand appear to
be rarely infected with T. evansi even in situations where they have been in close
contact with infected camels (Hoare, 1972; Leach and Roberts, 1981).
Dogs are occasionally infected and the course of infection is usually acute and
generally fatal if not treated. In addition to the other typical symptoms of
trypanosomosis the parasite may invade the eyes, causing conjunctivitis and keratitis,
and occasionally affecting the lens and the iris.
2.2. IN VITRO CULTIVATION OF TRYPANOSOMES
Cultivation of trypanosomes in culture medium has been done since the beginning of
the twentieth century (Novy and MacNeal, 1903). Initially, it was only possible to
cultivate the insect forms of the cyclically-transmitted trypanosomes by selecting
culture media and temperature (26°C) that mimic their growth requirements in the
insect vector (Brun and Schonenberger, 1979). For this reason it was believed that in
vitro cultivation of the mechanically transmitted species such as T. evansi was not
possible as there are no insect forms. This was also considered to serve as a tool for
their characterisation (Hoare, 1972).
Effective long-term culture systems for cultivation of bloodstream forms using
feeder-layer cells were later developed for T. hrucei (Hirumi et al., 1977), T. vivax
(Brun and Moloo, 1982), T. congolense (Gray et al., 1985; Ross et al. 1985) and T.
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gambiense (Yabu et al., 1986; Yabu and Takayanagi, 1986,1987; Yabu et al., 1989).
These studies showed that mammalian feeder cells were essential for the in vitro
growth of African trypanosome bloodstream forms at 37°C. The trypanosome
growth-supporting activity of both serum and feeder layer has been found to vary
considerably, even for different strains of the same trypanosome species. Thus
optimum culture conditions have to be established for each strain (Borowy et al.,
1988).
Despite the progress made in the cultivation of cyclically transmitted stocks of the
subgenus Trypanozoon, both with the procyclic (Brun and Schonenberger, 1979) and
bloodstream forms (Hirumi and Hirumi, 1990; Hesse et al., 1995), T. evansi was for
a long time cultivated successfully only in embryonated eggs or chick embryos and
not in a variety of culture media. Later on a biphasic culture system consisting of
rabbit fibroblasts feeder layer in a modified RPMI 1640 medium was developed for
T. evansi (Zweygarth et al., 1983).
A significant improvement in the cultivation of Trypanozoon species resulted from
the findings of Baltz et al (1985) that a major function of the feeder layer for such
parasites was its reducing capacity and that it can be replaced by reducing agents
such as 2-mercaptoethanol. About the same time Duszenco et al (1985) found that
feeder cells promote the growth of African trypanosome bloodstream forms by
continuously supplying cysteine and he axenically cultured T. brucei bloodstream
forms successfully by adding cysteine to the culture medium.
The major problem with this innovation was the rapid rate of cysteine oxidation
during incubation at 37°C. In mammalian cells the copper ion was identified as the
major catalyst for oxidation of cysteine in serum-supplemented culture media and a
non toxic, copper-specific chelating agent, bathocuproine sulfate (BCS) was found to
inhibit the autoxidation of cysteine (Duszenco et al., 1985). Yabu et al., (1989)
demonstrated that axenic culture system supplemented with cysteine and BCS was
indeed effective for supporting long-term culture of T. gambiense. Axenic
suspension culture systems are now used for propagation of other Trypanozoon
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species and this system has been effective in long-term maintenance of T. evansi
cultures.
2.3. DIAGNOSIS OFANIMAL TRYPANOSOMOSIS
Several factors are important in considering the presence of trypanosomosis. these
may be based on epidemiological, serological or clinical evidence. Knowledge of the
geographical distribution of the parasite is essential in identifying areas of endemicity
but diagnosis of trypanosomosis ultimately depends on the demonstration and
identification of the parasite in the host (Leach and Roberts, 1981). Thus sensitive
and reliable techniques for the diagnosis of infection are essential to ensure the
detection of infected animals and the effective application of chemotherapeutic
control measures. Furthermore in epidemiological studies it is often necessary to
determine the prevalence and incidence of parasites. Thus parasitological techniques
are often combined with immunological techniques to distinguish animals with active
infections from those which have experienced the disease but may have been cured.
This presentation looks briefly at the clinical, parasitological and immunological
aspects of diagnosis and some methods of characterisation relevant to T. evansi.
2.3.1. Clinical diagnosis
Epidemiological evidence of recent contact with possible vectors is an important
indication of the presence of trypanosomosis. This is more applicable to the tsetse-
transmitted trypanosome species rather than T. evansi. This is because the tsetse
belts in most endemic areas are well defined. The vectors of T. evansi, however are
not confined to well-defined zones and history of contact may not be properly
established. Chronic trypanosomosis and the wasting process associated with it may,
however, take several months to manifest itself and animals may have been removed
from the source of infection some months before the development of clinical signs.
Acute trypanosomosis may involve rapid loss of condition of affected animal(s),
sudden death in a group, acute febrile reactions and, trypanosomes are easily
detectable in the blood. However mild acute infections may pass undetected until
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they go into chronic stage and only loss of condition may prompt investigation, or
infections may be found in routine field surveys (Leach and Roberts, 1981).
2.3.2. Parasitological techniques
Parasitological techniques comprise methods for detecting the parasites in the blood
of infected host. These methods which are used either in the field or laboratory are
divided into two: The Standard Trypano^ome Detection Methods (STDM)
(Molyneux, 1975) include the wet, thin and thick blood smears, which are simple but
relatively less sensitive methods, requiring less sophisticated laboratory equipment
and utilising small volumes of blood; haemoconcentration and rodent inoculation
methods. The other techniques which are more suitable for laboratory or
experimental survey work include culture and column separation methods.
Wet blood film examination (Baker, 1970) is particularly useful for routine
examination of experimental animals (Leach and Roberts, 1981). In this method a
drop of blood obtained from an infected animal is placed on a clean microscope slide
and a coverslip placed on the drop of blood to allow an even spread on the slide.
This is examined at x40 objective of a light microscope. Usually 60-100 microscope
fields are examined (Killick-Kendrick, 1968).
Stained thick blood smears are more useful for field work (Killick-Kendrick and
Godfrey, 1963). The method of preparation is described by Maclennan (1957). The
main disadvantage of thick blood smear is distortions of trypanosomes during the
staining process which can cause difficulty in identification.
Thin blood smears are useful in the identification of species of trypanosomes
(Killick-Kendrick, 1968), although they have been considered to be far less sensitive
than the thick smears (Fiennes, 1952).
Simple concentration methods such as the Haematocrit Centrifugation Technique
(HCT) (Woo, 1970) have increased sensitivity over examination of blood smears in
the diagnosis of trypanosomosis. In the HCT suspected blood is centrifiiged in a
micro-haematocrit and trypanosomes are examined for at the plasma- buffy coat
interface either by direct inspection through the walls of the capillary tube, using a
17
Chapter two: Literature review
phase-contrast microscope, or by breaking the tube and making smears of the
interface material. The efficiency of this method in detecting T. brucei, T. evansi and
T. rhodesiense is estimated to be 85%. The method is capable of detecting
• 2
parasitaemias as low as 1x10 /ml of blood (Woo and Rogers, 1974).
The rodent inoculation method consists of sub-inoculation of whole blood into
rodents and periodic examination of blood from inoculated animals for 1 -2 months
following injection. This technique is most sensitive for detection of trypanosomes
of the subgenus Trypanozoon which are normally present in blood in low numbers
(Woo, 1970) and is found to be most effective at detecting sub-patent infections of T.
evansi (Payne et al., 1990). However this method suffers a number of disadvantages.
It is not convenient for use on the field due to the difficulty of maintaining large
numbers of rodents in the field. Several species of trypanosomes are either refractory
to rodents or are of low infectivity, or cause only transient infections (Godfrey, 1961;
Roberts and Gray, 1973; Leeflang et al., 1976). Laboratory animals are not often
available in endemic areas, hence this method is not used regularly on the field. It is
however very convenient for laboratory use.
Culture of suspected blood for the diagnosis of pathogenic trypanosomosis in animals
is not a satisfactory method because of the high risk of contamination by non¬
pathogenic trypanosomes of the sub-genus Megatrypanum, such as T. theilerv, and
bacteria (Hoare, 1972; Lanham, 1977).
The DEAE-cellulose column separation technique (Lanham and Godfrey, 1970) is
very useful in the laboratory for isolating large numbers of trypanosomes from blood
in pure suspensions for biochemical work. In this method red blood cells are
eliminated from the blood sample by passing it through an anion exchange column.
The erythrocytes which are negatively charged than the trypanosomes attach to the
column but the positively charged trypanosomes pass through and are subsequently
concentrated when the eluate is centrifuged. A miniaturised column was developed
for processing small quantities of blood (50-100 pi) (Lumsden et al, 1979).
However the high cost and complexity of this technique does not permit its routine
use for diagnosis of animal trypanosomosis (Leach and Roberts, 1981).
18
Chapter two: Literature review
Although parasitological techniques have been used in studies on infection with T.
evansi the major disadvantage with these methods have been that trypanosomes are
regularly absent from circulation due to oscillations in parasite populations. In a
survey of camel blood for T. evansi Godfrey and Killick-Kendrick (1962) showed
that the rat inoculation test demonstrated parasites in 27.6% of the animals while
microscopical examination of thick blood films detected parasites in only 12.4%. In
a similar survey in India T. evansi was detectei in 10.09% and 11.46%, respectively,
in buffaloes and cattle examined using HCT whereas the examination of blood films
revealed parasites in only 1.44% and 0.48% of buffaloes and cattle sampled (Payne,
1989).
After demonstration of parasites in the blood characterisation of the particular
trypanosome species is achieved on the basis of morphology, biochemical or
molecular characteristics.
2.3.3. Characterisation using isoenzyme analysis
Isoenzymes are multiple molecular forms of the same enzyme which usually bear
similar properties but differ in their electrophoretic mobilities due to differences in
electric charge caused by variations in their primary, secondary or tertiary molecular
structures. The primary variations have been classified as structural while the
secondary and tertiary variations are classified as post-translational. Structural
changes are known to occur at the level of transcription when the genetic codes of
various polypeptides that make up an enzyme are determined. Post-translational
changes are caused by modifications which occur after the polypeptide chain has
been synthesised and lead to the final form of the enzyme. Structural or post-
translational changes may not change the function of the resulting enzymes although
they may result in changes in the overall net charge leading to differences in
electrophoretic mobilities (Harris and Hopkinson, 1976).
Isoenzyme systems and their electrophoretic mobility differences have been used to
characterise different species of parasites including Trypanosoma (Murray, 1982;
Godfrey et al., 1987). Isoenzyme analysis has been particularly useful in
differentiating parasites of the subgenus Trypanozoon which are morphologically
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indistinguishable (Gibson et al., 1980; Gibson and Wellde, 1985; Godfrey et al.,
1990). Several enzymes have been identified in this subgenus which are useful in
distinguishing the various species. Of these 5 enzymes, namely, aspertate
aminotransferase (ASAT), phosphoglucomutase (PGM) malic enzyme (ME),
peptidase 1 (PEP1) and peptidase2 (PEP2) have been found to vary in different
isolates of T. evansi from camels. These have been used to differentiate T. evansi
from other members of the Trypanozoon subgenus (Gibson et al., 1980). Five
patterns of malic enzymes have so far been identified in T. evansi. (Gibson 1983;
Boid, 1988).
2.3.4. Characterisation using molecular methods
Current available techniques are able to characterise trypanosomes based on
differences in their genetic material which comprise the deoxyribonucleic acid
(DNA). Specific DNA fragments (probes), have been shown to be important in
characterising these parasites. These fragments are labelled either with radioactive
material or enzymes and the degree of similarity in test DNA samples is determined
by hybridisation reactions.
Molecular methods have been used to distinguish T. evansi from other members of
the subgenus Trypanozoon. These have been based mainly on the differences in
kinetoplast DNA between T. evansi and other members of the subgenus (Borst and
Hoeijmakers, 1979; Borst et al., 1987). The kinetoplast of the cyclically-transmitted
Trypanozoon parasites contains two DNA components consisting of 50-100
homogeneous maxi circles and 5,000-100,000 heterogeneous mini circles. T. evansi
and T. equiperdum differ from these other species in that although they have the
same number of mini circles these are homogeneous. In addition T. evansi
completely lacks maxi circles while T. equiperdum has maxi circles which are non
functional (Borst and Hoeijmakers, 1979). These difference distinguish T. evansi
from the other morphologically identical species.
Species-specific DNA fragments consisting of kinetoplast DNA (kDNA) sequences
(Masiga and Gibson, 1990) have been identified in T. evansi which have been found
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to be absent in all other trypanosome species. In this test a trypanosome sample is
hybridised with a probe on a blot to determine if the species is T. evansi.
Another DNA-based method of characterisation is the polymerase chain reaction
(PCR). This is an in vitro method that is used to amplify a segment ofDNA that lies
in between two regions of known sequences (primers) (Mullis and Faloona, 1987;
Saiki et al., 1988). These known sequences found on the DNA template are
recognised by the polymerase enzymes responsible for replication of the DNA as
regions from where replication is initiated. Species-specific primers have been
luentified in T. congolense and T. brucei (Moser et al., 1989) and T. evansi (Masiga
et al., 1992). In this method the two strands of a DNA test sample are separated
(denatured) by heating at appropriate temperature. This is incubated with a species-
specific primer in the presence of DNA polymerase. If the sample is from the
homologous species there is replication and a new strand ofDNA is synthesised. By
raising the temperature again the DNA template together with the newly synthesised
DNA are both denatured and lowering of the temperature again results into the
synthesis of new DNA using both the original and the new DNA as templates. As
this cycle is repeated more DNA is amplified. The reaction mixture is then run on
electrophoresis agarose gel where the intensity of the DNA band is compared to the
original test sample to determine whether DNA has been amplified.
2.3.5. Immunodiagnostic techniques
Immunodiagnostic approaches to the diagnosis of trypanosomosis are dependent on
the fact that parasites elicit an immune response in their host and the detection of the
antibodies produced is evidence that an infection has taken place. The range of
serological tests for diagnosis of various trypanosomes has been reviewed by a
number of authors (Killick-Kendrick, 1968; Molyneux, 1975; Nantulya, 1990;
Luckins, 1992). The major limitation of serological tests is that antibodies persists in
the host after parasites have been eliminated by chemotherapy (Luckins et al., 1979).
Thus the true infection status of a host can not be determined by the mere presence of
antibodies which could only indicate previous infection. Another obstacle to the
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widespread use of serological techniques in animal trypanosomosis has been the vast
diversity of antigens present in the trypanosome species (Gray and Luckins, 1976).
Trypanosome antigens can be divided into 2 groups: those which comprise the
surface coat of the organism and the internal antigens underlying the surface coat.
The surface coat comprise glycoproteins which are renewed each time the
trypanosome undergoes antigenic variation. A specific immune response of the host
is mounted against each new trypanosomal variant antigen (Cross, 1975). However,
because of their variant specificity such antigens will only detect antibodies produced
against homologous variants thus making them of little value in serodiagnostic tests.
Wilson and Cunningham (1971) found that the level of serum antibody to
heterologous antigen rarely reached positive values in the indirect fluorescent
antibody test (IFAT). Serological techniques are however, becoming increasingly
useful in the diagnosis of trypanosomosis
2.3.5.1. Serological testsfor Trypanosoma evansi
A number of chemical tests which depend on increased serum globulin content have
been described for T. evansi infection. These include the mercuric chloride test, the
formol gel test, and the thymol turbidity test (Luckins et al., 1979)
2.3.5.1.1. The mercuric chloride test
Mercuric chloride test has been used in the diagnosis of T. evansi infections in
camels. In this test a drop of the test serum is added to 1 ml of 1:25,000 aqueous
mercuric chloride solution. Positive serum forms a fine precipitate within a few
moments, but negative samples produce no precipitate after standing for 15 minutes.
Degrees of opalescence are recorded from +- to +++. The reaction with camels
infected T. evansi develops within 2-3 weeks of infection, remains positive
throughout but becomes negative after successful treatment (Killick-Kendrick, 1968).
A modification of this method was used in camels in Ethiopia and proved more
sensitive for detection of T. evansi than other tests, apart from rodent inoculation
(Pegram and Scott, 1976). Sera from camels infected with T. vivax and T. brucei also
gave positive results.
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The mercuric chloride test is thought to be due to a peculiar immune response of
camel to trypanosomosis (Killick-Kendrick, 1968). Conflicting reports exists,
however, as to the success of this technique in the diagnosis of T. evansi infections in
camels (Leach, 1961) and the test has not proved useful in other species of animals
apart from camels. (Killick-Kendrick, 1968).
2.3.5.1.2. The formol-gel test
This test is carried out by adding 2 drops of 40% formaldehyde to 1 ml of serum and
allowing the mixture to stand overnight. Positive serum forms an opaque gel. This
test although, used for several years for routine diagnosis of T. evansi infections was
later replaced by the quicker and relatively more reliable mercuric chloride test. The
formol-gel test was also applicable only to camels (Killick-Kendrick, 1968).
2.3.5.1.3. Indirect haemagglutination test
This test relies on the agglutination in the presence of antibody, of tanned
erythrocytes previously coated with soluble antigens obtained from disintegrated
trypanosomes collected from blood of experimentally infected rodents. The test was
shown to be highly sensitive in diagnosing experimental T. evansi infections (Gill,
1964) and is especially useful in bovine and equine species (Killick-Kendrick, 1968).
2.3.5.1.4. Complementfixation test
The complement fixation test has been used for routine diagnosis of T. evansi, T.
cruzi and T. equiperdum infections (Leach and Roberts, 1981). In this tests
complement is "fixed" by the antigen-antibody complex. An indicator consisting of
sheep red blood cells and anti sheep red cell serum is added. If complement is not
fixed, the red cells are haemolysed. But if complement was fixed the red cells
precipitate, indicating the presence of antibodies in the test serum.
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2.3.5.1.5. Indirectfluorescent antibody test (IFA T)
The IFAT has been used as a rapid screening test. It has been found useful for
diagnostic purposes following drug prophylaxis, and is reported to be a more useful
tool for surveys than the STDM (Zwart et al., 1973).
In IFAT antigens are prepared from blood smears, fixed in formaldehyde or acetone
and reacted with test sera. If antibody is present binding occurs which is visualised
using a fluorescent microscope after staining with a specific antiserum conjugated to
a fluorescent dye. The results are read and scored according to the intensity of
fluorescence. This test has been used to detect trypanosome antibodies in cattle and
camels. The tests, however, may not discriminate between trypanosome species
(Luckins et al. 1979; Luckins, 1992). The main disadvantages of IFAT are that the
test requires expensive and sophisticated equipment, and relies on subjective
comparison of results. Like other serological tests the IFAT only indicates that an
animal had been infected with a trypanosome but does not determine its current
status of infection.
2.3.5.1.6. Enzyme-linked immunosorbent assay (ELISA)
Another important serological technique employed in the diagnosis of T. evansi is the
enzyme-linked immunosorbent assay (ELISA). In this assay the test serum is reacted
with a trypanosomal antigen which is adsorbed onto polystyrene plates. The antigen-
antibody complex is incubated with enzyme-conjugated antiglobulin to the IgG
fraction of the particular animal species. The test is visualised by the addition of
enzyme substrate and chromogen and the presence of antibody is indicated by the
degree of substrate degradation. This is measured quantitatively by the resulting
colour change, in a spectrophotometer (Luckins, 1977).
The ELISA has several advantages over IFAT, including increased sensitivity,
simpler equipment and the elimination of the subjective bias in interpretation.
Luckins et al. (1979) compared the ability of five tests to detect both experimental
and natural infections of T. evansi in camels in the Sudan. They found that the
correlation of positive results obtained by assays with IgM levels, the mercuric
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chloride test and the formol-gel test with the presence of active infection was
unsatisfactory. However there was good correlation between results obtained using
IFAT and ELISA and proven infection. ELISA also has the added advantage of
being suitable for screening large numbers of samples (Luckins, 1977). However,
ELISA also suffers a major disadvantage, as in IFAT, in that the test cannot
differentiate between past and present infections.
2.3.5.1.7. Antigen-ELlSA
A modified ELISA suitable for detecting circulating antigens in the blood of infected
animals was developed by Rae and Luckins (1984). Circulating antigens comprise
the products of dead and degraded trypanosomes. These were found to be detectable
in rabbits infected with T. evansi or T. congolense 8-14 days after infection, with
antigen levels increasing progressively for 50-60 days after infection. Antigens were
not detectable in serum 7 days after trypanosomal drug treatment (Rae and Luckins,
1984). In antigen ELISA a trypanosome-specific antibody is used to coat a
polystyrene plate. Test serum is added onto the plates and the antigen in serum
captured by the coating antibody. A second antibody which is enzyme-labelled is
introduced which binds to the captured antigen. The reaction is visualised by
addition of substrate and chromogen as described for antibody ELISA.
The antigen ELISA is particularly useful to differentiate animals giving positive
reactions in serological tests as a result of persistence of antibodies after drug
treatment, and to identify animals with active infection. The antigen ELISA has been
found to correlate well with parasitological tests such as microscopy and mouse sub-
inoculation (Nantulya et al., 1989) and is considered the best available serological
test for the detection of current infection (Mutugi, 1993).
2.4. CONTROL
Control of vector-bome parasitic diseases is generally targeted towards interference
with the life cycle of the parasite involved, thereby breaking the transmission cycle
and limiting movement of parasite from host to host. Control methods used in
trypanosomosis are broadly categorised into three, namely methods directed against
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the vectors, the parasite or methods involving the host. The other two categories of
control methods have been directed mainly towards control of the tsetse-borne
diseases. This review looks at methods directed against the parasite.
2.4.1. Control methods directed against the parasite
Elimination of the source of infection carried by the insect vector is the most
practical method of controlling infections from non-cyclical transmissions such as T.
evansi, which is dependent on the existence of infections and close contact between
individual animals within the affected herd. This is achieved by drug treatment of
affected animals. Moreover it is very difficult to control or eliminate non-cyclical
vectors over large areas because these are widespread, and sometimes exceedingly
numerous in the environment within which most livestock live. Chemotherapy,




The use of trypanocides in the treatment and protection of animals is the most
common single method employed in the control of animal trypanosomosis. More
recent reviews of drugs active against trypanosomes, including the evolution of
trypanocides is given by Apted (1980) Leach and Roberts (1981), Losos (1986). The
effectiveness of chemotherapy and chemoprophylaxis of animal trypanosomosis
depends on a number of factors which include the species of trypanosomes causing
the infection, and the occurrence of resistant strains in the area (Losos, 1986).
Based on chemical structure the trypanocides currently used in livestock can be
divided into acid naphthylamine, phenanthridine, quinaldine and diamidine groups
(Losos, 1986). The most commonly used drugs against T. evansi infections are
described below.
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2.5.2. Suramin
Suramin is a synthetic trypanocide belonging to the naphthylamine group (Figure
2.1). This drug was developed in Germany during the World War II (1914-1918) and
became available in 1920. It was shown by Knowles (1925) to have activity against
experimental infections with T. equiperdum in horses and naturally occurring T.
evansi infections in camels, and in other species by Edwards (1926).
Suramin is a strongly ionic drug and binds readily to plasma proteins. It is excreted
slowly and traces can be found in the blood up to 3 months following intravenous
auministration, which accounts for its prophylactic activity (Dewey and Wormall,
1946). Suramin does not enter erythrocytes, nor cross the blood-brain barrier, hence
it is ineffective in the treatment of infections involving the central nervous system
(CNS). Suramin is administered intravenously as it causes severe local reactions
when given by other routes. It has no pronounced activity against T. vivax and T.
congolense infections of cattle and has only a therapeutic effect on T. simiae in pigs
(Stephen, 1966). With the exception of quinapyramine, suramin has greater efficacy
against the Trypanozoon subgenus compared to most of the modern trypanocides
which are mostly used in cattle. It had been for a long time the drug of choice in the
treatment of Trypanozoon infections of equidae (T. brucei, T. evansi and T.
equiperdum) as it is less toxic in equines compared to quinapyramine. The main use
of suramin has been the treatment of T. evansi infections in camels until the later
innovation of quinapyramine 1946-1950 (Williamson, 1970). Single intravenous
doses of 5-1 Og suramin in aqueous solution were curative but conferred only short
prophylactic effect of 1-4 months, and repeated use of small doses led to
development of drug resistance. Suramin-resistant T. evansi is susceptible to
quinapyramine treatment. Suramin was not replaced by the newer cattle drugs
mainly because the latter has been found to be either far less effective, or, like
quinapyramine, cause more severe toxic reactions in horses than in cattle.
Suramin may cause delayed toxicity, including nephritis. The drug has been shown
to aggregate in lysosomes (Smeethers and Jacques, 1968).
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Figure 2.1: Molecular structure of suramin.
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Despite its long clinical use the specific mode of action of suramin is poorly
understood. Suramin is however, known to bind to albumin and light-density
lipoprotein (LDL) in serum (Vansterkenburg et al., 1993) that enter the trypanosomes
primarily by receptor-mediated endocytosis of some of the serum proteins (Wang,
1995). Wang (1995) argued that since mammalian cells are also capable of
performing receptor-mediated endocytosis of serum proteins, the preferential toxicity
on trypanosomes exhibited by suramin must mean that either trypanosomes possess
more vigorous endocytic activities on serum proteins in general or certain suramin-
s^rum protein complexes are preferentially taken up by trypanosomes.
Suramin is known to be an inhibitor of many different dehydrogenases and kinases
from mammalian, bacteria, and fungal sources. It has been found to inhibit
dihydrofolate reductase, thymidine kinase and all the glycolytic enzymes in T. brucei
(Chello and Jaffe, 1972; Wilson et al., 1993). It is thought that suramin does not
affect trypanosomes by inhibiting the function of any of the glycolytic enzymes
inside the glycosomes. The genes encoding these enzymes are located in the nucleus,
and the enzymes are synthesised on free polysomes in the cytoplasm and imported
into the glycosomes posttranslationally without any proteolytic modification within
3-5 minutes (Hart et ai., 1987). It has been suggested that suramin possibly binds to
the glycolytic enzymes in the cytoplasm within this short period and interferes with
their import into the glycosomes (Wang, 1995). Since the glycolytic enzymes have
an average half-life of about 48 hours inside the glycosome (Clayton, 1987) the
inhibition of glycosomal protein import may lead to a gradual decrease of enzyme
concentrations in the glycosome and a slowing down of energy metabolism in
suramin-treated trypanosomes which has been observed in previous studies (Fairlamb
and Bowman, 1980a; 1980b). This proposed mechanism of action of suramin has
not been proven experimentally. However, it is considered that since resistance to
suramin has not been a serious problem after over 70 years of use this may support
the theory that suramin acts on multiple targets in trypanosomes (Wang, 1995).
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2.5.3. Suramin complex
Following the demonstration that suramin formed a precipitable salt complex when
mixed with pentamidine, thereby reducing the toxicity of the latter while preserving
its prophylactic activity, suramin complexes were produced with almost all the
available trypanocides (Williamson, 1970). A number of these complexes were
shown to have long prophylactic activity in cattle. However, the problem of severe
reaction at the site of injection, which often involved sloughing off of the drug depot
limited their general use. Among these was the quinapyramine complex which was
sb^wn to be suitable for prophylaxis against T. evansi infection in horses in India
(Gill and Malhotra, 1971).
2.5.4. Quinapyramine
Quinapyramine is a bis-quarternary salt synthesised from Surfen C molecule and
belongs to the quinaldine group of trypanocides. It has been used either as
quinapyramine dimethosulfate alone for therapeutic treatment or in combination with
quinapyramine chloride for prophylaxis.
Quinapyramine sulfate is a 4-amino-6-(2-amino-6-methyl pyramid-4-ylamino)-2-
methylquinoline-l-,l'dimetho (methyl sulfate); (C19H28N6O6S2, molecular weight
532.6, Figure 2.2). The compound is readily soluble in water (1:2 at 20°C), is active
against T. brucei, T. congolense, and T. vivax. It is used for curative treatment at the
recommended dose of 4.4 mg/kg, subcutaneously (Curd and Davey, 1950).
Quinapyramine sulfate is well tolerated by cattle but some animals show post
infection stress. Severe systemic reaction is observed in equines (Whiteside, 1960a).
The toxic effects can be reduced by dividing the dose into two equal halves and
administering the second half 5-6 hours later. Quinapyramine sulfate has marked
prophylactic effect but this property was found to facilitate the development of drug-
resistant organisms.
Quinapyramine chloride, 4-amino-6-(2 amino-6-methylpyrimid-4-ylamino)-2-
methylquinoline-1-, l'-dimethochloride dihydrate (C17H22C12N6) 2H20, molecular
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weight 417.3) is similar to the sulfate in physical appearance but it has very low-
solubility in water 1:850 at 20°C).
It was shown that subcutaneous injection of the chloride resulted in the formation of
a depot from which the drug was slowly released. However, blood concentrations
were too low to effect cure of established infections. This led to the introduction of a
mixture of the two compounds, quinapyramine sulfate (3 parts) and quinapyramine
®
chloride (4 parts), marketed as Antrycide Prosa.t by ICI Ltd. UK, for prophylaxis.
A revised formulation (RF) was later introduced which contained only half the
quantity of quinapyramine chloride. This was found to be as effective as the original
preparation, and at the same time produced less local tissue reactions. The RF also
had an added effect on T. simiae in pigs.
Quinapyramine was used extensively for treatment against infections caused by T.
vivax, T. brucei, T. congolense and T. evansi in all domestic animals. The Antrycide
®
prosalt has also been widely used, usually given every 2 months. (Unfortunately
widespread resistance to quinapyramine (Williamson, 1970; Leach and Roberts,
1981; Losos, 1986) led to the withdrawal of quinapyramine from the market in many
parts of Africa in the 1970s.) The drug was re-introduced in the market under two
®
different names. Tribexin Prosalt (quinapyramine sulfate:quinapyramine chloride,
in the ratio of 3:4; Indian Drugs and Pharmaceuticals Ltd, Hyderabad, India) is
recommended for use in T. evansi infections in donkeys and camels (Suryanarayana
et ai, 1985). The other product, Trypacide® (May and Baker, UK), is available in
two forms for field use. Trypacide sulfate is recommended for subcutaneous
treatment of clinical cases, and Trypacide Pro-salt® (quinapyramine sulfate:
quinapyramine chloride in the ratio of 3:2, May and Baker, UK) is recommended for
prophylaxis (Kinabo, 1993).
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NH2
Figure 2.2: Molecular structure of quinapyramine
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Due to the long pause in research following withdrawal of quinapyramine from the
market not much information is available on the mechanisms of action of this drug
(Kinabo 1993).
2.5.5. Isometamidium
Isometamidium (Samorin®, Trypamidium®) is a phenanthridinium compound whose
antitrypanosomal activity was demonstrated over 5 decades ago (Kinabo 1993). The
compound is similar to homidium except for an additional moiety of m-
amidinophenyl-azo-amine (Wragg et al., 1958) which is also part of the diamidine
molecule (Figure 2.3). Isometamidium is thus thought to be a 'hybrid molecule'
which exhibits some properties of homidium and diminazene.
Isometamidium is active against T. congolense and T. vivax in cattle. It is also of
value against infections caused by T. brucei and T. evansi in donkeys, horses and
camels (Zhang et al., 1991; Kinabo, 1993). It is administered intramuscular at doses
of 0.25 - 0.5 mg/kg for therapeutic purposes, and 0.5 - 1.0 mg/kg for prophylaxis.
The maximum dose for resistant cases is 2.0 mg/kg.
Figure 2.3: Molecular structure of isometamidium
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Isometamidium is rapidly detected in plasma following intramuscular administration.
Maximum plasma concentrations are attained within 1 hour following drug
administration (Gilbert and Newton, 1982; Kratzer et al., 1989; Kinabo et al., 1991)
and fall rapidly thereafter to low concentrations. Despite the rapid detection in the
plasma the bioavailability of isometamidium is very low (Kinabo and McKellar,
1990). This is because the drug is bound at the injection site where it forms a
primary depot from which it is slowly released to exert its prophylactic activity (Hill
and McFadzean, 1963; Kinabo and Bogan, 1988a).
The mechanisms of action of phenanthridinium drugs to which isometamidium
belongs is reviewed by Kinabo (1993). The primary mode of action of
isometamidium is thought to be the blockage of nucleic acid synthesis through
intercalation between DNA base pairs, inhibition of RNA polymerase, DNA
polymerase and incorporation of nucleic acid precursors into DNA and RNA. Other
biochemical reactions that have been suggested to contribute partly to their effects
include modulation of glycoprotein biosynthesis, lipid membrane transport and,
selective cleavage of kinetoplast DNA minicircles (Kinabo, 1993). Although the
primary mechanism of action i.e. blockade of nucleic acid alone may not explain the
basis of selective toxicity it has been suggested that there are a number of
biochemical peculiarities demonstrated in trypanosomes that appear to be candidate
targets for drug modulation which might explain the basis for selective toxicity.
These include the cleavage of kinetoplast DNA minicircles, a unique peptide,
trypanothione essential in maintaining the correct intracellular redox balance in
trypanosomes (Fairlamb, 1990); a peculiar AMP binding protein and the novel
glycosomes, organelles that contain a wide variety of enzymes involved in glycolysis,
glycerol metabolism, CO2 fixation, pyrimidine synthesis, purine salvage and ether
lipid synthesis (Kinabo, 1993).
2.5.6. Diminazene aceturate
Diminazene aceturate (Berenil , Farbwerke Hoechst AG), P,P'-
diamidinodizoaminobenzene diaceturate tetrahydrate (C22H29N9O6. 4H20;
molecular weight 587.6; Molecular weight base = 281.2; Figure 2.4) was developed
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chemically from Surfen C. It is readily soluble in water (1:14 at 20°C). The drug is
stable when dry but aqueous solutions are stable for only 2-3 days. Faircclough
®
(1963) stated that the stability of Berenil in solution has been increased by the
addition of phenyl dimethyl pyrazolone (antipyrine) as a stabiliser, by the
manufacturers.
Diminazene aceturate is the only member of the diamidine group used routinely for
treatment of trypanosomosis in small animals. It is the commonest drug used against
tsetse-transmitted trypanosomosis and is thought to qualify as a broad-spectrum
trypanocide Losos (1986). The drug is effective in cattle, sheep, horses and dogs
against T. congolense and T. vivax at 3-5 mg/kg, and against T. brucei at 5-7 mg/kg.
It is not effective against T. simiae. Doses of 10 mg/kg have been found to be
effective against T. evansi infection in cattle. The drug is administered
subcutaneously. Diminazene aceturate is well tolerated in cattle (Fairclough, 1963),
sheep, and man. Flowever, it has been known to produce severe toxic reactions in
camels at 7 mg/kg dose (Leach and Roberts, 1981), hence it is contraindicated. Low
tolerance has also been observed in dogs in which it causes vascular injury
manifested in brain damage (Losos, 1986). T. evansi infections have been shown to
be fully susceptible to Diminazene and the drug also has activity against T.
rhodesiense, and T. gambiense. Besides its trypanocidal effect, Diminazene has been
shown to have high activity against Babesia infections, as well as having
antibacterial and antifungal effects (Williamson, 1970; Leach and Roberts, 1981).
Diminazene aceturate is used primarily as a curative agent, and is extensively used
against cattle trypanosomosis. It is rapidly excreted from the body. Almost all the
drug is cleared through the kidneys within 24 hours following parenteral
administration of a dose. This property has been important in lessening the risk of
resistance development to the drug.
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Figure 2.4: Molecular structure of diminazene diaceturate
Diminazene binds to specific sites in DNA via electrostatic and hydrogen bond forces
(Hart et al., 1987). It also inhibits the kinetoplast topoisomerase II in trypanosomes,
resulting in cleavage of the minicircle DNAs. It is thought to interfere with RNA
editing and RNA tram'-splicing in trypanosomes (Wang, 1995).
Although resistance to diminazene in the field is not widespread quinapyramine and
melarsomine appear to be able to induce cross-resistance to diminazene, both in the
laboratory and in the field (Osman et al., 1992). Preliminary studies suggest that the
mechanism of resistance to diminazene is most likely the diminished uptake of the
drug by resistant trypanosomes (Peregrine and Mamman, 1993).
2.5.7. Arsenicals
2.5.7.1. Drug evolution
The use of inorganic arsenic in medicine dates back to the days of Hippocrates.
Orpiment (arsenic trisulfide) and Fowler's Solution (potassium arsenite) were used as
adjuncts to benzidine dyes in the early days of drug evolution. However, the
introduction of the synthetic aromatic arsenical, Atoxyl in 1905 marked the turning
point in the history of the therapeutic use of arsenic. This became the foundation of
Ehrlich and Hata's work which eventually resulted in the development of
arsphenamine (Salvarsan) in 1910 and later to tryparsamide both of which were
effective against human trypanosomosis (Williamson, 1970).
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The old arsenic preparations, however, continued to be used in the treatment of
animal trypanosomosis. Williamson (1970) recorded that Livingstone in his
missionary journey to Africa, used Fowler's Solution to treat a 'fly-struck mare'
(victim of nagana); Lingard in 1893 showed that the arsonite solution together with
cinchona alkaloids, had a therapeutic effect on the 'haematozoon' of surra, in India;
and Bruce in 1896 also demonstrated that infection due to tsetse-borne trypanosomes
were susceptible to treatment by arsenious oxide or sodium arsenite. Although
arsenic treatment was practised in human infections its toxic reactions prevented its
continued use in man.
Aliphatic compounds first prepared by Cadet in 1760 and characterised by Bunsen in
1837 (Williamson, 1970) were shown to be less toxic than inorganic arsenicals.
However, due to their excretion through the lungs they imparted garlic-type odour to
the breadth and were not acceptable. Atoxyl, which became the first acceptable
organic arsenical was discovered incidentally as a by-product in the production of the
triphenyl-methane dye, parafuscin. It was first thought to be a sodium salt of an
anilide of arsenic acid, isolated by Be'champ in 1863. A number of studies that
followed the use of Atoxyl led to the demonstration of its trypanocidal action by
Thomas and Breinl in 1905 and later its true chemical nature by Ehrlich and
Bertheim (Williamson, 1970).
Extensive use of Atoxyl in man brought to light its toxic effects on the optic nerve
which caused optic atrophy and blindness, and new search for less toxic organic
arsenicals continued. The result was the major discovery in 1910 of the
arsenobenzene compound, Salvasan (arsenamine) which was active in syphilis; and
an early precursor of tryparsamide, Arsenophenylglycine, was prepared.
Tryparsamide (p-glycine amidophenylarsonate) was discovered during the 1914-1918
war and was first synthesised by the condensation of Atoxyl and chloroacetamide, by
Jacobs and Heidelberger in 1922. It is a water-soluble salt which was found to be
highly effective in human trypanosomosis, especially the late stage Gambian disease,
for which it was the only available drug (Williamson, 1970). Unfortunately, optic
atrophy and blindness still occurred in 5% of treated cases. Tryparsamide was used
in combination with suramin between 1930-1940. Two newer drugs were later
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introduced by Friedheim - melarsen in 1938 and melarsoprol (mel B) in 1946-1949
(Friedheim, 1949). Melarsoprol was obtained by reacting a toxic trivalent arsenical,
melarsen oxide with British Antilewisite (BAL) (2,3-dimecapto propanol). The
resulting compound both retained its trypanocidal activity and became significantly
less toxic (Meshnick, 1984). Melarsoprol was found to be less toxic than
tryparsamide, and because of its lipid solubility it is able to cross the blood-brain
barrier. It has been used extensively for treatment of the late stages of human
trypanosomosis. A water-soluble analogue of melarsoprol, mel W (trimelarsan) and
an antimony-containing analogue of melarsoprol, Msb, have also been tested but
offered no advantage over melarsoprol (Williamson, 1970; Meshnick, 1984).
2.5.7.2. Melarsenoxide cysteamine
Melarsenoxide cysteamine (mel Cy, RM110, Cymelarsan , Rhone Poulenc
Toulouse, France), was discovered in 1985 as a member of the melaminyl
thioarsonite group of compounds invented in the 1940s (Raynaud el al., 1989a). The
bis (amino-ethylthio)-4 melaminophenylarsenine dihydrohloride (Figure 2.5) is a
water-soluble trivalent arsenical compound patented in 1985 (Friedhein), mainly for
use in camels (Bujon, 1990). It is related to the drug mel B, the arsenical drug used
for the treatment of late stage sleeping sickness in human trypanosomosis.
The introduction of mel Cy has been described as a clinical breakthrough in the
chemotherapy of T. evansi infections in camels because the existing drugs have not
been very much favoured in view of their high toxicity or lack of high efficacy (Ali et
al., 1985; Ali and Hassan, 1986). Mel Cy is effective primarily against infections
caused by T. evansi in camels, cattle, horses and buffaloes (Sones et al., 1989;
Raynaud et al. 1989a; Lun et al. 1991).
Mel Cy is presented as a sterile white freeze-dried powder for injectable solutions. It
is highly soluble in water. Mel Cy was used successfully to treat camels artificially
infected with T. evansi (Tager-Kagan et al., 1989). Subsequently, several workers
have reported the successful treatment of various animal species, naturally or
experimentally infected with T. evansi using mel Cy, including buffaloes (Lun, et al.,
1991), mice (Zweygarth and Kaminsky, 1990), cattle (Payne et al., 1994a), camels
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(Zelleke, et al., 1989; Otsyula, et al., 1992). Mel Cy is very effective against the
Trypanozoon of the T. brucei group., namely T. brucei, T. evansi and T. equiperdum,
in camels buffalo, goats and pigs, and in vitro (Lun et al. 1991; Otsyula, et al., 1992;
Zhang et al. 1992; Zweygarth and Kaminsky 1990; Zweygarth et al., 1992), on T.
evansi from horse, camel and cattle and T. rhodesiense and T. gambiense (Denning et
al., 1989).
Mel Cy has also been found to be effective against diminazene aceturate-resistant T.
brucei ( Zhang et al., 1992; Zweygarth and Kaminsky, 1990) and stocks of T. evansi
resistant to quinapyramine and suramin (Zweygarth and Kaminsky, 1990). Mel Cy
was found to be 2.2 - 2.7 times more active against in vitro T. brucei stocks
compared with a related, water-soluble arsenical, mel W (Trimelarsan) (Zweygarth
and Kaminsky, 1990). In mg/kg mel Cy was more effective than other arsenicals
(mel B and mel W) and suramin or diminazene on target parasites. It also seemed to
be more effective than mel W on central nervous infections of T. bucei although
with repeated daily treatment (Denning et al., 1989). Mel Cy has been used as part of
combination therapies in mouse models of secondary trypanosomosis (Jennings,
1993). It is not effective against T. congolense (Denning et al., 1989). On T. evansi
mel Cy is very quickly effective in early infections (low parasitaemia) or late
infection (very high parasitaemia) in acute disease models as well as early or late
stages of chronic disease models.
Mel Cy is a curative agent with no preventive or long acting effect (Denning et al.,
1989, Bujon, 1990). The recommended therapeutic dose in camels is 0.25-0.5 mg/kg
administered subcutaneously or by deep intramuscular injection in the neck (Bujon,
1990; Sones et al., 1989).
Studies of the pharmacokinetics of mel Cy have been reported by Baltz et al. (1989)
and Raynaud et al. (1989b). Following administration a peak plasma concentration
in cattle, horses and camels is achieved in about 15-30 minutes after which plasma
levels decline rapidly. Absolute bioavailability in camels was 70-80% (Raynaud et
al., 1989b). In view of this short duration of trypanocidal level in plasma mel Cy has
no prophylactic or long acting effect. The therapeutic index (lethal dose/therapeutic
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dose) of greater than 10 (Raynaud et al., 1989a) indicates that mel Cy is reasonably
safe for use at the recommended dose. The drug has rapid trypanocidal activity and
destroys trypanosomes within few hours. Complete recovery occurs rapidly
following subcutaneous or intramuscular administration.
At recommended dose levels Cymelarsan has been shown to be well tolerated. After
subcutaneous injection, mel Cy has been shown to induce only a transient local
reaction (swelling and oedema ) at the site of injection in cattle and camels which
resolve after a few days (Kinabo, 1993). The drug has a wide margin of safety with
maximum tolerated dose in the range of 3-4 mg/kg. It is safe for camels and has been
recommended for use in pregnant animals (Bujon, 1990).
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Figure 2.5: Molecular structure of melarsenoxide cysteamine (mel Cy)
The molecular events underlining the action of mel Cy have not been well
characterised. It has been suggested that they are similar to those of other arsenical
compounds such as melarsoprol. These compounds are thought to act primarily in
two ways. The first mechanism is by interference with the energy generation
processes through inhibition of pyruvate kinase (Flynn and Bowman 1974). The
second mechanism is by interaction with trypanothione (Fairlamb, 1990). Mel Cy is
thought to inhibit the metabolism of the cell by inhibition of trypanothione reductase,
an enzyme which is found to be absent in the host (mammalian cells) but which is
central to the regulation of the thiol/disulfide redox balance in the trypanosome.
2.6. CHEMOTHERAPYAND IMMUNE RESPONSE
This subject has been extensively reviewed by Doenhoff et al. (1991). The concept
of a combined action between drugs and the immune response was started by Paul
Ehrlich (1907). McDonah (1920) raised the possibility that antimony acted on
parasites in association with the protein particles in serum, and York (1925) reported
that antimalarial chemotherapy was likely to be more effective after patients had a
chance to acquire some immunity (reviewed in Doenhoff, et al., 1991). The
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relationship between drug and the immune response however was explored
experimentally between 1948-1949, when Taliaferro (1948), found that acquired
immunity was involved in the cure of malaria in chickens by quinine.
At present it is known that immunosuppression reduces the efficacy of experimental
chemotherapy of several parasitic diseases, including schistosomiasis (Sabah et al.,
1985; Brindley and Sher, 1987; Fallon et al., 1996), malaria (Lwin et al. 1987),
trypanosomosis (De Gee et al., 1983; Bitonti et al., 1986), and onchocerciasis caused
by Onchocerca lienalis (Bianco et al., 1986). Greater cure rates have been achieved
in immunosuppressed hosts infected with schistosomiasis and malaria by the
simultaneous administration of immune serum or immunoglobulin with a drug. This
further substantiates the existence of a close relationship between the immune
response and chemotherapy (Doenhoff et al, 1991).
The mechanisms of immune dependent chemotherapy has been extensively studied in
schistosomiasis. It is established that four schistosomal drugs (antimony,
oxamniquine, hycanthone and praziquantel) kill fewer (15-56% less) Schistosoma
adult worms in immunosuppressed mice than in immunologically intact control
animals. But the actions of two drugs niridazole and amoscanate, were independent
of the immune response (Sabah et al., 1985).
The efficacy of antimony, oxamniquine and praziquantel is enhanced by passive
transfer of immune serum simultaneously with drug administration in S. mansoni
infected mice, indicating the role of humoral immune effector mechanisms in this
phenomenon. Administration of serum alone does not have any deleterious effects
on the survival of adult S. mansoni confirming that the immune serum acts
synergistically with the drug (Lambertucci et al., 1989; Doenhoff et al., 1991).
Praziquantel for example, is thought to act by destabilising the surface lipid
membranes of S. mansoni. One of the early morphological changes is the disruption
of the membrane over the tubercles on the dorsal surface of male S. mansoni, and an
increase in parasite-specific antigenicity is detectable after treatment of the worms in
vitro (Harnett and Kusel, 1986). It has Been shown that antisera that kill worms
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synergistically with praziquantel, in vivo react particularly with the tubercles of drug-
treated male worms (Brindley and Sher, 1987).
The two antigens specifically implicated as targets of synergistically active antibody
in immune-dependent chemotherapy of S. mansoni are a 27 kDa polypeptide with
esterase activity, and a 200 kDa glycoprotein. Both these antigens are located on or
near the surface of the membranes but the epitopes relevant to antibody-assisted
worm killing by praziquantel normally remains unexposed until drug treatment. It is
suggested that membrane attachment may be a requirement for an antigen's
involvement in immune-dependent chemotherapy but this has not been
experimentally verified (Doenhoff et al., 1991).
A second school of thought suggests that antibodies may not act exclusive of cellular
effector mechanisms in immune-dependent chemotherapy. The drug Oltipraz has
been found to enhance cytotoxic effects of neutrophils against S. mansoni adults in
vitro (Mkoji et al., 1990). Rapid cellular infiltrations of worms occurring after
praziquantel treatment in vivo have been thought to be a manifestation of cell
mediated immune cytotoxicity that is dependent on prior drug-induced damage to the
parasite (Doenhoff et al., 1991).
In leishmaniasis pentavalent antimony therapy was found to be less effective against
Leishmania donovani in infected T-cell-deprived and glucocorticoid-treated mice
when compared with mice with intact immune responses. Furthermore, improved
results have been obtained from experimental and clinical treatment of L. donovani
with a combination of antimony and gamma interferon. It is suggested that the
cytokine enhanced the rate of intracellular killing of the parasite, thus controlling the
infection (Doenhoff et al., 1991).
Studies on trypanosomes have shown that in addition to trypanosomes which are
sequestrated from the drugs in cryptic sites and those which exhibit drug resistance,
trypanosomes can proliferate following drug treatment owing to a dysfunction in
normal immune responses. The curative effects of a number of trypanocidal
compounds have been found to be reduced in splenectomised animals suggesting that
a decrease in phagocytic activity influences drug efficacy. De Gee et al. (1983) and
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Bitonti et al. (1986) demonstrated that antibody specifically that directed against the
variant specific antigen, potentiates the effectiveness of difluoromethylornithine
(DFMO). Gilbert and Newton (1982) suggested that the efficacy of ethidium
bromide in curing cattle is dependent on an efficient antibody response. Frommel
(1988) also demonstrated that immnuosuppresssion effectively decreases the efficacy
ofmel B treatment in mice.
The phenomenon of immune-dependent chei otherapy has obvious implication on
the development of drug resistance. This was earlier demonstrated by Carter et al.
(1973). These workers found that the treatment of a transplantable mouse lymphoma
with asparaginase achieved a permanent cure in immunologically intact mice but not
in T-cell-deprived mice. These mice eventually died and their recurrent tumours
were found to be solidly asparaginase resistant. It was concluded that although the
main effects of the drug was the destruction of sensitive tumour cells, there was a
small residual of asparaginase-resistant cells that was destroyed by the host immune
response. In immunosuppressed animals, the drug-resistant tumour cells survived
and grew back to kill the host.
The interpretation of these results have been applied to many other situations
involving infections and drug treatment, especially infections involving rapid
replicative potentials. Frommel (1988) demonstrated that treatment of
immunosuppressed animals with a mel B dose that is curative in immunocompetent
animals results in the selection of drug-resistant trypanosomes.
This concept has now formed the basis for the selection of drug-resistant
trypanosomes using immunosuppressed laboratory hosts (Osman et al., 1992;
Mutugi, 1993).
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Resistance is defined as the ability of an organism to remain unaffected by noxious
agents such as poisons, toxins, irritants, or pathogenic micro-organisms in its
environment (Harinasuta and Bunnag, 1988). For the most part resistance is a genetic
endowment of an entire species with respect to a particular agent. It can be absolute,
in which case all members of the species are insusceptible to a specific agent. If
resistance is relative, racial and individual differences occur within the species, one
race or member being more resistant than the other (Harinasuta and Bunnag, 1988).
In the context of parasitology and trypanosomosis in particular two major types of
resistance are important: host resistance and parasite resistance. This thesis is mainly
concerned with resistance of parasites to drugs, and specifically resistance of
trypanosomes to trypanocides.
2.7.1.2. Drug resistance
Drug resistance has been defined in different ways. In malaria drug resistance was
defined as the ability of a parasite to multiply or to survive in the presence of
concentrations of a drug that normally destroy parasites of the same species or
prevent their multiplication. Such resistance may be relative (i.e. yielding to
increased doses of the drug tolerated by the host) or complete (withstanding
maximum doses tolerated by the host (WHO, 1963). Drug resistance has also been
defined as a significant increase in the ability of individual parasites within a strain to
tolerate doses of the compound which would be lethal to the majority of parasites in a
normal population of the same species (Harinasuta and Bunnag, 1988). A decrease
in sensitivity may be caused by non-genetic or genetic changes in the target cell. If a
change in sensitivity does not involve a change in chromosomal or
extrachromosomal DNA it is thought to be the result of phenotypic adaptation. This
may take place in culture after a long exposure to the drug under conditions
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favourable for the cell or organism. Phenotypic resistance is not stable and is
usually lost upon transfer to a drug-free medium. This instability, however, is to be
distinguished from regression of resistance which may be due to reduced fitness of
genetic mutants (Harinasuta and Bunnag, 1988).
Geary et al. (1986) described drug resistance as a stable genotypic variant, selected
from a normally sensitive population by drug exposure, that has the ability to survive
and multiply in the presence of normally effective drug concentrations.
2.7.1.3. Drugfailure
Drug failure describes a situation where by a drug, administered in the appropriate
dosage does not produce the recognised action against the target parasite for the
reasons that not enough of the drug or its active metabolite has reached the parasite
(Harinasuta and Bunnag, 1988). In contrast in a situation of drug resistance, the drug
has reached the parasite but the parasite has become adapted to the introduced
chemical environment and survives.
2.7.2. Drug resistance in parasites
2.7.2.1 Plasmodium falciparum
A report of the distribution of chloroquine-resistant Plasmodium falciparum malaria
(Harinasuta and Bunnag, 1988) suggests that resistance is widespread in countries all
over the world where P. falciparum malaria is endemic. Sulfadoxine/pyrimethamine
(S/P) introduced in the 1960s as the first line alternative antimalaria drug
combination suffered tremendous decline in cure rates, and there was need for use of
alternative drugs. Quinine, an old antimalarial drug regained its value because of
increasing occurrence of resistance to synthetic antimalarials (Harinasuta et al.,
1965). There have been reports in various parts of the tropics of reduction in efficacy
of Quinine (Harinasuta and Bunnag, 1988). Cross-resistance between chloroquine
and quinine has been observed in some strains of P. falciparum (Harinasuta and
Bunnag, 1988). Cases of primary resistance to mefloquine have also been reported in
Thailand and East Africa and primary resistance to combination of mefloquine with
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sufadoxine and pyrimethamine (MSP) has been reported in Indonesia (Harinasuta
and Bunnag, 1988).
2.7.2.2. Plasmodium vivax
Widespread resistance of Plasmodium vivax to pyrimethamine has been reported
(Harinasuta et al., 1985) and cross-resistance between pyrimethamine and proguanil
has also been observed. The tropical strain of P. vivax has been reported to be
particularly resistant to primaquine, an antirelapse drug used against the subtropical
strain of P. vivax (Harinasuta and Bunnag, 1988).
2.7.2.3. Other protozoa
Similar problems of drug resistance has been encountered in other protozoans. The
most commonly used drug for the treatment of amoebiasis and giardiasis have been
the 5-nitroimidazole derivatives such as metronidazole, tinidazole and secnidazole.
Metronidazole was first introduced for the treatment of Trichomonas vaginalis
infection and later intestinal amoebiasis. Relative resistance of T. vaginalis infection
to metronidazole and Giardia lamblia to quinacrine or metronidazole following
treatment has been reported (Harinasuta and Bunnag, 1988).
2.7.2.4. Helminths
Anthelmintic resistance of livestock helminths especially gastrointestinal nematodes
has constituted a serious problem to livestock industry in many countries (Kelly and
Hall, 1979; Geerts et al., 1997). Resistance to anthelmintics of nematodes in sheep,
goats and horses have been reported mainly from countries such as Australia, South
Africa, Netherland, New Zealand and countries of South America, where
anthelmintics have been used at high frequency. These include benzimidazole
resistance in Haemonchus spp, Ostertagia spp. Cooperia spp Teladorsagia spp and
Trichostrongylus spp (Borgsteed et al., 1996; Geerts et al., 1997).
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2.7.3. Drug resistance in trypanosomosis
2.7.3.1. Development ofdrug resistance
The most common causes of the development of drug resistance in trypanosomosis in
the field include underdosing of drug due to incorrect estimations of animal body
weight, especially in situations of mass treatment (Whiteside, 1961). Irregular use of
prophylactic and therapeutic drugs is another factor that favours the emergence of
drug-resistant trypanosomes. This occurs especially where there is high tsetse fly
challenge and leads first to 'individual' resistance and subsequently to 'areal'
resistance (Raether, 1988). Prophylactic drugs are known to induce resistance more
rapidly in trypanosomes than do therapeutic drugs. Therapeutic drugs reach
trypanocidal plasma levels relatively quickly and are believed to be rapidly
metabolised and excreted from the body. Prophylactic drugs, however, take a longer
time to be completely excreted from the body. Thus in areas with high incidence of
infection subcurative drug levels may already exist towards the end of protection
period. Repeat treatment is usually required to restore trypanocidal plasma
concentrations.
2.7.3.2. Natural resistance
Natural resistance has also been identified in trypanosomosis. Natural drug
resistance refers to the variation in drug sensitivity that is not dependent on previous
exposure to the drug concerned. This phenomenon has been demonstrated in T. vivax
and T. congolense. Strains of T. vivax from West Africa were found to be more
susceptible to homidium than were T. congolense strains from East Africa (Scott and
Pegram, 1974). In contrast, Williamson (1970) reported that T. congolense strains
appeared to be more susceptible to diminazene than were T. vivax. This varying
intrinsic sensitivity of these species was thought to explain the initial appearance of
homidium- resistant T. congolense strains and diminazene-resistant T. vivax strains
(Jones-Davies, 1967a, 1967b). Such variation could however be as a result of
persistent cross-resistance induced by other drugs used previously.
48
Chapter two: Literature review
Differences in drug sensitivities of stocks of the subgenus Trypanozoon have also
been reported. Dukes (1984) demonstrated that West African stocks of T. brucei
were not as sensitive to pentamidine and diminazene as typical East African stocks.
2.7.3.3. Cross-resistance
Cross-resistance refers to resistance to a drug which has developed as a result of
previous exposure of trypanosomes to a different drug of the same series or even to a
drug of unrelated series. The occurrence of trypanosomes showing cross-resistance
to several drugs has been well documented and is thought to be due to close
relationship between compounds (Whiteside, 1961; Williamson, 1970). Multiple
drug resistance has also been reported in a population of T. vivax in Kenya which
proved resistant to all available drugs including isometamidium chloride, diminazene
aceturate, homidium chloride and quinapyramine sulfate (Rottcher and Schillinger,
1985).
The widespread cross-resistance in trypanosomes to the few available trypanocides
has constituted one of the greatest problems in the use of both chemotherapy and
chemoprophylaxis in the control of animal trypanosomosis. Cross-resistance can
only be effectively controlled by using drugs which do not induce resistance to each
other and which can be used alternatively in the field when resistance to either drug
appears. The concept of "sanative" pairs of drugs was proposed by Whiteside
(1960b) after observation of the cross-resistance behaviour of trypanosomes to
prophylactic and curative drugs. These drug pairs include homidium /diminazene
and isometamidium /diminazene, which show no cross-resistance. In practice, for
curative programmes homidium is used until evidence of resistance appears then it is
replaced with diminazene which controls infections in cattle reinfected with
homidium-resistant trypanosomes, and homidium is used again after a period of one
year or more (Williamson, 1970). Isometamidium and diminazene are recommended
for use in prophylactic field programmes. Usually quarterly prophylactic injections
with isometamidium were supplemented by block treatment with diminazene at
regular intervals, such as every 6 months prior to routine treatment with
isometamidium (Williamson, 1970). Boyt (1985), however observed that the
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sanative drug diminazene will not control the situation if the challenge becomes too
high as a result of increasing rates of reinfection with resistant trypanosomes.
2.7.4. Stability of resistance to trypanocides
Observations on the stability of drug resistance in trypanosomes undergoing cyclical
transmission have been contradictory. Some observations (Whiteside 1962; Jones-
Davis, 1968) suggest that drug resistance is stable and transmissible, while other
investigators have assumed that drug resistance in a trypanosome population is
transient in the absence of drug pressure and infected animals. In a series of
experiments Gray and Roberts (1971a, 1971b) found that resistance to curative doses
of trypanocides was of a stable nature in T. vivax and T. congolense, while the
parasites were transmitted through tsetse and cattle. However, it was assumed that,
under field conditions competition between resistant and sensitive parasites in the
trypanosome population may lead to an advantage to the sensitive forms resulting in
a gradual disappearance of drug-resistant parasites. Similar studies (Osman et al.,
1992; Mutugi, 1993; Scott et al., 1996) suggests that resistance in trypanosomes
induced experimentally in either immunosuppressed or non-immunosuppressed
animals was stable when transmitted to non-immunosuppressed hosts, either via
syringe passage or cyclically through tsetse fly.
2.7.5. Relapse infections
The commonly used trypanocides such as diminazene, isometamidium and ethidium,
do not cross the blood-brain barrier or produce constant trypanocidal concentrations
in body cavity fluids and intracellular tissues (Luckins and Gray, 1979). In chronic
infections of T. brucei patent parasitaemia after drug therapy could occur because of
the appearance of parasite populations from such privileged sites as the cerebrospinal
fluid and/or intracellular tissue spaces. Similar relapse infections arising from
intracellular tissue spaces have also been found to occur in T. congolense infections
(Raether, 1988).
Melarsoprol and related arsenical drugs are able to cross the blood-brain barrier
because of their lipid solubility and hence are very useful in the treatment of late
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human trypanosomosis in which the central nervous system is involved. It has been
found that in chronic infections of T. brucei relapses may occur if treatment was
started too late because drug sensitivity changes as the infections progress. Complete
cure is obtained when drugs are given in the early stage of infection. Furthermore, in
late stage (T. brucei) infections with CNS involvement treatment with non-arsenical
drugs only results to apparent cure. This is because the parasites only disappear from
circulation but after a period of weeks they r -establish themselves in the circulation
(Jennings etal., 1979; Whitelaw etal., 1985).
2.8. MECHANISMS OF DRUG RESISTANCE
It is recognised that drug resistance can be heritable which means its development
may involve changes (mutations) in the genetic material (DNA) which can be passed
from one generation to the other (Geary et al., 1986). Drug resistance can also be
caused by non genetic changes in the target cell as a result of phenotypic adaptation
following prolonged exposure to drug under conditions favourable to the cell
(Georgopopulos, 1982). Such phenotypic resistance is not stable and is lost upon
transfer to a drug free medium. When cells or organisms which exhibit these
mutations are exposed to the action of a drug against which the resistance is
developed they are at a selective advantage over the cells without the mutation. As a
result the drug destroys the non mutant cells while the cells with the mutations
survive and reproduce. With continuous drug pressure this results in a gradual build
up of a resistant population.
There are differences in opinion as to the actual time point when drug resistant
mutants arise i.e. whether they arise because of the presence of the drug or whether
the drug only selects pre-existing mutants. The occurrence of resistance by both
processes has, however, been recognised. For example variations in drug sensitivity
that is not dependent on previous exposure to the drug concerned, has been
demonstrated in T. vivax to homidium (Scott and Pegram, 1974) and T. congolense to
diminazene (Williamson, 1970). It is also recognised that such resistance could be a
result of cross resistance induced by other drugs.
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Extensive work on drug resistance has mainly focused on diseases which are of
medical importance and only recently has attention been drawn to the study of
mechanisms of drug resistance involving diseases affecting animals. Different
proposals have been put forward as possible mechanisms by which pathogens evade
the actions of drugs.
2.8.1. P-glycoproteins and multidrug resistance (mdr)
The basis of what is presently called multidrug resistance was provided by the work
of Paterson and Briedler, and Juliano and Ling in the 70s (reviewed in Broxtermann
et al (1995). These Scientists selected Chinese hamster cells for resistance to
cytotoxic agents, dactinomycin and colchicine, respectively, and obtained cells that
were cross resistant to a broad group of drugs. They also found the expression of a
170 kDa plasma membrane protein associated with the resistant phenotype, a protein
which is now known as P-glycoprotein (Pgp) (Broxtermann et al., 1995).
Multidrug resistance (MDR) phenotype refers to cross resistance to several
structurally and functionally unrelated drugs which have different targets. Typically
it is found in antitumor drugs such as anthracyclines, vinca alkaloids, actinomycin D,
all of which have different targets. Cross resistance to such a wide variety of agents
has been thought to be caused by a decrease in drug concentration at the intracellular
target sites. This could be due to decrease in drug uptake, enhanced drug efflux, or
altered metabolism resulting in increased detoxification of the drug in the cell
(Broxtermann et al. , 1995).
MDR has been found to be present in normal mammalian tissue. However its real
function is not well known. It is suggested that it acts as an ATP-dependent
transporter in the liver, and has a role as a volume-regulated chloride channel. Low
levels of mouse MDR mRNA have been found in the kidney, placenta, heart and
adrenals, and the highest levels can be found in the endometrial glands of the uterus
during pregnancy. The mechanisms of activation of the MDR include mutation,
mRNA level changes, gene amplification or a combination of them (Upcroft, 1994).
The MDR gene has been cloned and identified in humans (MDR1) and its protein
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product P-glycoprotein (Pgp) has been identified as a drug transporter molecule,
causing drug transport out of cells (Broxtermann et al. , 1995).
The P-glycoproteins are large membrane proteins found in the plasma membrane of
cells that can function as energy-dependent extrusion pumps by forming channels
across the lipid bilayer of the plasma membrane. These confer resistance to cytotoxic
drugs by an active drug efflux system which removes a drug from cells so actively
that it does not have an oppoturnity to interaci with its cellular target (Ouellette and
Papadopoulou, 1993). Although P-glycoproteins are found in normal, drug sensitive
cells amplification or over-expression of the genes that code for these proteins have
been found to be a consistent feature in many drug resistant cells, such as cancer
cells, bacteria, yeast and protozoan parasites (Ouellette and Papadopoulou, 1993;
Upcroft, 1994).
Calcium channel blockers such as verapamil are known to reverse multidrug
resistance in mammalian and other cells (Ouellette and Papadopoulou, 1993).
2.8.2. Gene amplification
Gene amplification has been shown to be an important step in the development of
drug resistance in vivo in Leishmania species, and many drug resistant mammalian
cells (Segovia, 1994). The mechanism of resistance involves the overproduction of
the target gene product mediated by an increase in copy number, and consequently, in
RNA being expressed from the target enzyme gene (Segovia, 1994; Gueiros-Filho et
al., 1995).
Antifolates, such as methotrexate, are widely used as antitumor and antimicrobial
agents. These are inhibitors of dihydrofolate reductase (DHFR) which reduces
dihydrofolate to tetrahydrofolate which is essential for DNA synthesis. In parasitic
protozoa DHFR is encoded in a fusion polypeptide that contains the enzyme
thymidylate synthetase (TS). Overexpression of genes as a consequence of gene
amplification has been reported in methotrexate-resistant Leishmania major
(Segovia, 1994). Such lines show elevated activity ofDHFR and the amplif ration of
the structural bifunctional dhf-ts. Similar amplifications have been shown in L.
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mexicana made resistant to tunicamycin, an inhibitor of N-acetylglucosamine -1-
phosphate transferase (NAGT); and other species of Leishmania resistant to
oxianions and difluoromethylornithine (DFMO) (Foote and Cowman, 1994).
Resistance of Plasmodium species to antifolates has also been associated with
overproduction of the target enzyme, DHFR (Foote and Cowman, 1994).
2.8.3. Alteration of drug target
This involves alteration of the drug target in such a way that the drug is not able to
bind. This mechanism of resistance has been identified in bacteria such as
Streptococcus and Staphylococcus species. These alter their ribosomal structure to
become resistant to sulphonamides and tetracyclines (Bauemfeind and
Georgopapadakou, 1995). Also resistance due to alterations in an enzyme resulting
from point mutations in a gene that codes for that enzyme has been demonstrated in
Leishmania species (Segovia, 1994). Similar alterations in dihydropteroate
synthetase enzyme has been shown to be involved in the mechanism of resistance to
sulpha drugs in P. falciparum (Foote and Cowman, 1994).
2.8.4. Activation or development of alternative metabolic pathway
Resistance of gram negative bacteria to sulfonomides has been found to result from
the activation of an enzymatic bypass in the folic acid pathway (Bauemfeind and
Georgopapadakou, 1995).
2.8.5. Enzymatic inactivation or modification of drug
This forms an important mechanism of resistance to antibiotics such as the
production of p-lactamase against the P-lactams or production of penicillinase by
some bacteria.
2.8.6. Decreased intracellular accumulation
An important mechanism of resistance involve preventing a drug from reaching its
intracellular target. This could occur through altered drug transport or enzymatic
inactivation. Altered drug transport has been found to involve either decreased
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uptake (influx) or increased efflux of the drug. An increased drug efflux involves an
overefficient pump-out mechanism that pumps drug out almost as rapidly as it is
taken in such that the drug does not attain high enough concentration to be toxic to
the cell. This may involve the P-glycoproteins as observed in multidrug resistance
(see section 2.8.1) or related systems which are not exactly P-glycoproteins. The
latter are found in bacteria resistant to oxianions such as arsenite or antimony
(Ouellette and Papadopoulou, 1993).
Most studies on drug resistance indicate that there is decreased accumulation in
resistant parasites. It has been shown that uptake of sulpha drugs is reduced in
sulphadoxine-resistant P. falciparum (Foote and Cowman, 1994). Similarly
chloroquine-resistant P. falciparum are found to accumulate less chloroquine than
their sensitive counterparts. It is not fully established whether the reduced
accumulation of chloroquine is due to reduced uptake or enhanced efflux (Ward et
al., 1995). However biochemical and genetic evidence to the existence of an efflux
process have been reported (Krogstad et al., 1987). Verapamil, a classic reversal of
multidrug resistance in cancer cells, have been shown to increase chemosensitivity to
chloroquine in resistant isolates of P. falciparum. Ward et al. (1995) demonstrated
the existence of two phenotypically distinct resistance mechanisms in highly
chloroquine-resistant P. falciparum - one sensitive to verapamil and the other
insensitive. The verapamil sensitive component was suggested to be the component
which is modified in response to drug pressure.
Several Leishmania cell lines have been shown to be resistant to methotrexate
because of decreased uptake of the drug. This has been attributed to mutations in the
high affinity folate carrier, since methotrexate, an antifolate, is an DHFR inhibitor
(Segovia, 1994; Ouellette and Papadopoulou, 1993)
In trypanosomes decreased uptake of pentamidine was reported in T. brucei (Damper
and Patton, 1976; Berger et al., 1995). Reduced accumulation of radiolabelled drug
was associated with resistance to isometamidium (Sutherland et al., 1991, 1992a). A
mathematical model, however, failed to demonstrate that reduced accumulation was
due to reduced uptake of the drug (Sutherland et al., 1992b). More recent work
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suggest that resistance to melaminophenyl arsenicals in T. brucei (Carter and
Fairlamb, 1993; Scott et al., 1997) and diamidines in T. equiperdum and T. brucei
(Barrett et al., 1995; Carter et al., 1996) involved reduced accumulation as a result of
reduced uptake .
The work presented here was an attempt to further investigate into the mechanisms of
resistance to melaminophenyl arsenicals in trypanosomes by the exploration of drug
transport mechanisms in both the drug sensitive and drug resistant T. evansi.
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CHAPTER THREE
GENERAL MATERIALS AND METHODS
3.1. EXPERIMENTAL ANIMALS
All animals used in this study consist of adult female Tyler's original (TO)
30 gm. Mice were housed in approved facilities and fed mice cubes and
libitum.
3.2. TRYPANOSOMES
Studies were carried out on an Indonesian stock of T. evansi which had been cloned
and maintained at the CTVM as TREU 1840. Other details of isolation of this isolate
were not available. TREU 1840 was used to make drug resistant lines.
3.3. ANIMAL INFECTIONS
Trypanosomes were grown in mice for use in experiments requiring in v/vo-derived
trypanosomes. Depending on numbers of trypanosomes required for any experiments
one or more mice were infected with a particular stabilate. Mice were injected
intraperitoneally (i.p.) with 0.2 ml per mouse of frozen blood stabilate. For drug-
resistant trypanosome stocks only original stabilates (unpassaged) were used for mice
infections. However for the drug-sensitive stock up to three passages away from the
original stabilate were used. In this case 0.2 ml of blood from an infected mouse was
transferred to each of a new set ofmice. Parasitaemia was monitored by microscopic
examination of wet mount preparations of tail blood. Levels of parasitaemia were
determined by visual estimation of the approximate number of trypanosomes per
microscope field at x40 objective, according to the method of Herbert and Lumsden
(1976). At parasitaemias of approximately 5x10 /ml infected mice were
anaesthetised using halothane and bled terminally by cardiac puncture using heparin
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3.4. SEPARA TION OF TR YPANOSOMES FROM INFECTED MOUSE BLOOD
For use in in vitro assays requiring in v/vo-maintained trypanosome lines
trypanosomes were separated from infected mouse blood by anion exchange
chromatography using DEAE cellulose columns (Lanham and Godfrey, 1970).
DEAE-cellulose (Whatman, England, DE52), 500 gm, was suspended in 2 litres of
phosphate buffered saline (PS pH 8.0). The main bulk of the exchanger was allowed
to settle and the supernatant fluid containing the fines was removed. The DEAE
cellulose was washed again by decantation with 2 litres of PS solution. The pH was
adjusted to 8.0 using 5% orthophosphoric acid. The DEAE cellulose was further
washed 2 times after pH adjustment by decantation with 2 litres of PS solution. It
was then resuspended in fresh PS solution and sterilised by autoclaving. The DEAE
cellulose was stored at 4°C.
For separation of trypanosomes from 1-3 ml of blood the DEAE cellulose was gently
shaken to resuspend. Columns consisting of 60 ml plastic syringes were previously
prepared, plugged with approximately 5 gm of glass wool, sealed in autoclave bags
and autoclaved. Phosphate buffered saline solution containing 1% (w/v) glucose
(PSG, pH 8.0) was also previously prepared, filter sterilised using 0.22 pm acetate
membrane and stored at 4°C. The column was asceptically opened and mounted on a
burette stand. The glass wool inside the column was soaked by running some PSG
through the column. The column was packed carefully with successive volumes of
the DEAE cellulose slurry up to a height of 7-10 cm. The adsorbent was equilibrated
with 4 times volume of PSG which was allowed to elute. When the surface of the
adsorbent was firm 1-3 ml of heparinized infected blood was applied at the top and
allowed to enter into the adsorbent cellulose. PSG was run through the column by
addition of drops using a 5 ml plastic pipette until about 20-40 ml of eluate was
collected. The appearance of trypanosomes in the eluate was monitored by
microscopic examination of drops of eluate on a microscope slide using phase
contrast microscope. Trypanosomes in eluate were collected in universal bottles on
ice. The eluate was centrifuged at lOOOx g for 10 minutes to concentrate the
trypanosomes.
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3.5. PREPARATION OF TRYPANOSOMA EVANSI WHOLE BLOOD STABILATES
FOR CRYOPRESERVATION
Five to ten mice (depending on the number of stabilates required) were each injected
i.p., with 0.2 ml per mouse of blood of the appropriate trypanosome stabilate. At
high parasitaemia mice were bled under anaesthesia in 5 IU/ml final concentration of
heparin. The blood was pooled in a graduated centrifuge tube partially embedded in
ice. An equal volume of freshly prepared 15% dimethyl sulfoxide (DMSO, SIGMA)
in PSG was added to the blood and mixed thoroughly using a Pasteur pipette. The
blood/DMSO mixture was dispensed in aliquots of 0.5-1.0 ml into cryopreservation
tubes and capped. The tubes were first placed in the vapour phase of liquid nitrogen
for at least 4 hours or overnight. They were then transferred into the main liquid
nitrogen bank where they were stored at -181°C. Record cards containing the details
of stabilates were completed.
3.6. CLONING OF TRYPANOSOMES IN VIVO
In v/vo-derived drug-resistant trypanosomes were cloned in immunosuppressed mice
according to the method of Smith et al (1982). Eight to ten mice were treated
intraperitoneally with cyclophosphamide at 300 mg/kg body weight, 24 hours prior to
injection with trypanosomes. A frozen stabilate of the appropriate trypanosome stock
was removed from liquid nitrogen, thawed quickly by rubbing in between palms and
0.2 ml of the parasitaemic blood injected intraperitoneal into normal mouse.
Trypanosomes were grown for 2-3 days. When parasitaemia was in exponential
growth phase 10 pi of blood was taken asceptically from the snipped tail of the
infected mouse using a 20 pi Finn pipette and tip, and diluted in 90 pi of PSG/1%
normal mouse serum mixture on ice. Ten-fold serial dilutions of trypanosome
suspensions in PSG/1% mouse serum mixture were made. The dilutions were
examined microscopically and a dilution that gave a 0-1 trypanosome per
"microdrop" was found. This dilution was used for cloning.
To isolate a single trypanosome a microdrop (less than 0.2 pi) of the selected
trypanosome dilution was taken using a 0.2 pi pipette and tip and placed on a
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chamber of a piece of glass which was marked into square areas. The microdrop was
tiny enough to be viewed in its entirety under high magnification (x400) of a phase
contrast microscope. The area of the glass slide containing the microdrop was
humidified by inverting the glass slide, chamber down, on a small water bath
containing PBS pre-warmed to 37°C. The hanging drop remained intact for 3-5
minutes without appreciable evaporation taking place.
When a drop containing a single trypanoson 1 was selected, it was confirmed by a
second observer. The glass slide was then removed from the microscope and
everted. The hanging drop was enlarged by addition of more PBS from a 1 ml
disposable syringe. The enlarged drop was aspirated into a 1 ml syringe containing
0.2 ml of PBS. The chamber previously containing the single trypanosome was
washed twice with PBS. The initial drop together with the washings were injected
intraperitoneally into a single immunosuppressed mouse. In this way about 5-10
immunosuppressed mice were injected with single trypanosomes during each cloning
procedure.
Injected mice were examined for patent parasitaemia from day 6 post infection using
wet mount preparation of tail blood. Heavily infected blood was obtained by cardiac
puncture from an anaesthetised infected mouse and a stabilate prepared and stored in
liquid nitrogen. Clones selected for study were expanded in immunosuppressed mice
and a large number of such stabilates prepared and stored in aliquots of 0.5-1.0 ml in
liquid nitrogen until used.
3.7. ISOLATIONAND ADAPTA TION OF TRYPANOSOMA EVANSI IN VITRO
Bloodstream forms of T. evansi were isolated from infected mouse blood and adapted
to axenic growth according to the method of Baltz et al, (1985). A mouse was
infected with approximately 2xl05 trypanosomes i.p., from a frozen stabilate of T.
evansi TREU 1840. After 3 days when parasitaemia was increasing the mouse was
sampled for trypanosome isolation as follows: The tail of the mouse was swabbed
with 70% ethyl alcohol and allowed to dry. The tail was snipped with a pair of
scissors which had been cleaned with 70% alcohol. A drop of blood was expressed
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from the snipped end of the tail and 5pi collected without an anticoagulant, into a
sterile bijou.
A 24-well culture plate (FALCON, UK) was previously prepared by addition of 1 ml
of fresh T. evansi medium into each of 2 wells. 1.5 ml of sterile distilled water was
added into each of the outer wells to prevent evaporation. The plate was placed in
the CO2 incubator at 37°C. A 2.5 pi aliquot of sampled blood was placed at the
centre of one of the wells containing 1 ml of fresh medium. 1 ml of medium was
added to the rest of the blood in the bijou and mixed using a Pasteur pipette. The
trypanosomes in this suspension were counted and diluted to give a final
concentration of 2xl05/ml in 2 mis, when 1 ml of the diluted culture was added into
the second well. The plate was incubated at 37°C in a gassed incubator with 5% CO2
in air.
The culture plate was examined twice daily using phase contrast microscope for the
growth of trypanosomes. The medium in each well was changed individually. The
supernatant was passaged into succeeding wells of the 24-well plates according to the
density of trypanosomes in each well. Initially culture medium was changed twice a
day by removing 0.5-1 ml of culture and replacing with equal volume of fresh
medium. Depending on the density of trypanosomes in the well culture medium
could be removed from the top without agitating the entire culture, or the culture
suspension was mixed using a 1 ml pipette. 0.5 ml of culture supernatant removed
was passaged into a new well and 1-1.5 ml of medium added initially and thereafter
maintenance continued as in older wells.
Many trypanosomes died within the first 2 days of culture but growth became stable
thereafter. It was possible to change cultures once daily after the first 5 days.
Cultures were passaged into new wells until there were no trace of red blood cells
present in the wells. Cultures in these wells were then maintained until
trypanosomes were harvested. Stabilates of healthy cultures were prepared and
cryopreserved.
Cultures were judged to have become established, when they showed a steady
exponential growth after dilution. Trypanosomes were then harvested into sterile
61
Chapter three: General methods
universals, counted, and seeded in T-25 culture flasks. Cultures were seeded at the
density of lxlO5 trypanosomes/ ml in 6 mis of fresh medium. For the first 2 weeks
after transfer to the flasks cultures were examined and fresh medium provided every
24 hours. After establishment in the flask medium was changed every 2 or 3 days.
3.8. CULTURE CONDITIONS
Trypanosomes were grown in suspension (axenic) culture either in T-25 or T-75
flasks. The medium used was Eagle's minimum essential medium (MEM,) with
Earle's salts. This medium was supplemented with 10-15% heat-inactivated (56°C,
30 minutes) donor horse serum, 2 pM L-glutamine, hypoxanthine (HT), 100 pM
bathocuproinedisulfonic acid, non-essential amino acids, 100 pM L-cysteine, 100 pM
monothioglycerol and 0.2% glucose. Cultures were maintained routinely by diluting
to approximate density of either 105/ml over 2 days or 104/ml over 3 days, in 6-12
mis (for T-25 flasks) or 75 mis (for T-75 flasks) fresh medium. Flasks were
incubated at 37°C and 5% CO2 in air.
3.9. CRYOPRESER VA TION OF TRYPANOSOMA EVANSI CULTURES.
T. evansi cultures which were actively growing in the log phase, at a density of 1.5-
2xl06/ml of medium were harvested for cryopreservation. After examination of the
culture in either T-25 or T-75 culture flask the culture suspension was mixed using a
flamed sterile Pasteur pipette. A small volume of the culture supernatant was taken
and the numbers of trypanosomes counted, in the chambers of Neubauer
haemocytometer. The culture supernatant fluid from the flask was removed with
glass pipette and placed into a sterile universal, and centrifuged at lOOOx g for 10
minutes. The pellet was resuspended in 7.5% glycerol in fresh T. evansi medium to
give a final density of 3-5x106 trypanosomes/ml. The trypanosome/glycerol mixture
was dispensed into 1.8 ml cryopreservation ampoules. These were capped and
placed immediately in the vapour phase of liquid nitrogen for at least 4 hours or
overnight. They were then transferred into the main liquid nitrogen bank and stored
at -181 °C. Details of these stabilates were also kept on record cards.
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3.10. INITIATION OF TRYPANOSOMA EVANSI CULTURES FROM
CRYOPRESER VED STABILA TES.
Frozen ampoules of stabilates were removed from liquid nitrogen and thawed as
quickly as possible by placing in a pre-warmed water bath at 37°C. The culture was
diluted into 8 mis of chilled (4°C) T. evansi culture medium in a sterile universal and
centrifuged at lOOOx g for 10 minutes. The pellet was resuspended in 6 mis of fresh
medium. The trypanosome suspension was p1 iced in a sterile 25 Cm culture flask
and kept in a CO2 incubator at 37°C and 5% CO2 in air. The cap of the flask was
kept loose overnight (or at least 2 hours) for gas to equilibrate. Fast growing cultures
were changed and fresh medium provided after 24 hours. Slow growing cultures
were changed after 48 hours. Flasks were changed in each case. Thereafter the
cultures were maintained as routine.
3.11. CLONING OF TRYPANOSOMES IN VITRO
Trypanosoma evansi axenic bloodstream forms made resistant to Mel Cy were
cloned by limit dilution. Six 96-well plates were filled with 50 pl/well of fresh T.
evansi culture medium and placed in an incubator at 37°C and 5% CO2 to equilibrate.
T. evansi culture which was growing well was counted using a Neubauer
haemocytometer and diluted to a density of 4 trypanosomes/ml in 20 mis of medium.
The final trypanosome suspension was poured into a sterile trough and 50 p.1 volumes
were plated out to each of the wells of 96-well plates using a multichannel Finn
pipette. Plates were incubated at 37°C, 5% CO2 for 5-7 days. Plates were thereafter
examined for growth of trypanosomes in each of the wells. Healthy-growing cloned
populations were transferred individually to wells of a 24-well culture plate where
they were passaged and grown for 5 days. Established clones were transferred to T-
25 culture flasks and maintained routinely. Stabilates were prepared from each of the
clones and stored in liquid nitrogen.
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3.12. DRUGS AND CHEMICALS
• (R) • * •
Melarsenoxide cysteamine (mel Cy, Cymelarsan ) was kindly supplied by Rhone-
Poulenc, France; melarsoprol (mel B, Arsobal®) was provided by Specia, Rhone
Poulenc; diminazene aceturate (Berenil®) was donated by Hoechst A G, Germany;
quinapyramine chloride: quinapyramine sulfate 4:3 (Antrycide prosalt®) by ICI Ltd,
United Kingdom; suramin (Naganol®) was obtained from Bayer A G, Germany, and
cyclophosphamide monophosphate was obtained from SIGMA.
[2-3H]-adenosine (740-925 GBq/mmol'1 or 20-25 Ci/mmol"1) was purchased from
Amersham International Pic., UK, and stored at +4°C. Adenine (6-aminopurine),
inosine (hypoxanthine 9-D-ribofuranoside), adenosine (9-(3-D-ribofuranosyladenine)
and 2'deoxyadenosine were all obtained from SIGMA. Adenine, inosine and
deoxyadenosine were stored at room temperature and adenosine was stored at +4°C.
Mel B was supplied in solution in propylene glycol. It was also diluted in propylene
glycol for use in all experiments. Other drugs were dissolved in double distilled, de-
ionised water and filter-sterilised using 0.22 pm filter (Millipore). Quinapyramine
and Berenil® were prepared and used once only on the day of experiment. Suramin
and mel Cy were stored frozen at -20°C as a 10 or 100 mg/ml, or 1 mg/ml solutions
respectively.
For in vitro assays the drug solutions were prepared at lOOx final concentration
required in the assay. Concentrations of diminazene aceturate were calculated as
44.5% content of Berenil®.
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CHAPTER FOUR
PRODUCTION AND CHARACTERISATION OF MEL CY-RESISTANT
TRYPANOSOMA EVANSI POPULATIONS IN VIVO AND IN VITRO
4.1. INTRODUCTION
It has long been recognised that prolonged use of trypanocides for the treatment of
trypanosomosis promotes the development of drug resistant trypanosomes (Fulton
and Yorke, 1941). Consequently drug resistance has been investigated using
naturally occurring (Zhang et al., 1993) or laboratory produced (Osman et al., 1992)
drug resistant strains. In order to investigate the genetic or biochemical basis of drug
resistance it is necessary to have populations of trypanosomes that are identical
except for their response to a particular drug. Such populations can only be obtained
under controlled experimental conditions.
It has been shown that drug resistance is more likely to develop in
immunosuppressed animals than in hosts with intact immune systems (see Doenhoff
et al., 1991; Osman et al. 1992).
Besides the use of animal hosts, maintenance of drug resistant trypanosomes in vitro
would facilitate studies on the mechanisms of drug resistance. This would make it
possible for the various parasite adaptation mechanisms to be followed in the absence
of host interference. In vitro methods are increasingly being considered as useful
alternatives to animal hosts. They have an added advantage for species of
trypanosomes which are not infective to laboratory animals. However, for them to be
effective it is necessary that there is correlation of the in vitro results with in vivo
findings. To determine this there is need to undertake parallel studies in both in vivo
and in vitro systems. It is also important to ascertain that drug resistant trypanosomes
produced in vitro would maintain their normal characteristics when transmitted to the
animal host.
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The overall aim of this study is to investigate the biochemical basis of resistance to
melaminophenyl arsenicals in T. evansi. The specific aims presented in this chapter
include the following:
1. To produce drug resistant lines of T. evansi in vivo and in vitro from a drug
sensitive clone using a trivalent melaminophenyl arsenical drug, mel Cy.
2. Characterise drug resistant lines with respect to their behaviour in normal host,
and sensitivity to mel Cy.
3. Determine the stability of the resistance phenotype produced by mel Cy in vivo
and in vitro.
4. Determine any cross resistance between mel Cy and other commonly used
trypanocides.
5. Compare the effect of different induction methods on development of drug
resistance.
6. Determine any correlation between the results of in vitro assays with in vivo
sensitivity tests.
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4.2. METHODSAND RESULTS
4.2.1. In vivo determination of sensitivity of Trypanosoma evansi TREU 1840 to
mel Cy
A preliminary dose titration was carried out to determine the sensitivity of T. evansi
TREU 1840 to mel Cy, and a sub-curative dose to be used for initiation of induction
of resistance.
Groups of 5 mice each were injected intraperitoneally (i.p.) with 0.2 ml of a 1:100
dilution of whole blood stabilate (containing approximately 105 trypanosomes), in
PBS. Wet blood smear preparations of tail blood from infected mice were examined
daily for patent parasitaemia.
At rising parasitaemia each group of mice was treated with one of the following
doses of mel Cy: 0.01, 0.05, 0.1, 0.5 and 1 mg/kg, i.p. The drug was administered in
0.1 ml/10 gm body weight. Tail blood was again examined for parasitaemia 24 hours
post treatment and subsequently three times a week, for 60 days.
From this data minimum curative dose (MCD ioo) i.e. the lowest dose of mel Cy at
which no relapse was detected in all treated mice throughout the period of
observation, was determined.
Results of this experiment are discussed in Section 4.2.4.2.1.
4.2.2. Induction of resistance to mel Cy in Trypanosoma evansi in vivo
Attempts were made to generate mel Cy resistant trypanosomes from TREU 1840
using both immunosuppressed and normal (immunocompetent) mice.
Immunosuppression of mice was carried out using either cyclophosphamide
treatment or sublethal whole body irradiation. The relapse method of Osman et al.,
(1992) was used in induction.
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4.2.2.1. Induction of resistance in Cyclophosphamide-treated mice
Five mice were each injected i.p, with 300 mg/kg cyclophosphamide, 4 hours prior to
inoculation with trypanosomes. Approximately lxlO5 trypanosomes in 0.2 ml
suspension of whole blood diluted in PBS was injected, i.p. Wet mount preparations
of tail blood of infected mice were examined daily for parasitaemia. At rising
parasitaemia mice were treated with 0.1 mg/kg mel Cy, i.p. Tail blood was examined
3 times a week for parasitaemia. Relapse parasitaemia detected was allowed to attain
exponential growth. The mouse was then bled terminally under anaesthesia, in 5
IU/ml heparin. 0.2 ml of the parasitaemic blood was passaged into each of 5 new
cyclophosphamide-treated mice for the next stage of treatment.
At log phase of the new infection mice were allocated to 2 or 3 treatment groups.
One group was treated with the dose at which the parasites relapsed (current dose)
and the other group(s) were treated with slightly higher dose(s). Mice were
examined daily for relapse parasitaemia to be passaged into a new set of
immunosuppressed mice. This process was repeated until a resistant population was
obtained. Intermediate stabilates were prepared at various stages of induction.
Resistant populations derived were cloned in cyclophosphamide-treated mice.
4.2.2.1.1. Results of induction ofresistance in cyclophosphamide-treated mice
A summary of the progression of induction in cyclophosphamide-treated mice is
shown in Figure 4.1. A high degree of resistance to mel Cy (up to 30 mg/kg) was
achieved over a relatively short period of time.
At the initial steps it was possible to increase doses only slightly each time, starting
from a subcurative dose of 0.1 mg/kg. However, above 2.0 mg/kg dose the
trypanosomes markedly gained resistance and it became possible to significantly
increase the stepwise doses and obtain relapses in relatively short periods of time.
Induction of resistance from 0.1-30 mg/kg mel Cy was achieved by 12 passages, over
5 months period.
The relapse population at 30 mg/kg mel Cy was sub-passaged in 5
cyclophosphamide-treated mice and treated with 30 mg/kg mel Cy. Infection was not
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cleared by this dose. Parallel treatment was carried out in 5 normal mice and relapses
obtained from 3/5 treated mice. This population was expanded in
cyclophosphamide-treated mice and a stabilate prepared. This resistant line was
designated CR1. From CR1 5 clones were derived in cyclophosphamide-treated
mice. Two clones, designated CR1.2 and CR1.3 were expanded in
cyclophosphamide-treated mice and stabilates made for further characterisation.
4.2.2.1.2. Stabilising resistance
A.fter preliminary tests on stability of resistance to mel Cy attempts were made to
stabilise the resistance produced in vivo.
The CR1 parasites were again selected with 40 mg/kg mel Cy (maximum tolerated
dose ofmel Cy in mice) in cyclophosphamide-treated mice. The relapse population
obtained was designated CR2. The CR2 were sub-passaged 11 times successively in
cyclophosphamide-treated mice and treated each time with 40 mg/kg mel Cy. At the
end of these passages the growth rate of the parasites was not affected by drug
treatment. This population was designated CR3.
The CR3 population was tested in cyclophosphamide-treated and normal mice by
infection and treatment with 40 mg/kg mel Cy. Infection was not cleared in both the
normal and immunosuppressed mice, and the growth rate of the parasites was not
reduced. A stabilate of the relapse population in cyclophosphamide-treated mice was
expanded in 5 cyclophosphamide-treated mice. Three clones derived from this
stabilate were designated CR3.1, CR3.2 and CR3.3.
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Figure 4.1 : Summary of induction of mel Cy resistance in cyclophosphamide-treated mice
using subcurative dose treatment. A group of 5 mice was treated with 300 mg/kg
cyclophosphamide, i.p., 4 hours prior to inoculation with trypanosomes. 0.2 ml of frozen
whole blood stabilate of TREU 1840 was injected, i.p. Two to 3 days later when infections
were established mice were treated with a starting subcurative dose of 0.1 mg/kg mel Cy. Wet
mount preparations of tail blood of treated mice were examined daily for relapses. When a
relapse was detected the mouse was bled terminally, under anaesthesia. 0.2 ml of parasitamic
blood was passaged into each of a new set of 5 immunosuppressed mice. At rising
parasitaemia of the new infection mice were divided into 2 or 3 treatment groups. One group
was treated with the dose at which the parasites relapsed. The other group(s) was treated with
slightly higher dose(s). This process was repeated until a highly resistant population was
obtained.
Resistant populations at 30 and 40 mg/kg doses were cloned by injection of single
trypanosomes in immunosuppressed mice.
Figures represent doses of mel Cy in mg/kg. body weight. Only doses that were continued in
the induction are presented.
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4.2.2.2 Induction ofmel Cy resistance in immunosuppressed mice using sublethal
whole body irradiation
Induction was carried out as described for the cyclophosphamide-treated mice.
However mice were immunosuppressed by exposure to 600 rads gamma irradiation
from a 137Cs source, 24 hours prior to infection. A starting subcurative dose of 0. 1
mg/kg mel Cy was used. Smaller incremental doses of mel Cy were used. A
population resistant to 30 mg/kg mel Cy (Ikl, Figure 4.2. ) was sub-passaged into 5
irradiated and 5 normal mice and treated with the same dose. The relapse from
irradiated mice group was expanded in 5 irradiated mice and a stabilate prepared.
This stabilate was cloned in cyclophosphamide-treated mice. Stabilates of clones
were prepared and stored in liquid nitrogen.
4.2.2.2.1. Results of induction of resistance in immunosuppressed mice using
sublethal whole body irradiation method
A summary of the procedure for induction of resistance in irradiated mice is shown in
Figure 4.2. Development of resistance in this group was not as rapid at the initial
stages compared to the cyclophosphamide-treated mice group. More rapid increase
in doses could only be achieved above 6 mg/kg. Below this dose attempts to increase
doses rapidly led to failure to obtain relapse parasitaemias.
Using this method a population selected with 30 mg/kg mel Cy was also obtained
after 12 passages over a period of 5'/2 months. This population was designated IR1.
The IR1 parasites were not cleared from circulation by treatment with 30 mg/kg mel
Cy, in both normal and immunosupressed mice.
Five clones were derived from IR1. One clone, IR1.4, was expanded and
characterised.
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Figure 4.2 : Summary of induction of mel Cy resistance in immunosuppressed mice
using sublethal whole body irradiation. A group of 5 mice was exposed to 600 rads of
gamma irradiation from a l37Cs source 24 hours prior to inoculation with
trypanosomes. 0.2 ml of frozen whole blood stabilate of TREU 1840 was injected,
i.p. Two to 3 days later when infections were established mice were treated with a
starting subcurative dose of 0.1 mg/kg mel Cy, i.p. Wet mount preparations of tail
blood of treated mice were examined daily for relapses. When a relapse was detected
the mouse was bled terminally, under anaesthesia. 0.2 ml of parasitaemic blood was
passaged into each of a new set of 5 immunosuppressed mice. At rising parasitaemia
of the new infection mice were divided into 2 or 3 treatment groups. One group was
treated with the dose at which the parasites relapsed. The other group(s) was treated
with slightly higher dose(s). This process was repeated until a highly resistant
population was obtained. A population resistant to 30 mg/kg dose was cloned by
injection of single trypanosomes in immunosuppressed mice.
Figures in circles represent doses of mel Cy in mg/kg administered in 0.1 ml/10 kg
body weight, i.p. Only doses that were continued in the induction are presented.
Arrows indicate trend of increasing subcurative doses.
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4.2.2.3. Induction ofmel Cy resistance in immunocompetent mice
Induction procedure was similar to that described for immunosuppressed mice.
However, non-immunosuppressed mice were used in attempt to produce drug
resistance. Drug doses were increased very slowly. A dose level was repeated
several times to ensure relapses on the next dose.
4.2.2.3.1 Results of induction ofresistance in immunocompetent mice
A summary of the induction procedure in immunocompetent mice is shown in Figure
4.3. The development of resistance in this group was exceptionally slow. It was
necessary to carry out 2 or more sub-passages at the same dose to obtain relapses.
Relapse populations took very long time to appear and produced transient and scanty
parasitaemias. Failure to obtain relapse parasitaemias at various dose levels was
common.
It took 5 '/2 months to obtain relapses up to 1.0 mg/kg mel Cy, the curative dose for
the drug sensitive clone. Relapses were obtained at 1.4 mg/kg mel Cy but only after
24 months of induction. Beyond this dose it was even more difficult to obtain
relapses. It became necessary to discontinue this induction process for lack of time.
4.2.3. Induction ofmel Cy resistance in Trypanosoma evansi in vitro
T. evansi TREU 1840 bloodstream forms were isolated from infected mouse blood
and adapted to axenic in vitro growth as described in Section 3.8. Trypanosomes
were maintained in the continuous presence of increasing subinhibitory
concentrations of mel Cy, starting from 0.1 r|g/ml. Fresh drug was introduced every
2 or 3 days when the culture medium was replenished. From the initial dose of 0.1
r|g/ml the concentration of mel Cy was increased gradually by doubling the
concentration added to the suspension cultures. Cultures were maintained in one
concentration of drug until they achieved similar growth rate as the wild type cultures
maintained in the absence of drug. The resistant population (MCR1) obtained was
cloned by limit dilution method. Stabilates of clones were prepared and stored in
liquid nitrogen for further characterisations.
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Figure 4.3: Induction of mel Cy resistance in immunocompetent mice using
subcurative dose treatment and relapse method. 5 normal mice were injected
with 0.2 ml of frozen whole blood stabilate of TREU 1840, i.p. Two to 3 days
later when infections were established mice were treated with a starting
subcurative dose of 0.1 mg/kg mel Cy, i.p. Wet mount preparations of tail
blood of treated mice were examined daily for relapses. When a relapse was
detected the mouse was bled terminally, under anaesthesia. 0.2 ml of
parasitaemic blood was passaged into each of a new set of 5 immunosuppressed
mice. At rising parasitaemia of the new infection mice were divided into 2 or 3
treatment groups. One group was treated with the dose at which the parasites
relapsed. The other group(s) was treated with slightly higher dose(s).
Induction was discontinued after 24 months with relapses only at 1.4 mg/kg
dose.
Figures in boxes represent doses of mel Cy in mg/kg body weight administered
in 0.1 ml/10 kg body weight. Only doses that were continued in the induction
are presented.
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4.2.3.1. Results of induction ofmel Cy resistance in Trypanosoma evansi in vitro
The culture-adapted TREU 1840 (WTAX) was cultivated in the continuous presence
of increasing concentrations of mel Cy starting from 0.1 pg/ml. A population of
trypanosomes that tolerated the continuous presence of 20 pg/ml of mel Cy,
designated MCR1 was obtained after 6 months of cultivation in the presence of the
drug. A stabilate of this population was prepared and stored in liquid nitrogen.
Several clones were derived from the MCR1 line. One clone, MCR1.1, was
characterised.
A summary of the derivation of all the drug resistant lines is given in Table 4.1
Table 4.1: A summary of derivation of mel Cy resistant lines of Trypanosoma













30 mg/kg IR1 IR1.4 Irradiated mice




40 mg/kg CR2 - Cyclophosphamide-
treated mice




20 r)g/ml MCR1 MCR1.1 In vitro culture
Legend: The unselected drug sensitive T. evansi TREU 1840 maintained in mice
(WT) was passaged successively in either cyclophosphamide-treated mice or
gamma irradiated mice. Infected mice were treated with increasing subcurative
doses of mel Cy, i.p., and relapses obtained. Relapses at the highest selection
dose were stabilated and cloned in immunosuppressed mice. TREU 1840 was
also adapted to in vitro axenic growth (WTAX) and selected using increasing sub¬
inhibitory concentrations of mel Cy in culture. The resistant population obtained
was cloned in vitro by limit dilution method.
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4.2.4. Characterisation of mel Cy resistant trypanosome lines in vivo
4.2.4.1. Mice infections
The behaviour of drug resistant trypanosome lines derived using cyclophosphamide-
treated mice (CR1, CR2) irradiated mice (IR1) and cultures (MCR1) was studied in
comparison to the wild type (WT) parasites. A group of 5 non-immunosuppressed
mice were infected with approximately 10" trypanosomes/mouse from each of drug
resistant lines. Infected mice were examined daily for parasitaemia using wet mount
preparation of tail blood, up to the time of death. (Mice were killed under approved
conditions when there was evidence of distress as a result of infection.) The
characteristics studied included infectivity to normal mice, prepatent period (time
between injection with trypanosomes and detection of parasites in the blood), and
virulence (determined by the number of days to death after infection).
4.2.4.1.1 Results of characterisation of drug resistant trypanosome lines in
mice
A summary of the characteristics of the drug resistant lines in mice is shown in Table
4.2
Infectivity: The drug resistant lines derived from either methods of induction
namely, using immunosuppressed mice or in vitro cultivation, all maintained 100%
infectivity to normal mice.
Prepatent period: The average prepatent periods of the resistant populations derived
from cyclophosphamide-treated mice (CR1 and CR2) and gamma-irradiated mice
(IR1) ranged from 1.4-1.6 days. The mean prepatent period for the WT parasites was
1.4 days.
Virulence: In infections with CR1 average number of days to death was 12.6 (range
11-15); CR2 was 8.6 (range 5-14), IR1 was 10.6 (range 8-17) and WT was 5.4 days
(range 4-7)
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Number of days to
death of infected mice
Range Mean Range Mean
WT 5 5/5 1-2 1.4 4-7 5.4
CR1 5 5/5 1-2 1.6 11-15 12.6
CR2 5 5/5 1-3 1.4 5-14 8.6
IR1 5 5/5 1-3 1.4 8-17 10.6
Legend: Five normal mice were each injected, i.p., with approximately lxl0J
trypanosomes in 0.2 ml of diluted stabilate of each of the resistant lines. Stabilates
were diluted 1:100 in PBS. Wet mount preparations of tail blood of infected mice
were examined daily for parasitaemia, up to the time of death. Infectivity was
determined as the number ofmice that developed patent parasitaemias after injection
with trypanosomes; prepatent period represents the number of days between injection
ofmice with trypanosomes and detection of the parasites in the blood.
4.2.4.2. In vivo drug sensitivity tests
The sensitivity to mel Cy of drug resistant trypanosome lines and the culture-adapted
wild type was determined in non-immunosuppressed mice.
Groups of 5 mice were injected with approximately lxlCF trypanosomes per mouse,
i.p., from a selected stabilate. Tail blood was examined daily after infection. At
rising parasitaemia the groups of mice were treated with 10, 20, 30 or 40 mg/kg mel
Cy (drug resistant lines); or, 0.25, 0.5 or 1 mg/kg mel Cy (culture-adapted wild type).
Wet blood smear preparations of tail blood of treated mice were examined 24 hours
after treatment, and thereafter 3 times a week for 60 days.
Minimum curative dose (MCDioo) was determined for each trypanosome stock.
Resistance factor (RF) was calculated as the value of MCDioo (drug
resistant)/MCDioo (Drug sensitive). The RF represents the number of times that the
drug sensitivity of resistant clone decreased compared to the unselected (drug
sensitive) clone. The higher the RF the higher the level of drug resistance.
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4.2.4.2.1 In vivo response ofTrypanosoma evansi isolate TREU1840 to mel Cy
The results of the in vivo response of TREU 1840 (WT) to mel Cy is shown in Table
4.3A. A dose of 0.01 and 0.05 mg/kg produced relapses in all 5 treated mice in each
group. With 0.01 mg/kg mel Cy parasites were not cleared from circulation and
growth rate was not affected. With 0.05 mg/kg only 2/5 mice were cleared of
parasites 24 hours after treatment. Infections however, relapsed after 8 and 15 days
post treatment, respectively.
Doses of 0.1 and 0.5 mg/kg mel Cy produced relapses in 4/5 and 1/5 treated mice,
respectively. The relapses occurred between 14-33 days (0.1 mg/kg) and 36 days (0.5
mg/kg). 1.0 mg/kg mel Cy produced complete cure in all treated mice and represents
the drug sensitive dose. 0.1 mg/kg was selected as a suitable subcurative dose for
initiation of induction of resistance.
4.2.4.2.2. In vivo response ofdrug resistant Trypanosoma evansi to mel Cy
In v/vo-derived populations
The in vivo responses to mel Cy of the drug resistant trypanosomes produced in mice
are shown in Tables 4.3B & C. The CR1 trypanosomes relapsed following treatment
with 20, 30, and 40 mg/kg mel Cy doses respectively. Parasitaemias were not cleared
from circulation in all 5 treated mice at each dose level. At doses of 20 and 30 mg/kg
mel Cy, the growth rate of the parasites was not affected by the drug. However, at 40
mg/kg reduced parasitaemia (estimated by reduction in number of trypanosomes per
microscope field at x400 magnification) was observed after 24 hours. The parasites
however multiplied thereafter and high parasitaemias were re-established.
Similarly relapses were obtained with CR3.1 parasites when infected mice were
treated with 20, 30 and 40 mg/kg mel Cy. In each group of mice treated with 20 and
30 mg/kg parasites were not cleared from circulation and growth was not affected.
However, at 40 mg/kg mel Cy, parasitaemia was cleared in 1/5 mice. This mouse
relapsed 23 days after treatment.
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In v/Yro-derived populations
In the WTAX trypanosomes (which represent the drug sensitive control population
for the cultured lines) 3 out of 5 treated mice relapsed at 0.25 mg/kg dose. The
duration of appearance of relapse in the 3 mice averaged 13.3 days (range 11-18
days). No relapses were obtained at 0.5 and 1.0 mg/kg mel Cy. This gives a
minimum curative dose for this stock of 0.5 mg/kg mel Cy (Table 4. 4A)
The MCR1.1 parasites were not cured at 4o mg/kg mel Cy (Table 4.4B). All 5
treated mice relapsed at each of 20, 30 and 40 mg/kg doses. Parasitaemias were not
cleared from circulation in each of the treatment groups. Slightly reduced growth
rate was observed at 40 mg/kg dose.
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A: TREU 1840 (WT)
Drug dose Number of Number of Number of days
(mg/kg) mice relapses before relapse
treated
0.01 5 5 1,1,1,1,1
0.05 5 5 1, 1, 1,8, 15
0.1 5 4 14, 18, 18, 33
0.5 5 1 36
1.0* 5 0 NA
B: CR1
Drug dose Number of Number of Number of days
(mg/kg) mice relapses before relapse
treated
20 5 5 1, 1, 1, 1, 1
30 5 5 1, 1, 1, 1, 1
40 5 5 1, 1, 1, 1, 1
C: CR3.1
Drug dose Number of Number of Number of days
(mg/kg) mice relapses before relapse
treated
20 5 5 1, 1, 1, 1, 1
30 5 5 1, 1, 1, 1, 1
40 5 5 1, 1, 1, 1,23
D: CR3.1st
Drug dose Number of Number of Number of days
(mg/kg) mice treated relapses before relapse
20 5 1 18
30* 5 0 NA
40 5 0 NA
Tables 4.3: In vivo
responses of
Trypanosoma evansi
TREU 1840 and its in
v/vo-derived drug
resistant derivatives, to
mel Cy. Groups of 5
normal mice were





(WT), panel A; the in
v/vo-derived drug
resistant lines, CR1,
panel B, CR3.1, panel
C; or the in v/vo-derived
resistant line passaged
15 times in mice with
no drug treatment,
CR3.1st, panel D. At
rising parasitaemia the
groups of mice were
treated with varying
doses of mel Cy, i.p.
Tail blood of treated
mice was examined
after 24 hours and
thereafter 3 times a
week, using wet mount
preparations, for 60
days, with respect to
appearance of patent
parasitaemia.
* = Minimum curative dose (MCDioo); NA = not applicable;
1 = infection not cleared from circulation after treatment.
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of Number of days
before relapse
0.25 5 3 11, 11, 18
0.50 5 0 NA









of Number of days
before relapse
20 5 5 1, 1, 1, 1, 1
30 5 5 1, 1, 1, 1, 1









of Number of days
before relapse
10 5 5 1, 1, 1, 1, 1
20 5 5 1, 1, 1, 1, 1
40 5 2* 1, 1
Table 4.4: In vivo
responses of the culture-
adapted TREU 1840
(WTAX) and its in
vitro-derived drug
resistant derivatives, to
mel Cy. Groups of 5
normal mice were





(WTAX), panel A; the
in vfrro-derived drug
resistant line, MCR1.1,
panel B; or the in vitro-
derived resistant line





ofmice was treated with
varying doses of mel
Cy, i.p. Tail blood of
treated mice was
examined after 24 hours
and thereafter 3 times a
week, using wet mount
preparations, for 60
days, with respect to
appearance of patent
parasitaemia .
* =3 mice died of drug toxicity.
NA = not applicable
1 = infection not cleared from circulation after treatment
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4.2.5. Characterisation of drug resistant trypanosomes in vitro
4.2.5.1. In vitro drug assays
The sensitivity to mel Cy of both drug sensitive and drug resistant populations was
determined in vitro, using a cell proliferation assay (PROMEGA). This assay
measures growth inhibition of trypanosomes at varying concentrations of
trypanocide. The principle involves the conversion of a substrate in the assay by
viable cells to an easily detectable product. Specifically the assay measures the
conversion of a tetrazolium substrate to a blue formazan product. The colour change
is quantified using an ELISA plate Reader.
Trypanosomes in logarithmic phase of growth were either separated from infected
mouse blood or harvested from culture suspensions. Cultures were diluted 24 hours
prior to assay. In case of mice isolations the trypanosomes were washed by
centrifugation at lOOOx g for 10 minutes. The pellet was resuspended in 10 mis of T.
evansi medium and centrifuged again for 10 minutes at lOOOx g. The final pellet was
resuspended in 5 mis of T. evansi medium for counting. Trypanosomes were counted
using the Neubauer haemocytometer and the density adjusted to 2xl05/ml using T.
evansi medium.
The trypanosome suspension was distributed in 1 ml aliquots into 6 sterile bijoux.
Six 10-fold serial dilutions of mel Cy were prepared at lOOx final concentration in
assay in sterile double distilled deionised water. The final concentrations of mel Cy
in assays were 0.01, 0.1, 1, 10, 100. and 1000 T]g/ml.
Ten pi of each drug dilution was added to 1 ml of trypanosome suspension in a bijou.
An equivalent volume of drug solvent was added to each of control cultures. 96-well
tissue culture plates were prepared by adding about 150 pi of sterile distilled water in
each of the outer wells. The test wells received 100 pi of the trypanosome/drug
mixture. Trypanosomes in each drug concentration were incubated in triplicate while
the control cultures without drug were incubated in 6 wells. Blanks consisting of T.
evansi medium and no trypanosomes were also incubated in 6 wells. Plates were
incubated at 37°C in 5% CO2 atmosphere, for 28 hours.
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At the end of incubation Promega Cell Titre Kit was used to measure the extent of
cell proliferation as follows: 15 pi of the Promega Dye Solution was added to each of
test wells and the plates were incubated for 4 hours at 37°C and 5% CO2 in air. 100
pi of Promega Solubilisation Solution was added to each test well and plates were
kept in humid chamber overnight (or at least 4 hours). Absorbance was read in a
spectrophotometer (ELISA plate Reader) at 570 t|m.
Absorbance values of the blanks were subtracted from test wells and means of
readings were calculated. Growth of trypanosomes in test wells was calculated as a
percentage of growth in control wells without drug. From these data growth
inhibition curves were plotted. Minimum inhibitory concentrations (IC50) were
determined from inhibitory curves using the GRAFIT computer software. IC50
represents the concentration of drug which inhibited the growth of trypanosomes by
50% compared to the control incubations with no added drug.
Resistance Factors were calculated as IC50 (drug resistant line )/ICso (drug sensitive
line). The Resistance Factor indicates the number of times the drug sensitivity of the
resistant line decreased compared to the unselected clone.
4.2.5.1.1 In vitro response ofTrypanosoma evansi isolate and its drug resistant
derivatives to mel Cy
The growth inhibition curves of the drug sensitive (WT, WTAX) and their respective
drug resistant derivatives CR3, MCR1.1) in the presence of increasing concentrations
of mel Cy are shown in Figure 4.4. A summary of the IC50 values and resistance
factors determined from similar curves for these and other resistant lines is shown in
Table 4.5. Large increases (over 300-fold) in the level of mel Cy resistance in the
drug resistant lines were observed.
In the resistant lines derived from immunosuppressed mice, mel Cy resistance
increased from IC50 of 2.9 r|M in WT to 646.0 r|M in CR3 representing a 221-fold
83
Chapterfour: Production and characterisation of resistance
Figure 4.4: In vitro growth inhibition curves showing decrease in sensitivity of in vivo-derived
(CR3, panel a) and in vhro-derived (MCR1.1, panel b) drug resistant Trypanosoma evansi to mel Cy.
Trypanosomes were separated from mouse blood or harvested from cultures in exponential phase of
growth. 2x105 trypanosomes were incubated in 100 p.1 of T. evansi culture medium at 37°C, for 28
hours, in the presence of increasing concentrations (0.01-1000 rig/ml) of drug. The extent of
proliferation of cells was determined using PROMEGA cell proliferation assay Kit. Growth at each
drug concentration was calculated as percentage of control cultures with no drug added. Triplicate
wells were used for each drug concentration and control cultures were incubated in 6 six wells. Bars
represent standard errors ofat least 3 experiments.
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increase in resistance. Increases in resistance were, not uniform in all resistant lines.
Resistance factors ranged from 82.0 in IR1 to 221.4 in CR3.
The three cloned populations CR1.2, CR1.3 and IR1.4 exhibited relatively higher
levels of resistance compared to their respective uncloned resistant parents (CR1 or
IR1). The CR3.1 clone however, showed lower RF (93.4 ) compared to its uncloned
(CR3) parent (RF = 221.4).
Among the in v/vo-derived resistant lines, the highest increase in resistance
(RF=221.4) was observed in CR3 which had been passaged 11 times in mice in the
presence of 40 mg/kg mel Cy. In the culture-derived line an IC50 value of 530.0 r|M
in MCR1.1 compared to 1.7r|M in WTAX represented a 315-fold increase in
resistance to mel Cy; being the highest increase in resistance of all the selected lines.
The sensitivities of the mouse-maintained wild type (WT) and its culture-adapted
variety (WTAX) were similar. IC50 values were 2.9 r|M and 1.7 r|M, respectively.
Variable increases in resistance levels were attained in the drug resistant lines
regardless of whether they were selected in cyclophosphamide-treated mice,
irradiated mice or by in vitro cultivation.
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Table 4.5: In vitro response of Trypanosoma
derivatives to mel Cy.
T. evansi Mel Cy-resistant IC50 (pM) Resistant factor
unselected line line (RF)










Legend: Trypanosome cultures in log phase of growth were diluted to a density of 2x 1 O^/ml
in T. evansi culture medium. Cultures were incubated in 100 pi volumes in 96-well culture
plates in the presence of varying concentrations of mel Cy, at 37°C and 5% C02 in air, for
28 hours. Control incubations with no added drug were included in each experiment. Test
cultures were incubated in triplicate and control cultures in 6 wells. The extent of
proliferation of cells at each drug concentration was measured using a cell proliferation
assay kit (POMEGA). Percentage growth was calculated and growth inhibition curves
plotted. IC5o values were determined using the GRAFIT computer software. Data values
represent average of at least 2 experiments.
IC50 = concentration of drug which inhibited growth of trypanosomes by 50% compared to
control growth in absence of drug.
RF = resistance index calculated as value of the IC50 (drug resistant 1 ine)/IC50 (drug sensitive
line). It represents the number of times the drug sensitivity of the resistant line has
decreased compared to the unselected line.
4.2.6. Stability of resistance studies
4.2.6.1. Stability of resistance after transmission to immunocompetent mice
The drug resistant lines derived in immunosuppressed mice (CR1, CR3, CR3.1, IR1)
and in culture (MCR1.1) were each passaged into immunocompetent mice. lxlO5
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trypanosomes from either the whole blood or culture stabilate were injected into a
group of 5 normal mice, i.p. Mice were examined for patent parasitaemia using wet
blood smear preparations of tail blood. At rising parasitaemia each group of mice
was treated with 30 or 40 mg/kg mel Cy. The treated mice were examined for 60
days for any relapse parasitaemias.
4.2.6.2. Stability after severalpassages in the absence ofdrug pressure
The CR3.1 parasites were passaged 15 times, over a period of 12 weeks, in normal
mice with no drug treatment.
Whole blood stabilate of CR3.1 parasites was diluted 1:100 in PBS and 0.2 ml of
diluted stabilate injected into each of 2 mice. The mice were examined for
development of parasitaemia. At high parasitaemia (usually 5-7 days post infection)
a mouse was bled under general anaesthesia. Parasitised blood obtained was diluted
1:100 in PBS and 0.2 ml injected into each of a new set of two mice. This process
was repeated until a population that had been passaged through 15 sets of mice with
no drug treatment (CR3.1st) was obtained. Intermediate stabilates were prepared at
the 5th and 10th passages.
The culture-derived clone MCR1.1 was passaged by continuous cultivation in T.
evansi medium for 5 months with no addition of drug in the culture medium. This
population was designated MCR 1.1st.
The drug sensitivities of the two passaged lines were tested in mice by infection and
treatment with 10, 20 30, and 40 mg/kg mel Cy; and in vitro using the in vitro drug
sensitivity assay.
In addition the MCRl.lst. line was tested for stability by re-introduction of the
selective dose of mel Cy (20 pg/ml) into the culture medium, after cultivation for 5
months in absence of drug.
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4.2.6.3 Results of studies on stability of mel Cy-induced resistance
4.2.6.3.1. Stability upon transmission to immunocompetent hosts.
Infections with both CR1 and IR1 resistant lines were not cured by their selection
dose of 30 mg/kg mel Cy. In CR1 relapses occurred in 3/5 treated mice. In IR1
parasites were not cleared from circulation in 5/5 treated mice. Similarly, all 5
treated mice were not cured when CR3 and CR3.1 lines were each passaged to 5
immunocompetent mice and treated with 40 mg/kg mel Cy.
The in v/Yro-derived MCR1.1 was also not cured by 40 mg/kg mel Cy in normal mice.
Parasitaemias were not cleared from circulation in all the 5 treated mice. However a
slight reduction in levels of parasitaemia was observed.
4.2.6.3.2. Instability in vivo of the in vivo-derived mel Cy resistance after
severalpassages through mice or cultivation in the absence ofdrugpressure.
The drug sensitivities of the resistant lines passaged 15 times through normal mice
(CR3.1st) or cultivated in vitro for 5 months (MCR1.1st), in the absence of drug
pressure were tested for resistance in normal mice. A reduction in resistance to mel
Cy was observed in the in v/'vo-derived drug resistant clone (Table 4.3D). Whereas
the unpassaged clone CR3.1 was not cured by 40 mg/kg mel Cy complete cure of
CR3.1st was obtained with 30 mg/kg dose and only 1/5 treated mice relapsed at 20
mg/kg dose. The single relapse occurred 18 days post treatment. In the unpassaged
resistant line parasites were not cleared in all 5 treated mice at 20 mg/kg mel Cy.
4.2.6.3.3 Stability in vivo of the in vitro-derived mel Cy resistance after several
passages through mice or cultivation in the absence ofdrugpressure.
No evidence of loss or reduction of resistance in vivo was observed in the culture-
derived resistant clone (MCR1.1st) after cultivation for 5 months in the absence of
drug (Table 4.4C). These parasites were not cured by 40 mg/kg mel Cy, similar to
the unpassaged clone (MCR 1.1). Parasites were not cleared from circulation
following treatment and growth rate was not affected.
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4.2.6.3.4 Instability in vitro of the in vivo-derived mel Cy resistance after several
passages through mice or cultivation in the absence ofdrugpressure
A marked reduction in IC50 was observed in the in v/vo-derived resistant line
(CR3.1st) after 15 passages in mice in absence of drug treatment (Table 4.6). A
mean IC50 of 8.3 r|M was obtained in comparison to 270.6 r)M in the unpassaged
(CR3.1) line. This represents a 32.6-fold reduction in tolerance of the drug compared
to the unpassaged line.
Table 4.6: Stability ofmel Cy-induced resistance in Trypanosoma evansi after
several passages in absence of drug pressure.
T. evansi Mel Cy resistant IC50 0lM) Resistant factor




MCR1.1 st. 345.0 202.9
Legend: Trypanosome cultures in log phase of growth were diluted to a density of 2xl05/ml
in T. evansi culture medium. Cultures were incubated in 100 pi volumes in 96-well culture
plates in the presence of varying concentrations of mel Cy, at 37°C and 5% CO2 in air, for
28 hours. Control incubations with no added drug were included in each experiment. Test
cultures were incubated in triplicate and control cultures in 6 wells. The extent of
proliferation of cells at each drug concentration was measured using a cell proliferation
assay kit (POMEGA). Percentage growth was calculated and growth inhibition curves
plotted. IC50 values were determined using the GRAFIT computer software. Data values
represent average of at least 2 experiments.
IC50 = concentration of drug which inhibited growth of trypanosomes by 50% compared to
control growth in absence of drug.
RF = resistance index calculated as value of the IC50 (drug resistant line) / IC50 (drug
sensitive line). It represents the number of times the drug sensitivity of the resistant line has
decreased compared to the unselected line.
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4.2.6.3.5 Stability in vitro of in vitro-derived mel Cy resistance after several
passages through mice or cultivation in the absence ofdrugpressure
The in vitro response of the culture-derived resistant clone after cultivation for 5
months in the absence of drug pressure (MCRcl.lst) is also shown in Table 4.6. The
IC50 of 345.0 r|M was only 1.5-fold less than that of the unpassaged line (530.0 r)M).
This shows that resistance in this population was stable within this period.
Following re-introduction of the selective dose (20 r)g/ml mel Cy) after 5 months of
withdrawal from cultures the MCR 1.1st parasites continued to grow at this
concentration for 2 weeks. Reduced growth of trypanosomes was observed in the
first few days after re-introduction of drug. Thereafter there was recovery and
cultures attained similar growth rate as the control cultures with no added drug.
4.2.7. Cross- resistance between mel Cy and other trypanocides
The in vitro sensitivities of mel Cy resistant T. evansi lines to other commonly used
trypanocides were determined in comparison to those of the unselected lines. The
trypanocides tested included mel B, diminazene aceturate (Berenil®), quinapyramine
and suramin. Details of their sources are given in Section 3.3
4.2.7.1. In vitro drug assays
In vitro drug sensitivity assays to assess for cross-resistance were carried out as
described in Section 4.2.5.1. However, several drugs were used apart from mel Cy.
Drug dilutions were prepared as described below.
Quinapyramine was prepared from a 1 mg/ml stock solution for use at the following
final concentrations in assay. 0.01, 0.1, 1,10, 100, 1000 r|g/ml.
Berenil® was prepared as a 1 mg/ml solution. This was used as the highest dilution
for the assay. Final Berenil concentrations in the assay included 0.1, 1, 10, 100, 1000
and 10,000 r|g/ml.
Suramin was used at the same final concentrations as Berenil®. Dilutions were made
from either a 10 mg/ml or 100 mg/ml frozen stock solutions.
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Mel B dilutions were prepared in propylene glycol beginning with a 1 mg/ml
(R)
dilution. Final concentrations in the assay were the same as in Berenil and suramin.
4.2.7.2 Results ofcross resistance between mel Cy and other trypanocides in vitro
Growth inhibition curves of mel Cy sensitive and mel Cy resistant trypanosomes
incubated with increasing concentrations o. mel B, Berenil, quinapyramine and
suramin, are shown in Figures 4.5 a-d. The mean IC50 values determined from
similar curves are given in Table 4.7. A summary of IC50 showing cross resistance
between mel Cy and other trypanocides in two resistant lines (CR3 and MCR1.1) is
shown in Figures 4.6 and 4.7, respectively.
4.2. 7.2.1 Cross-resistance between mel Cy and mel B (Figure 4.5a)
Moderate to high levels of cross-resistance to mel B were expressed in vitro in the
mel Cy resistant populations. The lowest increase (11-fold) in resistance to mel B
was observed in CR1 parasites which showed 89-fold increase in resistance to mel
Cy (Table 4.7). The highest increase (48-fold) in resistance to mel B was found in
the IR1 population which acquired 82-fold increased resistance to mel Cy.
Intermediate increases of 14-fold and 36-fold resistance to mel B were observed in
CR1.2 and CR3, respectively. No evidence of increased resistance to mel B was
observed in the MCR1.1 parasites.
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4.2.7.2.2 Cross-resistance between mel Cy and diminazene aceturate (Berenil ,
Figure 4.5b)
In vivo derived resistant lines:
High levels of cross resistance to Berenil® were detected in all the drug resistant
populations tested. An increase in mel Cy resistance of 89-fold in CR1 line was
accompanied by 30-fold increase in resistance to Berenil®. Increase of 196-fold
resistance to mel Cy in CR1.2 was also accompanied by 24-fold increases in
resistance to Berenil®. The increased resistance to mel Cy in CR1.2 (RF=195.9)
compared to uncloned parent (CR1. RF= 89.0) was not reflected in higher resistance
to Berenil® in the same stock. However in CR3 an increase in mel Cy resistance of
221-fold was accompanied by a high (53-fold) increase in resistance to Berenil . An
82-fold increase in resistance to mel Cy in IR1 was also accompanied by 57-fold
(1?)
increase in resistance to Berenil .
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In vitro derived resistant lines:
In the in vz/ro-derived drug resistant line (MCR1.1) relatively low level of cross-
resistance to Berenil® was detected. A 315-fold increase in resistance to mel Cy in
(It)
this line was accompanied by a 25-fold increase in resistance to Berenil .
4.2. 7.2.3 Cross-resistance between mel Cy and quinapyramine (Figure 4.5c)
Low cross-resistance to quinapyramine in the in vzvo-derived drug resistant
trypanosomes:
A low increase in resistance to quinapyramine was observed in the drug resistant
lines derived in vivo, ranging from 2.6-fold in CR1 to 5.9-fold in CR1.2 parasites.
Lack of cross-resistance between mel Cy and quinapyramine in the in vzYro-derived
resistant lines:
No increase in resistance to quinapyramine was observed in the MCR1.1 resistant
line. The IC?o (1.6 pM) was the same (1.6 pM) as the drug sensitive (WTAX) stock.
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Quinapyramine
Log drug conc. (g/ml)
Figure
4.5c: In vitro growth inhibition curves of mel Cy sensitive and mel Cy resistant







4.2.7.2.4 Lack ofcross-resistance between mel Cy and suramin in vitro (Figure
4.5d)
No evidence of increased resistance to suramin was found in the mel Cy resistant
lines derived in vivo. Although a 2-fold reduction in sensitivity to suramin was
observed in CR3 this falls within the normal limits of variability of the assay.
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Figure
4.5d: In vitro growth inhibition curves of mel Cy sensitive and mel Cy resistant
Trypanosoma evansi incubated with different concentrations of Suramin
On the contrary two of the in v/'vo-derived resistant lines showed moderate to marked
increase in sensitivity to suramin ranging from 2.3-fold increase in CR1 line to 53-
fold increase in IR1 line.
There was no change in sensitivity to suramin in the in wYro-derived resistant line


















Figure4.7:Crossresistancbetweem lyandothertrypanoc des.Cultur - daptedtrypan somewinc ateda densityof2xl05/mlmediuminthepresenceofvaryingc cent ationsfeachdrug,a37°Cd5%CO2ini ,for28 hours.Eachdr gconcent ationwaincubatedtriplicat .Controlltur swi hd ga dedwereincubated6 wells.Growthameasuredusingc lproliferatioas ay(PROMEGA).Growthae cd gconcent ationw calculatedaspercent geofgrowthtrypan somesinthabsen eofdrug.IC50v lu swedete min dfrogrowth inhibitioncurvesusi gt eGraf tcomput rsoftware.Ea hd tp intrepresen smeaIC50fromale t3experiments. 1=melCy,2Berenil®,3=quinapyraminea d,4-surami .
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Mel Cy Mel B Berenil Quinapyramine Suramin
WT 2.9 13.0 35.7 768.0 2240.0
CR1 260.0 148.0 1059.0 2023.0 980.0
CR1.2 572.0 175.0 889.0 4560.0 2800.0
CR3 646.0 468.0 1904.0 2215.0 4550.0
IR1 240.0 493.0 2040.0 - 42.0
WTAX 1.7 7.0 13.6 1.6 38.5
MCR1.1 530.0 - 340.0 1.6 41.3
Legend: Trypanosome cultures in exponential phase of growth were diluted to a density of
2xl05/ml in T. evansi culture medium. Cultures were incubated in 100 p.1 volumes in 96-
well culture plates in the presence of varying concentrations of each trypanocide, at 37°C
and 5% CO2 in air, for 28 hours. Control incubations with no added drug were included in
each experiment. Test cultures were incubated in triplicate and control cultures in 6 wells.
The extent of proliferation of cells at each drug concentration was measured using a cell
proliferation assay kit (POMEGA). Percentage growth was calculated and growth inhibition
curves plotted. IC50 values were determined using the GRAFIT computer software. Data
values represent average of at least 2 experiments.
IC50 = Concentration of drug that inhibited growth of trypanosomes by 50% compared to
control growth in absence of drug.
4.2.8. Test for occurrence of naturally resistant sub-populations of
Trypanosoma evansi TREU 1840
To determine if sub-populations resistant to mel Cy were originally present in T.
evansi TREU 1840 3 attempts were made to select the culture-adapted wild type
using 20 r]g/ml concentration of mel Cy. Drug was introduced into cultures once
when the medium was changed. Cultures were thereafter carefully maintained and
examined for surviving trypanosomes.
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Parasites that tolerated 20 r|g/ml concentration ofmel Cy were not obtained from the
original isolate.
4.2.9 Modification of sensitivity to trypanocides in culture-adapted
Trypanosoma evansi
A general increase in drug sensitivity was observed in the culture-adapted T. evansi
(WTAX) when compared to the mouse-maintained wild type (WT, Table 4.7). Low
increases of 1.7-fold, 1.9-fold and 2.6-fold resistance to mel Cy, mel B and Berenil®,
respectively were observed. However, marked increases in sensitivity to
quinapyramine (up to 480-fold) and suramin (up to 58-fold) were also observed.
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4.4. DISCUSSION
Induction of high levels of mel Cy resistance in T. evansi was achieved using
subcurative dose treatment and relapse method in immunosuppressed mice. Similar
levels were attained by in vitro cultivation of trypanosomes in the presence of
increasing sub-inhibitory concentrations of drug. A 40-fold increase in resistance in
vivo and over 300-fold increase in vitro were observed.
Induction of resistance experimentally in this study did not cause major changes in
the natural characteristics of the parasites, apart from modifying their drug
sensitivity. This makes them suitable material for studies of mechanisms of drug
resistance. It also indicates that the method by which the parasites acquired
resistance experimentally is a true reflection of their mechanisms of acquisition of
resistance in nature. Hence valid conclusions can be made from observations on
these parasites.
The decreased virulence observed in the resistant trypanosomes may be a result of
decreased growth rate. Attainment of high parasitaemias was observed to be delayed
in the resistant compared to the unselected line. Reduced growth rate in T. evansi
made resistant to suramin was reported by Mutugi et al., (1996). The growth rate of
mel Cy resistant trypanosomes at this instance, however, was not studied.
There were no marked differences between the use of immunosuppressed mice and in
vitro system in the time taken to attain high resistance levels. Similar induction
periods have been achieved by previous workers, in mice (Osman, et al., 1992,
Pospichal et al., 1994) and in culture (Ross and Barns, 1996).
It was found from all the three induction methods that the most crucial stages were
the initial steps, requiring very small incremental doses. Once these stages were
accomplished the parasites rapidly gained resistance. Higher stepwise increases were
then possible and relapses occurred within relatively short time periods. Similar
observations have been reported on induction of mel Cy, diminazene aceturate and
isometamidium resistance in T. evansi using immunosuppressed mice (Osman et al.,
1992).
100
Chapter four: Production and characterisation ofresistance
This initial difficulty in the rate of development of resistance followed by an apparent
"breakthrough" resulting in rapid increase in resistance has not been explained. This
may have to do with the mechanism of selection. It has been suggested that
resistance is the result of mutational events occurring at low frequency in individual
trypanosomes which are usually eliminated by antibodies in immunocompetent host
following treatment (Osman et al., 1992). These mutants tend to survive and benefit
from natural selection in immunosuppressed hosts. Lower drug doses may ensure the
preservation of this minute segment of the population in immunosuppressed hosts.
A.s induction progresses there is a build up of resistant mutants. With time these
would replace the more susceptible population resulting in rapid responses to higher
doses of drug, as seen in this study.
In contrast to the successful development of resistance in immunosuppressed mice it
was extremely difficult to induce high resistance to mel Cy in immunocompetent
mice. Osman et al. (1992) previously reported unsuccessful attempts to develop mel
Cy and diminazene resistance in immunocompetent mice. These authors could not
induce resistance beyond 0.5 mg/kg using either mel Cy or diminazene. In this study,
resistance was induced up to 1.4 mg/kg in immunocompetent mice.
Osman et al. (1992) and Pospichal et al. (1994) previously induced mel Cy resistance
using immunosuppressed mice. Zhang et al. (1993), however, reported successful
induction of mel Cy (and diminazene) resistance in T. evansi using
immunocompetent mice. In this study Tyler's original (TO) mice were used for
induction of resistance. However, both Osman et al. (1992) and Zhang et al. (1993)
used the same type of mice (Swiss white) in their studies. Therefore failure to
develop resistance in immunocompetent mice observed in this study can not be
attributed to strain variations in host responses to therapy.
This study highlights the importance of the role played by host immunity in the
chemotherapy of parasitic infections. It shows that immunosuppression of the host
considerably reduces the efficacy of antitrypanosomal drugs and can lead to rapid
development of high levels of drug resistance.
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Previously the part played by the host in the development of drug resistance was not
recognised (Doenhoff et al., 1991). It was thought that the host provided a passive
medium in which trypanosomes and drugs interacted without interference.
Innovations of methods to immunocompromise the host prior to infection such as
splenectomy (Jansco and Jansco, 1935) led to increased understanding of this
concept. This method was found to reduce the efficacy of suramin, and led to rapid
development of suramin resistance in experimentally immunosuppressed animals.
The rapid development of drug resistance in immunosuppressed hosts has serious
implications in trypanosomosis as this disease is known to adversely affect the host
immune system. Besides, in endemic areas animals at risk of trypanosomosis are
often found with other protozoan infections such as babesiosis and toxoplasmosis.
These may induce various degrees of immunosuppression in affected hosts. Besides
infection with immunosuppressive pathogens, other forms of stress including
intercurrent infections with helminths (Fakae and Chiejina, 1993), poor nutrition, or
even pregnancy may constitute indirect ways by which the natural resistance of
trypanosome-infected animals is compromised. Results from this study suggest that
such situations would encourage the development and spread of drug resistant
trypanosomes.
The immune dependence of chemotherapy is known to occur in a variety of other
parasitic and microbial infections in both man and animals (see Doenhoff et al.
1991). Early experimental evidence of the inter-relationship between drugs and
immunity were observed in chicken malaria in which it was found that acquired
immunity played a key role in achievement of cure with quinine treatment. Similar
observations in S. mansoni showed that several drugs killed fewer adult worms in
immunosuppressed mice (Sabah et al., 1985). The efficacy of antimony,
oxamniquine and praziquantel was found to be increased by concurrent passive
transfer of immune serum with administration of drug. Similarly, the efficacy of
antileishmanial drug, sodium stibogluconate, against L. donovani infections have
been shown to be considerably reduced in immunosuppressed mice (Iwobi et al.
1991).
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Among the drugs used against animal trypanosomosis the efficacy of quinapyramine
has been reported to depend on a fully functional host immunity (Sen et al., 1955).
The prophylactic properties of homidium bromide are thought to be dependent on the
stimulation of the host immune mechanisms after initial clearance of infection by the
drug (Gilbert and Newton, 1982). In human trypanosomosis the efficacy of mel B
treatment in mice has been shown to be reduced by immunosuppression (Frommel
1988), and the efficacy of difluoromethyl ornithine (DFMO) has also been shown to
depend on the supporting role of antibodies (De Gee et al., 1983).
Results from this study suggest that a population of trypanosomes naturally resistant
to the selection dose of mel Cy was not originally present in the unselected isolate.
These may have been formed during the induction experiment by adaptation and
subsequent selection. Similar findings were made by Pospichal et al. (1994). These
authors further confirmed this hypothesis by demonstrating that an intermediate
population of T. brucei obtained during induction showed intermediate sensitivity
between the original unselected clone and the drug resistant clone.
The results of in vitro drug sensitivity assays for mel Cy agreed well with the in vivo
sensitivity tests. For example the 2-fold decrease in minimum curative (MCDioo) in
the culture adapted WTAX parasites was reflected in a 1.7-fold decrease in IC50
values in vitro.
The variability of IC50 for mel Cy between the drug resistant lines indicates that they
were at different levels of resistance in vivo. This show the limitation of in vivo
methods in detecting higher levels of resistance. In this case responses could not be
measured beyond 40 mg/kg mel Cy due to the toxicity of this drug in mice beyond
this dose.
The mel Cy resistance induced in immunosuppressed mice and in culture both
appeared stable after a single passage in immuncompetent mice. However, after
several passages in the absence of drug pressure it was found that the resistance
developed in vivo was not stable. It is possible that with further passages in mice in
the absence of drug resistance may be ultimately lost. This finding differs from some
other observations on the stability of resistance to mel Cy. Osman et al., (1992)
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reported that resistance to mel Cy induced in T. evansi using irradiated mice was
stable after a single passage through immunocompetent mice. This is in agreement
with the finding in this study. Scott et al. (1996) however, found that passaging of
two mel Cy resistant T. brucei lines after removal of drug pressure had no detectable
effect on levels of drug resistance. Those mel Cy resistant lines were also
successfully transmitted through Glossina, undergoing complete cyclical
development with no loss in levels of resistance. Stability of mel Cy induced
resistance after cyclical transmission through tsetse has also been reported by
Pospichal et al. (1994).
In contrast the mel Cy resistance induced in vitro in this study was found to be stable.
This shows that the two induction systems selected for different resistance
phenotypes, one exhibiting stable resistance and the other unstable. Reports from
field workers suggest that drug resistance may or may not be stable (Harinasuta and
Bunnag, 1988). It is thought that back mutations occurring after withdrawal of drug
could result to reduction or loss of resistance (Harinasuta and Bunnag, 1988).
Cross resistance between mel Cy and mel B observed in this study is expected since
both compounds are trivalent melaminophenyl arsenicals. Other workers have also
reported cross resistance between melaminophenyl arsenicals. Fairlamb et al.
(1992a) reported high levels of cross resistance between sodium melarsen, a
pentavalent melaminophenyl arsenical and the trivalent arsenicals, melarsen oxide,
melarsoprol and trimelarsen, in T. brucei. However, no cross resistance was
expressed to phenylarsine oxide which lacks the melamine ring. Similarly 14-fold
reduction in sensitivity to mel B in mel Cy resistant T. brucei was demonstrated by
Pospichal et al. (1994). Ross and Bams (1996) showed cross resistance between mel
Cy and mel B in T. evansi.
Cross resistance between melaminophenyl arsenicals suggests common mechanisms
of uptake. It has been proposed that melaminophenyl arsenicals are taken up by
trypanosomes via a common purine transporter. This transporter was found to be
altered in an arsenical-resistant line of T. brucei (Carter and Fairlamb, 1993). It
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would be interesting to determine if the resistant lines produced in the present study
also possess altered purine transport systems.
High levels of cross- resistance to Berenil® were also observed in mel Cy resistant
lines produced in this study. Cross resistance between diamidines and
melaminophenyl arsenicals have been observed previously by a number of workers:
High levels of cross resistance to diminazene aceturate and pentamidine in vivo in
mel Cy resistant T. evansi was reported by Osman, et al. (1992). Fairlamb et al.
(1992a) reported varying degrees of cross resistance to stilbamidine (38-fold),
3erenil® (31.5-fold), propamidine (5.7-fold) and pentamidine (1.5-fold), in T. brucei
selected using a pentavalent melaminophenyl arsenical, sodium melarsen. Pospichal
et al. (1994) also found cross resistance to 2 diamidines: diminazene aceturate (47-
fold) and pentamidine methanosulphonate (34-fold), in T. evansi made resistant to
mel Cy. Ross and Barns (1996) also reported cross resistance between mel Cy and
Berenil . Frommel and Balber (1987) selected drug resistant clones of T. brucei
• • . (R)
using melarsoprol (mel B) and found that these were cross resistant to Berenil .
Zhang et al. (1993) reported the induction of resistance to mel Cy in T. evansi which
became cross resistant to both Berenil® and pentamidine. These authors found that
• • (R) •
the sensitivity of Berenil -resistant clones to mel Cy varied: Two T. evansi clones
(Si •
and one T. equiperdum clone which were Berenil resistant remained very sensitive
to mel Cy. In contrast another Berenil®-resistant T. evansi clone became at least 128-
fold more resistant to mel Cy than its parental clone. It was suggested that Berenil®-
resistant clones displayed two different types of resistance: a single drug resistance
demonstrated by clones which remained sensitive to mel Cy, and cross resistance ,
illustrated by the clone which showed cross resistance to mel Cy.
This study show that mel Cy-resistant T. evansi possess only one type of resistance
mechanism which displays cross resistance to the diamidines.
It is suggested that resistance to arsenical drugs and the diamidines is based on
altered drug transport (Bacchi, 1993). Carter and Fairlamb (1993) suggested that the
melaminophenyl arsenicals as well as the diamidines are taken up on a common
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transporter. The common feature of recognition is thought to reside in the melamine
and benzamidine moieties, respectively (Fairlamb et al. (1992b).
Cross resistance between melaminophenyl arsenicals and quinapyramine is not
common. There are conflicting reports on the occurrence of cross resistance between
this group of arsenicals and quinapyramine. Ross and Barns (1996) found that
induction of resistance to mel Cy in a T. evansi strain in vitro did not result to
increased resistance to quinapyramine. Posnichal et al. (1994), on the other hand
reported high level of cross resistance (40-fold) to quinapyramine in procyclic forms
of T. brucei with low resistance to mel Cy. Zhang et al. (1993), found clones of T.
evansi selected for resistance to mel Cy, Berenil® and suramin to be more sensitive to
quinapyramine in vivo than the parent clone.
No cross resistance between mel Cy and suramin was found in this study in
agreement with previous reports (Zhang et al. 1993; Pospichal et al. 1994; Ross and
Barns 1996). Cross resistance between arsenicals and suramin have not been found
in field isolates (Ross and Barns, 1996). Fairlamb et al. (1992a) reported a low level
of cross resistance (5.8 -fold) to suramin in melarsen-resistant T. brucei. Very little
is known about resistance mechanisms to suramin as this drug is known to have
several drug targets in the parasite.
It was found in this study that moderate to high increases in sensitivity to
trypanocides occurred when T. evansi TREU 1840 was adapted to in vitro growth. It
is likely that adaptation to in vitro culture resulted to some modification of the
sensitivities of this isolate especially to quinapyramine and suramin, resulting to
increased sensitivity to the two drugs. This observation differs from that of Brown et
al. (1987) who found that adaptation of T. congolense stocks to in vitro culture did
not change their sensitivities to isometamidium.
The results of the in vitro drug sensitivity assays with mel Cy were found to correlate
well with the in vivo drug sensitivity tests. This shows that this in vitro assay is




ARSENICAL-INDUCED IN VITRO LYSIS OF DRUG-SENSITIVE AND
DRUG-RESISTANT TRYPANOSOMA EVANSI
5.1. INTRODUCTION
Bloodstream forms of trypanosomes are known to be extremely sensitive to trivalent
aromatic arsenicals. Upon exposure to drug in vitro the parasites rapidly lose
motility and undergo lysis (Clarkson and Amole, 1982; Fairlamb et al., 1989). Loss
of motility was attributed to inhibition of critical enzymes of glycolysis. Arsenicals
inhibit fructose-6-phosphate 2-kinase, an enzyme that produces the glycolytic
intermediate, fructose-2, 6-bisphosphate. Fructose-2, 6-bisphosphate is a specific
activator of pyruvate kinase in the strictly glycolytic long slender trypanosome. This
slows down glycolysis and significantly reduces ATP production (Van Schaftingen et
al., 1987).
It is suggested that a unique dithiol-containing dipeptide, dihydrotrypanothione (N1.
o
N -bis (gluthathionyl) spermidine) is a primary target for arsenical drugs. The
arsenic moiety of the arsenicals is thought to combine rapidly within the cell with the
-SH groups on trypanothione to form a stable arsenical-trypanothione complex, Mel
T. Mel T secondarily acts as a competitive inhibitor of trypanothione reductase, a
flavoprotein disulphide oxidoreductase (Fairlamb, et at., 1989). Trypanothione
reductase together with dihydrotrypanothione is essential for the regulation of the
correct intracellular redox balance. These protect trypanosomes from oxidant
damage (Fairlamb et al., 1992b). Fairlamb et al. (1992b) showed that trivalent
arsenicals irreversibly inhibit trypanothione reductase in vitro. The depletion of free
trypanothione and the blockage in the recycling of oxidized trypanothione lead to
increased oxidant stress. This is partially responsible for trypanosome lysis caused
by arsenicals (Fairlamb, et al., 1989; Yarlett et al., 1991).
Studies on the mechanisms of resistance to arsenical drugs (Fairlamb et al., 1992b)
have shown that resistance is not due to overproduction of the primary or secondary
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drug targets. Other studies by Yarlett et al. (1991) on T. brucei failed to demonstrate
inactivation of drug as a mechanism of resistance. More recent studies (Damper and
Patton, 1976; Carter and Fairlamb. 1993; Ross and Barns, 1996), suggest that normal
trypanosomes concentrate trivalent arsenicals more efficiently than arsenical resistant
organisms. Toward investigation of decreased uptake as a mechanism of resistance
development it is necessary to establish the mode of uptake or entry of arsenical
drugs into trypanosomes.
Besides the need for methods for rapid assessment of arsenical susceptibility of
trypanosomes, in vitro lysis by arsenicals (Yarlett et al. (1991) can be utilised to
explore mechanisms of arsenical uptake into trypanosomes. Based on the
observation that melamine antagonises the trypanocidal activity of melaminophenyl
arsenicals, Carter and Fairlamb (1993) utilised the trypanolytic effect of melarsen
oxide, to determine other compounds that compete for the same receptor. This study
showed for the first time that melarsen oxide was taken up by an adenosine
transporter.
This study aims to investigate further the involvement of adenosine transport in the
uptake of melaminophenyl arsenicals, in T. evansi. This will be achieved by the
determination of the interaction between two arsenical drugs (mel Cy and mel B,)
and adenosine transport system in T. evansi, using an in vitro spectrophotometric
lysis assay. The specific aims considered in this chapter include the following:
1. To ascertain whether the arsenicals (mel Cy and mel B) cause lysis of T. evansi
similar to that observed with other arsenical drugs in related species or strains.
2. Determine to what extent in vitro lysis assay can differentiate between mel Cy-
sensitive and mel Cy-resistant trypanosomes.
3. Measure cross resistance between mel Cy and other melaminophenyl arsenicals
using in vitro lysis assay.
4. Identify which compounds inhibit lysis of T. evansi by mel Cy and mel B with a
view to establishing the mode of uptake into the parasite.
5. Compare the response to in vitro lysis of the in vivo-and in vitro-derived drug
resistant T. evansi.
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5.2. MATERIALS AND METHODS
5.2.1. Trypanosomes
Trypanosomes derived using both the in vivo and in vitro systems were used in this
study. The mouse-maintained lines include the drug sensitive isolate (WT) and its
drug resistant derivatives (CR2, CR3, CR3.1, CR9d, and CRnd). The CRga and CRud
were intermediate stabilates prepared from sub oassages of CR2 at 40 mg/kg mel Cy.
CRgd and CRud were passaged 9 and 11 times, respectively. Parasites were still
growing in the presence of the drug. The culture-adapted lines included the drug
sensitive isolate (WTAX) and its drug resistant derivative (MCR1.1).
5.2.2. Arsenical drugs
Two trivalent melaminophenyl arsenical drugs, mel Cy and mel B, were used in the
lysis experiments. Their sources have been described in the General Methods (see
section 3.3). Mel Cy was prepared and diluted to appropriate concentrations fresh in
distilled deionised water. This was used once on the day of the experiment. Mel B
was diluted in propylene glycol and stored in aliquots at 4°C for up to 4 weeks.
5.2.3. Other chemicals
(R)
Inhibitors including adenosine, adenine, inosine and Berenil were obtained and
stored as described in the General Methods (section 3.3). Stock concentrations of
adenosine, adenine and inosine were prepared by dissolving in 25 mM NaOH.
Dilutions were made in PSG and stored in aliquots of 0.5 ml at -20°C. These were
(g)thawed once and used on the day of the experiment. Diminazene (Berenil ) was
prepared fresh in double distilled water and also used once on the day of the
experiment. The amount of diminazene was calculated as 45% content of Berenil®.
5.2.4. Lysis assays
Trypanosomes either separated from mouse blood or harvested from culture
supernatant were washed by centrifugation at 1 OOOx g for 10 minutes. The pellet was
suspended in 1.5 ml of PSG in an Eppendorf tube, and washed two times by
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centrifugation at lOOx g for 6 minutes in a biofuge. The pellet was resuspended in
PSG at a density of 108 trypanosomes/ml. Trypanosomes separated from mouse
blood were kept on ice.
Nine hundred pi of lysis buffer (Carter's Balanced Salt Solution, CBSS, (Fairlamb et
al., 1992a), consisting of 25 mM Hepes/120 mM NaCl/5.4 mM KC1/0.55 mM
CaCl2/0.4 mM MgS(V5.6 mM Na2HP04/l 1.1 mM glucose, pH adjusted to 7.4 with
NaOH; were added to spectrophotometer cuvettes and kept at 37°C on a water bath.
Trypanosome suspensions were prewarmed to 37°C for 5 minutes. Aliquots of 100
;.'l cells, containing 107 trypanosomes were added to each incubating tube. Inhibitors
prepared at lOOx the required concentration in assay were added in 10 pi volumes.
Arsenical drugs were prepared at 50x final concentration in assay. 20 pi amount
were added at 20 seconds intervals to incubation mixture, at the start of the
experiment. Readings were taken at zero time (to) when the arsenical was added.
Thereafter lysis was measured at 5 minutes intervals in a spectrophotometer, for 30
minutes. As the trypanosomes were lysed by the arsenical there was decrease in
turbidity and more light was transmitted. Decrease in absorbance was recorded at a
wavelength of 750 qm in a spectrophotometer.
Control incubations consisting of trypanosomes in lysis buffer each received 20 pi of
solvent instead of arsenical drug. A second control consisting of trypanosomes plus
arsenical drug and no inhibitor was included in inhibition experiments. Each
experiment was repeated at least 2 separate times.
The effect of increasing concentrations of adenosine, adenine, inosine and Berenil®




5.3.1. In vitro lysis of mouse-adapted Trypanosoma evansi lines by mel Cy.
5.3.1.1. Drug sensitive trypanosomes
The lysis of drug sensitive T. evansi (WT) is shown in Figure 5.1a. Mel Cy caused
lysis of drug sensitive trypanosomes in a concentration and time dependent manner.
Little or no measurable lysis occurred at 0.1 pM mel Cy. Absorbance curves at this
dose were similar to control with no added drug. At 0.25 pM lysis was detectable
after 10 minutes incubation with the drug. Appreciable lysis occurred at 0.5 pM after
5 minutes incubation. Rapid lysis occurred at 1.0 pM mel Cy, but the 5 minutes
delay in onset was still maintained. Immediate and rapid lysis was observed at
concentrations of 2.5 pM and above.
5.3.1.2. In vivo-derived drug resistant trypanosomes
Lysis of the in v/vo-derived drug resistant trypanosome lines (CR2, CR3 and CR3.1)
are shown in Figures 5.1 b-d. There was variable degree of lysis in each of the drug
resistant population. All the three resistant lines were not lysed by 1.0 pM
concentration of mel Cy (Figure Id). This showed that there was a definite increase
in resistance. Partial lysis was observed with 10-50 pM mel Cy in all the resistant
lines (Figures lb, c and d). Partial lysis also varied between the different resistant
lines, being least in the CR2 and greatest in the CR3.1. The extent of this partial
lysis was comparable to the lysis at 0.25-0.5 pM in the drug sensitive line, and may
suggest a 100- fold increase in tolerance to the drug in vitro. More lysis occurred
between 100 and 500 pM mel Cy in these resistant lines. However, lysis was not




Figure 5.1: In vitro lysis of the mouse-maintained Trypanosoma evansi by increasing
concentrations of mel Cy. a, drug sensitive isolate (WT); b, c and d, in v/vo-derived
drug resistant lines (CR2, CR3, CR3.1). lxlO7 trypanosomes prewarmed to 37°C
were incubated in 1 ml of lysis buffer in spectrophotometer cuvettes. Varying
concentrations of mel Cy were added to each incubation mixture at the start of the
experiment. Absorbance due to presence of live trypanosomes was measured at time
zero (t0) when the arsenical was added. Thereafter lysis was measured at 5 minutes
intervals for 30 minutes. As the trypanosomes were lysed by the arsenical there was
decrease in turbidity and more light was transmitted. Decrease in absorbance was
recorded at a wavelength of 570 pm in a spectrophotometer. Control incubations
with trypanosomes and no arsenical were included in each experiment. Each
experiment was repeated at least 3 separate times and similar results were obtained.
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5.3.2. In vitro lysis of culture-adapted Trypanosoma evansi by mel Cy
5.3.2.1. Lysis ofdrug sensitive trypanosome cultures
Figure 5.2a shows lysis of culture-adapted, unselected T. evansi (WTAX) by mel Cy.
Lysis was largely similar to that observed in the mouse-maintained unselected line
(WT). However, slightly more lysis was observed at 0.25 and 0.5 pM concentrations
compared with the WT parasites. Although rapid lysis occurred at 1.0 pM lysis at
doses of 2.5 and 5.0 pM were less rapid compared to lysis at equivalent doses in the
WT.
5.3.2.2. Lysis of in vitro-derived drug resistant trypanosomes
Lysis of the in v/fro-derived drug resistant T. evansi (MCR1.1) is shown in Figure
5.2b. High resistance to in vitro lysis was shown by these parasites as opposed to the
in v/'vo-derived lines. Trypanosomes were not lysed by 50 pM mel Cy, representing
over 200-fold increase in resistance to mel Cy compared to WTAX. Partial lysis
occurred at 100 pM. Increased lysis at 250 pM was only similar to lysis at 0.25 pM
in the drug sensitive parasites, and lysis was not complete at 500 pM concentration.
5.3.3. Inhibition of mel Cy lysis in Trypanosoma evansi
5.3.3.1. Inhibition ofmel Cy lysis in mouse-adapted Trypanosoma evansi
Effect of inhibition of lysis by mel Cy of drug sensitive T. evansi maintained in mice
was investigated using purine compounds such as adenine, adenosine and inosine;




Figure 5.2: In vitro lysis of the culture-adapted Trypanosoma evansi by increasing
concentrations ofmel Cy. a, drug sensitive isolate (WTAX); b, in vitro-derived drug
resistant line (MCR1.1). lxlO7 trypanosomes prewarmed to 37°C were incubated in
1 ml of lysis buffer in spectrophotometer cuvettes. Varying concentrations (pM) of
mel Cy were added to each incubation mixture at the start of the experiment.
Absorbance due to presence of live trypanosomes was measured at time zero (to)
when the arsenical was added. Thereafter lysis was measured at 5 minutes intervals
for 30 minutes. As the trypanosomes were lysed by the arsenical there was decrease
in turbidity and more light was transmitted. Decrease in absorbance was recorded at a
wavelength of 750 pm in a spectrophotometer. Control incubations with
trypanosomes and no arsenical were included in each experiment. Each experiment




























5.33.1.1. Inhibition ofmel Cy lysis by adenosine
Lysis of the drug sensitive T. evansi (WT) by 1 pM mel Cy was inhibited in a
concentration and time dependent manner by adenosine (Figure 5.3a). Adenosine
concentrations in 1 and 2x excess (1 and 2 pM) of mel Cy had very little or no effect
on mel Cy lysis. However 5x excess (5 pM) concentration delayed lysis up to 10
minutes. Thereafter only about 50% lysis occurred compared to control incubations
with 1.0 pM mel Cy. Increased inhibition of lysis was observed at lOx excess
adenosine and lysis was delayed up to 15 minutes. At 50x excess (50 pM) adenosine
protected trypanosomes from mel Cy lysis up to 20 minutes, and less than 20% lysis
occurred. Maximum protection was obtained at lOOx excess (100 pM)
concentration. At this concentration lysis was delayed up to 20 minutes and over
90% protection was achieved.
5.3.3.1.2. Inhibition ofmel Cy lysis by adenine
Adenine inhibited lysis of T. evansi by mel Cy in a similar manner as adenosine
(Figure 5.3b). However adenine appeared to be more potent at inhibition compared
to adenosine. Some inhibition of lysis was observed even at 1 and 2x excess (1 and 2
pM) concentrations of adenine. Similarly increased protection was observed at 5 and
lOx excess (5 and 10 pM) concentrations of adenine. Lysis was delayed up to 15 and
20 minutes, respectively. At 50x excess (50 pM) lysis was delayed for 25 minutes
and approximately 95% protection was achieved. Complete inhibition of lysis was
observed at lOOx excess (100 pM) concentration of adenine and no lysis was
detected after 30 minutes incubation with the drug.
5.3.3.1.3. Lack ofinhibition ofmel Cy lysis by inosine
No measurable inhibition or delay of lysis by 1 pM mel Cy for 30 minutes was
observed with up to lOOx excess (100 pM) concentrations of inosine (Figure 5.3c).
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5.3.3.1.4. Inhibition ofmel Cy lysis by Berenil®
A dose-dependent inhibition of lysis by 1 pM mel Cy was observed with Berenil®,
similar to adenine and adenosine (Figure 5.3d). No inhibition of lysis was observed
• (It) ... •
with up to 2x excess (2 pM) Berenil , but inhibition occurred at 5x excess (5 pM)
concentration. Markedly enhanced inhibition (approximately 95%) was observed at
lOx excess (100 pM) concentration of Berenil®, compared to the same concentration
of adenine and adenosine. At 50x excess (50 pM) there was complete (100%)
inhibition of lysis.
5.3.3.2. Inhibition ofmel Cy lysis in culture-adapted trypanosomes by adenosine
Comparative studies on inhibition of lysis by mel Cy were done on the culture-
adapted T. evansi using adenosine. Similar to the mouse-maintained trypanosomes
adenosine inhibited lysis by 1 pM mel Cy in the WTAX trypanosomes in a dose-
dependent manner (Figure 5.4). Little inhibition occurred at lx excess concentration.
In these trypanosomes, 50x excess concentrations of adenosine conferred 100%
protection from lysis by 1 pM mel Cy.
5.3.4. In vitro lysis of mouse-maintained Trypanosoma evansi by mel B
5.3.4.1. Lysis ofdrug sensitive trypanosomes
Results of mel B lysis of the drug sensitive T. evansi maintained in mice (WT) are
shown in Figure 5.5a. Similar to mel Cy, mel B caused lysis of drug sensitive
trypanosomes in a concentration and time dependent manner. However, mel B
appeared to be less effective in lysing drug sensitive trypanosomes compared to mel
Cy. 10-15 pM concentrations of mel B caused little lysis, similar to lysis by 0.1-0.25
pM mel Cy in the same parasites. Rapid lysis occurred at 20 pM mel B. This was
equivalent to 0.5 pM mel Cy lysis. 50 pM mel B caused rapid lysis comparable to
1.0 pM mel Cy in these trypanosomes, being over 50 times excess of mel Cy. Lysis






Figure 5.4: Inhibition of mel Cy lysis in culture-adapted Trypanosoma evansi
(WTAX) by increasing concentrations of adenosine. lxlO7 trypanosomes separated
from mice blood were prewarmed to 37°C and incubated in 1 ml of lysis buffer, at
37°C. Adenosine was prepared at lOOx final concentrations in assay. 10 pi volumes
were added to incubating trypanosomes. Mel Cy (MC) prepared at 50 times final
concentration of 1 pM, was added in 20 pi volumes at the start of the experiment.
Absorbance was first measured at zero time (t0) when the arsenical was added.
Blocking of mel Cy lysis by adenosine was measured at 5 minutes intervals for 30
minutes. Absorbance was recorded at 570 r|m in a spectrophotometer. Two controls
were included in this experiment: one consisted of trypanosomes and no arsenical, and
the second of trypanosomes and mel B but no inhibitor (adenosine). The experiment
was repeated 2 separate times and similar results were obtained.
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5.3.4.2. Lysis of in vivo-derived drug resistant trypanosomes by me/ B.
Lysis of the in v/'vo-derived drug resistant trypanosomes (CR3.1) by mel B is shown
in Figure 5.5b. Contrary to observations with the drug sensitive line, mel B was very
efficient in lysing the drug resistant trypanosomes. No lysis was obtained at 10 pM
concentration and very little lysis occurred with 20 pM. Pronounced lysis was
observed at 50 pM mel B although lysis was delayed up to 10 minutes. Rapid lysis
occurred at 100 and 250 pM concentrations in these trypanosomes. This was
equivalent to lysis by 50 pM mel B in the drug sensitive parasites. A 5 minutes delay
in lysis was maintained even at high concentrations ofmel B.
5.3.5. In vitro lysis of culture-adapted Trypanosoma evansi by mel B
5.3.5.1. Lysis ofdrug sensitive trypanosomes
Lysis of the culture- adapted drug sensitive (WTAX) trypanosomes is shown in
Figure 5.6a. Similar to the mouse-maintained parasites, mel B was less effective in
lysing the cultured drug sensitive trypanosomes. No lysis was obtained in the
presence of 5 pM mel B. Flowever, more lysis was observed at 10 and 15 pM
compared to WT parasites. Rapid lysis occurred at 20 pM and above concentrations
of mel B. Lysis was complete at 40 pM mel B. There was delay in lysis for up to 5
minutes at concentrations of 10-20 pM, but immediate lysis was observed at 25 pM
and above concentrations ofmel B.
5.3.5.2. Lysis of in vitro-derived drug resistant trypanosomes by mel B
Lysis of the in vitro-derived drug resistant T. evansi (MCR1.1) is shown in Figure
5.6b. Little or no lysis was observed at 50 pM mel B. Some lysis occurred at 100
pM after 10 minutes delay. More lysis occurred at 250-500 pM. This represents a




















Figure 5.5: In vitro lysis of the mouse-maintained Trypanosoma evansi by increasing
concentrations of mel B. a, drug sensitive isolate (WT); b, in vz'vo-derived drug
resistant clone (CR3.1). lxlO7 trypanosomes were prewarmed and incubated in 1 ml
of lysis buffer, at 37°C. Mel B prepared at lOOx final concentrations in assay was
added in 20 pi amounts to each incubation mixture at the start of the experiment.
Absorbance due to presence of trypanosomes was measured at time zero (t0) when
the arsenical was added. Lysis represented by decrease in absorbance was measured
at 5 minutes intervals for 30 minutes, at 750 pm, in a spectrophotometer. Control
incubations with trypanosomes and no arsenical were included in each experiment.
Each experiment was repeated at least 3 separate times and similar results were
obtained. Doses are in pM mel B.
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Figure 5.6: In vitro lysis of the culture-adapted Trypanosoma evansi by increasing
concentrations of mel B. a, drug sensitive isolate (WTAX); b, in vitro-derived drug
resistant clone (MCR1.1). lxlO7 trypanosomes from cultures were prewarmed and
incubated in 1 ml of lysis buffer at 37°C. Mel B prepared at lOOx final concentrations
in assay was added in 20 pi amounts to each incubation mixture, at the start of the
experiment. Absorbance due to presence of trypanosomes was measured at time zero
(t0) when the arsenical was added. Lysis represented by decrease in absorbance was
measured at 5 minutes intervals for 30 minutes, at 750 pm in a spectrophotometer.
Control incubations with trypanosomes and no arsenical were included in each
experiment. Experiments were repeated at least 3 separate times and similar results
were obtained. Doses are in pM mel B.
123
Chapterfive: Arsenical-induced lysis
5.3.6. Inhibition of mel B lysis in the mouse-maintained Trypanosoma evansi
5.3.6.1. Lack of inhibition ofmel B lysis by adenosine and adenine
No inhibition of lysis by 20 pM mel B was observed with the addition of up to lOOx
excess concentrations of either adenosine or adenine (Figure 5.7 a, b). This was in
contrast to the observation on inhibition of mel Cy lysis by these compounds in the
same parasites.
5.3.6.2. Lack of inhibition ofmel B lysis by inosine.
Similar to observations on mel Cy lysis, no inhibition of lysis by 20 pM mel B was
observed with up to lOOx excess concentrations of inosine (Figure 5.7c).
5.3.6.3. Inhibition ofmel B lysis by Berenif
Results of inhibition of mel B lysis of WT trypanosomes by Berenil® are shown in
Figure 5.7d. Concentration dependent inhibition of lysis was observed . No
inhibition was observed at lx excess (20 pM) concentration of Berenil , but
pronounced inhibition occurred at 5 and lOx excess (100 and 200 pM). At 50x
excess (1000 pM) Berenil®, over 90% protection from lysis was observed. lOOx
excess (2000 pM) concentration of Berenil® completely inhibited lysis by 20 pM mel
B.
5.3.7. Inhibition of mel B lysis of culture adapted Trypanosoma evansi
5.3.7.1. Lack of inhibition ofmel B lysis by adenosine and adenine
Similar to the observations on the mouse-maintained T. evansi there was no
inhibition of lysis by 20 pM mel B in the culture-adapted trypanosomes up to 1 OOx
excess (2000 pM) concentrations of either adenosine or adenine (Figures 5.8 a & b).
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5.3.7.2. Lack of inhibition ofmel B lysis by inosine
No inhibition of lysis by 20 pM mel B was observed with up to lOOx excess (2000
pM) concentrations of inosine (Figure 5.8c), similar to observations on mel Cy.
5.3.7.3. Inhibition ofmel B lysis by Berenil®
Berenil® inhibited lysis by 20 pM mel B in the culture-adapted trypanosomes, in a
dose-dependent manner (Figure 5.8d). Approximately 90% protection was achieved
with 50x excess concentrations of Berenil®. At lOOx excess there was complete
inhibition of lysis. Intermediate inhibitions were observed at lOx excess Berenil®.
(1?)
lx excess Berenil did not inhibit lysis.
5.3.8. Stability of mel Cy- induced drug resistance using in vitro lysis assay
5.3.8.1 Lysis ofdrug resistant trypanosomes growing in the presence ofdrug
Lysis of the intermediate stages of drug resistant trypanosomes growing in the
presence of the maximum selective dose of mel Cy in mice is shown in Figures 5.9a
and b. The CRgd trypanosomes passaged 9 times in the presence of drug were not
lysed by 10 pM mel Cy (Figure 5.9a). The CRud passaged 11 times, while still in the
presence of drug, were not lysed by 20 pM mel Cy. At concentrations of 50-100 pM
mel Cy lysis was delayed for 25 minutes. Rapid lysis of these parasites occurred at
250 pM mel Cy. This shows a high increase in tolerance to mel Cy by trypanosomes
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Figure 5.9: Lysis of in vz'vo-derived drug resistant Trypanosoma evansi growing in
the presence of selective concentrations of mel Cy. Trypanosomes selected with 40
mg/kg mel Cy were passaged, a, 9 times (CR9a); and, b, 11 times (CRnd) in the
presence of 40 mg/kg mel Cy. Lysis assays were carried out before withdrawal of




5.3.8.2. Lysis of in vitro-derived drug resistant Trypanosoma evansi growing in
the absence ofdrug by meI Cy.
In vzYro-derived resistant trypanosomes growing in the absence of drug for up to 4
weeks were tested for lysis by mel Cy at different time points after withdrawal of
drug. The results are shown in Figures 5.10a-c. At 12, 19 and 26 days following
withdrawal of drug trypanosomes were not lysed by 50 pM mel Cy. Little lysis
occurred at 100 pM and rapid lysis was only observed at 250-500 pM mel Cy. These
observations were similar to those on the main stabilate before drug was withdrawn
for the stipulated periods of time (see Figure 5.2b).
A summary of experiments and the characteristics of the different T. evansi lines






















Figure 5.10: Lysis of in vitro-derived drug resistant Trypanosoma evansi (MCR1.1)
by mel Cy after cultivation in the absence of drug for a, 12 days, b, 19 days and, c, 26
days. After completion of induction in vitro drug was withdrawn from resistant
cultures and lysis assays using mel Cy were carried out at the specified number of
days. Lysis assays were carried out as described above. No reductions in resistance
were observed. Doses ofmel Cy are in pM.
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5.4 DISCUSSION
To investigate the mode of uptake of melaminophenyl arsenical drugs into T. evansi
the susceptibility of these parasites to in vitro lysis by mel Cy and mel B was studied.
Competition for uptake on the same transporter by different purine compounds, as
well as diamidines was also investigated.
The results show that mel Cy and mel B caused lysis of drug sensitive and drug
resistant T. evansi to different extents. The partial lysis of drug resistant
trypanosomes at low concentrations of drug observed in this study has been
previously reported: Scott et al. (1997) measured lysis of mel Cy-selected T. hrucei
by 4 different arsenical drugs, mel Cy, mel Ox (melarsen oxide), mel B and phenyl
arsenoxide. The authors similarly found that arsenical resistance was expressed to all
the four arsenicals to different extents. Concentrations of mel Ox up to 100 pM had
no noticeable effect on the mel Cy resistant isolate (247MelCyR). However, mel Cy
caused partial lysis at 50 pM concentration, similar to our findings. More lysis
occurred at 500-1000 pM mel Cy, but lysis was neither rapid nor complete at these
high concentrations, similar to results presented here.
Other authors have reported higher doses for lysis of drug resistant trypanosomes by
arsenicals. Yarlett et al. (1991) found that arsenical resistant T. rhodesiense isolates
required up to 37-fold higher concentrations of melarsen oxide to cause lysis within
30 minutes. The trypanosome strain isolated from patients who relapsed after several
courses of mel B treatment required at least 18-fold greater concentrations of
melarsen oxide to cause lysis, compared to the susceptible strains. Fairlamb et al.
(1992b) found that melarsen-resistant T. brucei was completely unaffected by
melarsen oxide concentrations up to 100 pM, indicating a 200-fold resistance
compared to the drug sensitive population.
The pattern of lysis by mel Cy in the drug resistant trypanosomes derived in this
study indicates that these parasites still maintained some level of sensitivity to mel
Cy in vitro. The differences between the resistant and sensitive populations only lay
in the concentration and time of exposure to drug. This may suggest that the resistant
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trypanosomes concentrate the arsenical but at a slower rate compared to the drug
sensitive parasites.
The in vitro -derived drug resistant line (MCR1.1) showed higher resistance to lysis
by mel Cy compared to the mouse-derived resistant lines. The in vitro system may
thus represent a more efficient method of selection of drug resistant trypanosomes. It
was also observed (see Chapter 4) that the in vitro-derived resistance was more stable
in the absence of drug than the in v/vo-derived resistance. The differences in
susceptibility to in vitro lysis between these resistant lines may be a result of the
differences in stability of resistance in the two populations.
The inhibition of mel Cy lysis by adenosine and adenine indicate that these
compounds compete with mel Cy for the same transporter, suggesting a common
mode of uptake. This is in agreement with the findings of Carter and Fairlamb
(1993) on T. brucei using melarsen oxide. Similar inhibitions of arsenical lysis by
adenine and adenosine were reported by Scott et al. (1997), and Ross and Bams
(1996).
The dose dependent and saturable inhibition of mel Cy lysis by Berenil® means that
• (E)
inhibition was competitive. This suggests that Berenil and mel Cy interact with a
common transporter. This agrees with previous reports on melaminophenyl arsenical
drugs and the diamidines (Carter and Fairlamb, 1993; Scott et al., 1997; Ross and
Barns. 1996).
The existence of a common transport mechanism has been suggested as an
explanation for cross resistance between melaminophenyl arsenicals and diamidines
in T. brucei (Carter and Fairlamb, 1993) and T. equiperdum (Barrett et al., 1995).
The benzamidine rings in the diamidines and the melamine ring ::: the
melaminophenyl arsenicals have been proposed as similar structures that are
recognised by the transporter (Fairlamb et al., 1992b).
That transport of melaminophenyl arsenicals takes place by a specific selective
mechanism was demonstrated using a lipid soluble trivalent arsenical, phenyl
arsenoxide, which lacks the melamine ring (Carter and Fairlamb, 1993). Lysis of T.
brucei by phenyl arsenoxide was not inhibited by lOOx excess concentrations of
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adenine, adenosine or dipyridamole, in vitro, suggesting that this compound did not
enter trypanosomes via purine transport system. It is thought that due to its lipid
solubility phenyl arsenoxide diffuses passively across the lipid membrane of
trypanosomes without requiring a specific transporter. This may explain why it is not
inhibited by purine transport inhibitors.
The uptake of another melaminophenyl arsenical, mel B was also investigated in this
study. It was observed that mel B was less effective in causing lysis of the drug
sensitive trypanosomes. On the other hand it was very potent in lysing drug resistant
trypanosomes. Similar observations on mel B lysis have been reported by Yarlett et
al. (1991) and Scott et al. (1997). Yarlett, et al. (1991) found that in susceptible
isolates of T. rhodesiense amount of drug causing 50% lysis (L50) was higher for mel
B compared to melarsen oxide. In contrast, in arsenical resistant isolates lower L50
were consistently observed for mel B over melarsen oxide. These resistant parasites
required 17-37 fold higher concentrations of melarsen oxide but 3-10 fold
concentrations of mel B to cause lysis within 30 minutes. Scott et al. (1997) also
found that approximately 25-fold higher concentrations of mel B was required to
bring about lysis similar to that observed at 1 pM mel Cy in drug sensitive T. brucei.
On the contrary mel B was the most effective of three melaminophenyl arsenicals at
lysing drug resistant parasites, with partial lysis occurring at 50 pM, similar to our
results.
This study showed that mel Cy is a more potent trypanocide in vitro compared to mel
B.
Absence of competitive inhibition of mel B lysis by adenosine, adenine and inosine
suggests that mel B, though a melaminophenyl arsenical, may not be transported into
trypanosomes via an adenosine transport system.
It is interesting that Berenil® inhibited lysis by both mel Cy and mel B, since lysis by
mel Cy was inhibited by adenine and adenosine and lysis by mel B was not. It means
there is a common transport system between Berenil® (diamidine) and the two
melaminophenyl arsenicals. If this is the case then it also means that
melaminophenyl arsenicals have more than one mechanisms of uptake into drug
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sensitive trypanosomes. One of these must be an adenosine transport system which
mediates the transport of mel Cy and other melaminophenyl arsenicals such as
melarsen oxide, but not mel B. Berenil transport into trypanosomes may also
involve more than one transporter: an adenosine transporter shared with mel Cy, and
an alternative unidentified transport mechanism shared with mel B. Alternatively it
may be associated with a non- adenosine transport system which is shared by both
mel Cy and mel B.
Scott et al. (1997) also found that mel B induced lysis was not blocked by adenine
and adenosine but it was blocked by Berenil® and pentamidine. These authors found
that Berenil® and pentamidine inhibited lysis by two other melaminophenyl
arsenicals, mel Ox and mel Cy. He also considered the possibility of a non-
adenosine transporter for these compounds.
The results presented here argue against the suggestion of one transporter for the
uptake of all melaminophenyl arsenicals. It is possible that there are some
unidentified alternative routes of uptake of some melaminophenyl arsenicals such as
mel B into trypanosomes. It is possible that the lipid soluble mel B diffuses passively
into the trypanosome as an alternative pathway. However the fact that lysis by mel B
was inhibited in a clear dose dependent manner by Berenil but not by adenine or
adenosine, show that a more specific selective mechanism of uptake is involved.
This study suggests that an alternative non-adenosine transporter which has not yet
been identified may mediate for uptake of some melaminophenyl arsenicals into
trypanosomes, in addition to the P2 adenosine transporter.
Based on concentration of arsenical required to cause lysis it was possible to
differentiate the drug sensitive from the drug resistant trypanosomes using the in
vitro lysis assay. This assay was also able to demonstrate the cross resistance
between mel Cy and mel B detected using in vitro growth inhibition assays. The
assay further confirmed the differences in stability of resistance between drug
resistant lines developed in vivo and in vitro. These all show that the simple lysis
assay is a suitable test for identification of arsenical resistant trypanosome.
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The observations on the lysis of trypanosomes by both mel Cy and mel B and the
inhibitions of lysis by the two arsenicals was broadly similar in both the in vivo-
derived and the in v/fro-derived trypanosome lines. This again shows that in vitro
systems can be conveniently used as substitute for animal models in studies of
mechanisms of drug resistance.
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CHAPTER SIX
STUDIES ON ADENOSINE UPTAKE IN DRUG SENSITIVE AND
DRUG RESISTANT TRYPANOSOMA EVANSI
6.1. INTRODUCTION
Purine and pyrimidine nucleotides function as precursors of nucleic acid (DNA and
RNA synthesis), carriers of high-energy phosphate bonds, modulators of enzyme
activities and constituents of certain co-enzymes, besides their involvement in sugar
and energy transfer reactions (Hammond and Gutteridge, 1984). Many mammalian
cells possess two pathways for the synthesis of purine nucleotides. The most
common is the de novo pathway. This produces inosine monophosphate (IMP) from
simple precursors such as glycine and formate. Some other mammalian cells rely on
salvage of preformed purine bases and nucleosides present in the circulatory system
(Hammond and Gutteridge, 1984).
Studies on several parasites, e.g. Trichomonas foetus, T. vaginalis, (Wang, et al.,
1983), Plasmodium species (Hensen et al., 1980), Trypanosoma brucei, T.
congolense (James and Born, 1980), T. rhodesiense (Sanchez et al., 1976), and
Leishmania promastigotes (Aronow et al, 1987; Ogbunude et al., 1991; Baer et al.,
1992) show that protozoans in general are unable to synthesise their own purines (de
novo synthesis). They therefore rely on salvage pathways to utilise purines from the
host fluids.
The purine ring is commonly found and available to the parasite as nucleosides,
nucleobases, as charged nucleotides, or as polymers in nucleic acids. Investigations
on the acquisition and metabolism of the purine ring by trypanosomatids have
demonstrated that these pathways are distinct from those used by mammals
(Hammond and Gutteridge, 1984; Cohn and Gottlieb, 1997). Presently, knowledge
of the biochemical pathways as well as enzymes involved in purine metabolism in
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trypanosomatids is leading to the development of trypanocidal drugs based on
substrate analogs (Craig and Eakin, 1997).
The acquisition of the purine ring begins with the transport of purine nucleosides and
nucleobases across the plasma membrane. Besides being permeable to these
substrates purines and purine derivatives are absorbed into parasites by specific
mediated transport processes (Henson et al., 1980; Aronow et al., 1987). Transport
of purines across parasites's plasma membrane also presents a promising target for
the control of diseases caused by members of Trypanosomatidae (Cohn and Gottlieb,
1997).
To date no purine transporter per se has been isolated from any trpanosomatid (Cohn
and Gottlieb, 1997). However, studies on transport of nucleosides in several species
of protozoa (Manjra and Dusanic, 1973; Kidder et al., 1978; James and Born, 1980;
Henson et al., 1980; Wang et al., 1983; Ogbunude et al., 1991; Baer et al, 1992),
suggest that there is considerable variation in the expression of purine transport
systems in these parasites. L. donovani, for example was shown to possess two
transporters with preferential ability to transport adenosine and inosine (Aronow et
al., 1987). Similar studies on T. brucei and T. congolense (James and Born, 1980)
showed that adenosine was the most important purine for these parasites.
Adenosine transport has recently been implicated in the mechanism of resistance to
arsenical drugs (Carter and Fairlamb, 1993). This study showed that melarsen-
sensitive T. brucei have two high affinity adenosine transport systems. A PI type
which also transports inosine, and a P2 type which also transports adenine and
melaminophenyl arsenicals. A melarsen-resistant clone of T. brucei was found to
have lacked P2 transport suggesting that resistance to these arsenicals was due to loss
of uptake. Investigations on the mode of uptake of arsenical drugs using mel Cy and
mel B in this study (see Chapter 5) indicate that melaminophenyl arsenicals may have
more than one mechanism of uptake into trypanosomes.
The study presented in this chapter was an attempt to further explore into the
mechanisms of adenosine uptake in drug sensitive T. evansi, using adenosine uptake
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inhibition. The study also evaluates how these transport functions are altered in drug
resistant populations. The specific aims include the following:
1. To investigate the specific uptake pathways by which adenosine is taken up into T.
evansi in comparison with other related species of trypanosomes.
2. To assess the extent to which alternative substrates affect the uptake of adenosine
on these transporters.
3. To investigate the basis of cross resistance between diamidines and
melaminophenyl arsenicals observed in this and other reported studies.
6.2. MA TERIALS AND METHODS
6.2.1. Trypanosomes
Studies were carried out using trypanosomes maintained in mice (WT, CR3, CR3.1)
as well as those cultivated in vitro (WTAX, MCR and MCR1.1).
Cryopreserved blood stabilates ofmice-maintained trypanosome lines were grown in
two mice for use in each experiment. Trypanosomes at high parasitaemia
(approximately 4xl08/ml) were separated from mice blood by anion exchange
chromatography, as described in the General Methods. In vzYro-maintained
trypanosomes were harvested from healthy growing cultures in logarithmic phase of
growth.
Trypanosomes obtained from either mice isolations or culture suspensions were
washed in PSG (pH 8.0) by centrifugation at lOOOx g for 10 minutes. The pellet was
resuspended twice in 1.5 ml of PSG in sterile Eppendorf tube, and centrifuged at
lOOx g for 6 minutes each time, using a biofuge. The trypanosomes were finally
resuspended in 1 ml of uptake juffer (CBSS, pH 7.4, Fairlamb, et al., 1992a)
containing 1% bovine serum albumin (BSA). A 1:50 dilution of the trypanosome
suspension was counted using a Neubauer haemocytometer, and density of cells
adjusted to 1.25x10 /ml using uptake buffer.
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6.2.2. Uptake assays
Tritiated adenosine was prepared by diluting 5 pi to each 1 ml of 5 pM
nonradiolabelled (cold) adenosine. Aliquots of 80 pi of prewarmed cells containing
107 trypanosomes in uptake buffer were added to each incubation tube. Inhibitors
consisting of adenine, inosine, deoxyadenosine or Berenil® were prepared at 50x the
required concentration in assay, and 2 pi volumes were added to incubation mixture.
Uptake was initiated by the addition of 5 pM tritiated adenosine (final concentration
in assay was 1 pM; specific activity 2.5 mC; mmof') to each incubation tube at 20
seconds intervals. Reaction mixtures were incubated for 5 minutes at 37°C.
At the end of incubation 100 pi of ice cold 1 mM nonradiolabelled adenosine
solution in PBS (Stop Solution) was added to incubation medium. The whole
mixture was transferred quickly to an Eppendorf filtration unit containing 0.45 pm
cellulose acetate filter (COSTAR). Filtration tubes were centrifuged at maximum
speed (lOOx g) for 40 seconds in a biofuge. The filters were rinsed with 0.5 ml of
Stop Solution and centrifuged at lOOx g for 1 minute. The top of the Eppendorf tube
was snipped off using a pair of scissors. The filter holder was removed and the top
part snipped off using a "micro tube cutter". The lower piece containing the filter
membrane was transferred to a scintillation vial and dried in an oven at 50°C,
overnight (or at 100°C for 1.5 hours). One ml of scintillation fluid (PACKARD,
UK) was added to each scintillation vial, the cap screwed tight and the amount of
radioactivity incorporated read in a scintillation counter.
The amount of adenosine uptake was calculated from values of incorporated
radioactivity (counts per minute, CPM) and expressed as pmoles/10 trypanosomes.
Control incubations consisting of trypanosomes and tritiated adenosine with no
inhibitor added were included in every experiment. Also blanks consisting of uptake
buffer and Tritiated adenosine with no trypanosomes were included to estimate for
non-specific binding of radioactivity. Duplicate tubes were used for each assay.
Experiments were repeated 2-4 times. The average of the readings of the blank
incubations were deducted from each experimental data.
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The amount of adenosine uptake in control incubations consisting of trypanosomes in
the absence of inhibitor represented total (100%) uptake. The amount of inhibition
of adenosine uptake in the presence of each inhibitor was calculated as percentage of
control.
The effects of inhibition of adenosine uptake by 1 mM adenine, 1 mM inosine or 100
pM Berenil® were measured as single inhibitors or in combination with one or the
other inhibitor, in both the drug sensitive and drug resistant populations. The effect
of increasing concentrations of the different inhibitors on uptake of 1 pM adenosine
in the presence of either adenine or inosine were also measured. Concentrations
ranged from 0.01-1000 pM. Both drug sensitive and drug resistant trypanosomes
were characterised.
6.3. RESULTS
6.3.1. Inhibition of adenosine uptake in Trypanosoma evansi maintained in
mice
6.3.1.1. Drug sensitive line
The results of inhibition of adenosine uptake in the mouse-maintained unselected T.
evansi clone (WT) using 1 mM adenine, 1 mM inosine and 100 pM Berenil®, either
singly or in combination are shown in Figure 6.1.
Inosine, adenine and Berenil® all inhibited uptake of adenosine to variable extents.
Inosine caused 23.2± 2.9% inhibition of total uptake at 1 mM concentration, gi.ing a
residual uptake of 76.8%. One mM concentration of adenine caused 53.6±3.8%
inhibition, giving a residual uptake of 46.4%. Taken together both inosine and
adenine inhibited a total of 76.9% (range 66.1-100.4%) of total adenosine uptake in
these parasites. However in the presence of a combination of both 1 mM adenine
and 1 mM inosine uptake of 1 pM adenosine was completely inhibited (99.0±0.3%).
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also mediating the transport of inosine and the other adenine, similar to T. brucei
(Carter and Fairlamb, 1993).
Deoxyadenosine, a deoxidised form of adenosine is similar in structure to adenosine
except for the absence of one oxygen atom in the pentose sugar unit of the molecule,
caused 97.1 ±0.6% inhibition of adenosine uptake.
Berenil® at 100 pM concentration inhibited 33.2±2.3% of adenosine uptake. In the
presence of adenine addition of 100 pM Berenil® did not result to further increase
(50.5 ±6.1%) in inhibition of adenosine uptake beyond that caused by adenine alone
(53.6±3.8%). On the other hand, addition of 100 pM Berenil® in the presence of 1
mM inosine resulted to a 4-fold increase in inhibition (88.4±2.6%) of adenosine






Figure6.1:Inhibitionofuptakef1pMaden sineinthv/vo-maintaineddrugsensitiveTrypanosomaevansi(WT).lxlO7 trypanosomesin80piofu akebufferwereincubatedwith1pMtritiatedade osinet37°C,fo5minutes.Inhibitors consistingof1mMinosine(I),mMadenine(A ,1mMdeoxyadenosine(De xyads)or100pMBerenil®( N);ithers ngly orinc mbinationwereadd din2-4pivolumes.Reactionmixtureswerefilter dbycentrifugationthrough0.45pmacetatfilte (COSTAR),atlO xg.Trypanosomestra pedofilterswe ewashedwit0.5mlofnonradiolabeled(cold)adenosine.Filter weredriedat50°Covernight.Incorp r tedradioactiv tyw sre dinascintillationcoun er.Uptakeofadenosinewacalculated fromc untsofdecompositionsfradioactivity.Amounofinhibiti nwascalculatedaspercentageofupt keofcontrol incubationsitheabsenceofinhibitorsubtr tedfrom100.Barsrepresentstandarderro sofm ansale s4experi ents.
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6.3.1.2. Drug resistant line
Figure 6.2 shows results of inhibition of adenosine uptake in the in v/vo-derived drug
resistant population, CR3. In these trypanosomes, adenine, inosine and Berenil® (as
well as deoxyadenosine) also caused varying levels of inhibition of uptake of
adenosine. However there were marked changes in the activity of the individual
transporters when compared with the wild type. Inosine alone caused 81.0±2.8%
inhibition at 1 mM concentration. Hence uptake at the alternate transporter was
approximately 19.0%. Adenine alone inhibited 38.1 ± 1.3% of uptake leaving a
residual uptake of approximately 61.9%. This represents a 4-fold decrease in uptake
at the adenine/adenosine (P2) transporter and 1.3-fold increase in the
inosine/adenosine (PI) transporter (Carter and Fairlamb, 1993).
In the drug resistant parasites a combination of 1 mM adenine and 1 mM inosine also
led to complete (98.9+0.5%) inhibition of uptake of 1 pM adenosine suggesting that
two adenosine transporters were present in the drug resistant population. One is
inhibited by inosine and the other by adenine.
Inhibition by 1 mM deoxyadenosine was also similar to that observed in the
unselected line with percentage inhibition of 96.1+0.6
Hundred pM Berenil® alone inhibited 30.7+4.5% of adenosine uptake. In
• • • ..... • ®combination with inosine there was almost 4-fold increase in inhibition by Berenil
(98.5+1.4%), similar to the observations on the drug sensitive line. However
complete inhibition was not achieved with Berenil® in the presence of inosine.
Interestingly, combination of Berenil® with 1 mM adenine in these drug resistant
parasites resulted to a 2-fold increase in inhibition (70.0+9.9) beyond that caused by
adenine alone (38.1 + 1.3%). This increased inhibition was not observed in the drug
sensitive clone.
Results of inhibition of adenosine uptake in the second in v/vo-derived drug resistant
line, CR3.1 is shown in Figure 6.3. Inhibitions were similar to those observed on the
CR3 parasites. Inosine inhibited 66.3+0.8%, giving a residual uptake at the
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Figure6.3:Inhibitionofuptakef1pMadenosineinthv/vo-deriveddrugresistantTrypanosomaevansi(CR3.1). lxlO7trypanosomesin80piofupt kebufferwereincuba edwith1pMtritiatedadenos ne37°C,for5minut s.Inhibito s consistingof1mMinosine(I),mMadenine(A ),or100pMBerenil®( N);ithersinglyorinc mbi ationwe eadd di 2-4pivolumes.Reactionmixtureswerfilter dbycentrifugationthrough0.45pmacetatfilt r(COSTAR),atlO xg. Trypanosomestra pedofil erwe ewashedwit0.5mlofnonradiolabeled(co d)adenosine.Filtew redr eat50°C overnight.Incorp ratedradi activitywasre dinascintillationcoun r.Uptakofadenosinewacalcul tedfromcountsf decompositionsfradioactivity.Amountofinhibiti nwascalcul tedasper entageofuptakefcontrolincubationsthe absenceofinhibitorsubtractedfrom100.Duplicateexperimentswenotcarri doutwiththisli e.
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adenine/adenosine transporter of 33.8%. This represents a 2.7-fold decrease in
uptake compared to the unselected (WT) population. Adenine inhibited 35.4±16.8
giving a residual PI uptake of 64.6% which represents a 1.4-fold increase in uptake
at this transporter. Again complete inhibition (100.0%) was observed in the presence
of both adenine and inosine, suggesting the presence of a bipartite adenosine
transport system in these parasites.
In this drug resistant clone Berenil® alone inhibited 17.3% of adenosine uptake,
which represents a 2-fold decrease in the amount of inhibition by Berenil®.
Combination of Berenil® and inosine resulted to 96.4% inhibition of uptake similar
to the CR3. Addition of Berenil® in the presence of adenine resulted to 65.3%
inhibition, representing 1.5-fold increased inhibition beyond that produced by
adenine alone.
6.3.2. Inhibition of adenosine uptake in the culture-adapted Trypanosoma
evansi lines
6.3.2.1. Drug sensitive trypanosomes
Results of inhibition of adenosine uptake in the culture-adapted unselected T. evansi
(WTAX) is shown in Figure 6.4. Inosine inhibited 20.5±3.7% of total adenosine
uptake, giving a residual P2 uptake of 79.5%. Adenine inhibited 82.2±11.7% of total
adenosine uptake, giving a residual PI uptake of 17.8%. Similar to the WT parasites
the presence of saturating concentrations of both inosine and adenine led to complete
inhibition of adenosine uptake in the WTAX parasites.
Deoxyadenosine caused inhibition of 89.5±0.8% in these parasites.
Similar observations to those on the mouse-maintained WT were made on inhibitions
by Berenil® in the WTAX. Berenil® inhibited 42.4±5.4% of total adenosine uptake.
A combination of 100 pM Berenil® and 1 pM adenine did not result to further
increase in inhibition (80.2±6.1%) to that caused by adenine (82.2±11.7%). Again
addition of 100 pM Berenil® in the presence of 1 mM inosine resulted to 3.9-fold




Figure6.4:Inhibitionofuptakef1pMadenosineithculture-adapteddr gsensitivTrypanosomeva i(WTAX). lxlO7trypanosomesin80iofupt kebufferwereincuba edwith1pMtritiatedadenosine37°C,for5minut s. Inhibitorsconsistingof1mMinosine( ),mMade ine(A ),1mMdeoxyadenosine(D oxyads),r100pMBerenil® (BN);eithers nglyorinc mbinationwereadd din2-4pivolumes.Reactiomixtureswerefilter dbycentrifugation through0.45pmacetatefil er(COSTAR),atlO xgTrypanosomestra pedofil erwe ewashedwit0.5mlofnon radiolabeled(co d)adenosine.Filt rw redr edat50°Covernight.Incorporatradi c ivitywasre diascintillation counter.Uptakofaden si ewacalcul tedfromcountsfdecomp sitio sfradioa tivity.Amountofinhibiti nwas calculatedaspercentageofu t kefcont olincubationsitheabsencofinhibitorsubtract df om100.Barsrepresent standarderrorsofme nsfatle t3experim nts.
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6.3.2.2. Drug resistant lines
Figure 6.5 shows results of inhibition of uptake of 1 pM adenosine in the in vitro-
derived drug resistant population, MCR1. Similar to the in v/'vo-derived lines there
were marked changes in activity of adenosine transporters in these resistant
trypanosomes. Inosine alone inhibited 92.4±5.6 % of total adenosine uptake as
opposed to 20.5% in the wild type, giving a residual P2 transport of 7.6%. This
represented over 10-fold decrease in P2 uptake compared to the drug sensitive
(WTAX) parasites. Adenine on the other hand inhibited 44.6±9.9% of adenosine
uptake giving a PI transport of 55.4%. This represents a 3.1-fold increase in
percentage uptake at the PI compared to the WTAX. Again almost complete
inhibition (95.7±4.3%) was obtained with the addition of saturating concentrations of
both adenine and inosine.
Deoxyadenosine inhibited 89.4±10.2% of total uptake.
In the MCR1 trypanosomes addition of 100 pM Berenil in the presence of 1 mM
inosine did not result to further increase in inhibition (89.6±8.6%) to that caused by
inosine alone (92.4±5.6%). Again similar to observations on the in v/vo-derived drug
resistant lines (CR3 and CR3.1) addition of 100 pM Berenil® in the presence of 1
mM adenine led to a moderate (1.4 fold) increase (63.5±5.4%) beyond that caused by
adenine alone (44.6±9.9).
Results of inhibition of adenosine uptake in in v/Yro-derived drug resistant clone,
MCR1.1 is shown in Figure 6.6. Inhibitions were similar to those observed in the
MCR1 population. Inosine inhibited 86.9± 11.5% of total uptake. Hence the P2
transport was approximately 13.1%, representing a 6-fold decrease in P2 "ptake.
Adenine inhibited 57.4±8.3% of adenosine uptake, giving a PI uptake of about
42.6%. This represents a 2.4-fold increase in PI uptake compared to the drug
sensitive control. Addition of saturating concentrations of both adenine and inosine
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Figure6.6:Inhibitionofuptake1pMadenosineithivzfro-deriveddrresista tTrypanosomaevansi (MCR1.1).lxlO7trypanosomesin80iofu takebufferwereincubat dwith1ptritia edadenosin37°C,for 5minutes.Inhibitorsconsistingof1mMinos e( ),mMadeni e(A )or100pMBerenil®( N ;thers gly orinc mbinationwereaddedi2-4pvolu es.Reactionmixtureswerfilterbycentrifugatiothrough0.45p acetatefilt r(COSTAR),lO xg.Trypanosomest appedofil erweshedwit0.5mofnradiolabeled (cold)adenosine.Filt rsw edri dt50°Covernight.Incorpor t dradi ctivitywasre diascintillat ncounter. Uptakeofadenosinw sc lcul tedfromcountfdecomp sitio sfradioa tivity.Am unofinhibitiw s calculatedaspercent geofuptakec n rolincubationsthabsenceofinhibitsubtractedfrom100.Bar representstandarderrorsofm an3experiments
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Addition of 100 pM Berenil® in the presence of inosine similarly did not lead to any
further increase (89.5±3.2%) in inhibition beyond that caused by inosine alone
(86.9±11.5%). Similar to observations on the MCR1 population, addition of 100 pM
(&) •
Berenil to 1 mM adenine resulted to a moderate (1.3-fold) increase (75.1±4.4%) in
inhibition compared to inhibition by adenine alone (57.4±8.3%).
6.3.3. Effect of increasing concentrations of inhibitors on adenosine uptake
6.3.3.1. Drug sensitive trypanosomes
The effect of increasing concentrations of inhibitors on uptake of 1 pM adenosine
was measured in the in v/vo-maintained unselected T. evansi (WT), its drug resistant
derivative (CR3), as well as the culture-adapted unselected line (WTAX). Results of
inhibition of uptake in the WT by inosine and adenine are shown in Figure 6.7a& b.
There was very little inhibition with increasing concentrations of inosine alone and a
dose-dependent effect was not apparent. However, in the presence of 1 mM adenine
inosine inhibited uptake in a dose-dependent manner such that at 1 mM concentration
of inosine inhibition was complete. The concentration of inosine that inhibited 50%
of adenosine uptake (EC50) in the presence of adenine was 5.1 pM. A dose-
dependent inhibition by adenine alone was more pronounced (Figure 6.7b).
Inhibition increased with 1 pM adenine (22.3±7.9%) and maximum inhibition at 100
pM adenine was 56.1±9.8%. This approximates the value at 1 mM adenine (53.2%)
in the single dose inhibitions shown in Figure 6.1. In the presence of 1 mM inosine
higher increases in inhibition occurred with increasing concentrations of adenine.
Rapid inhibition occurred at concentrations of adenine above 1 pM (48.0%) and
near-saturation inhibitions were obtained at concentrations of 10-50 pM adenine
(87.4-94.2%). The transporter was completely saturated at 100 pM adenine. The
EC50 value for adenine in the presence of 1 mM inosine was 1.16 pM.
Rapid concentration dependent inhibition of adenosine uptake by adenine was also
observed in the WTAX, in the presence of 1 mM inosine (Figure 6.8b), Saturation
was achieved above 50 pM adenine, and the EC50 for this inhibition was 0.83 pM.
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Figure 6.7 : Effect of increasing
concentrations of inhibitors on uptake
of 1 pM adenosine in the in vivo-
maintained drug sensitive
Trypanosoma evansi (WT). a,
inhibition by inosine alone (open
circles), and, inosine in the presence
of 1 mM adenine (closed circles); b,
inhibition by adenine alone (open
squares) and adenine in the presence
of 1 mM inosine (closed squares), lx
107 trypanosomes were incubated at
37°C, for 5 minutes with 1 pM
tritiated adenosine and increasing
concentrations of each inhibitor.
Inhibitor concentrations ranged from
0.01-1000 pM. Uptake of adenosine
was measured and percentage
inhibition determined, as described in
the text. Each data point represents an






















Figure 6.8: Effect of
increasing concentrations of
inhibitors on uptake of 1 pM
adenosine in the in vitro-
adapted drug sensitive
Trypanosoma evansi (WTAX).
a, inhibition by inosine in the
presence of 1 mM adenine,
and, b, inhibition by adenine in
the presence of 1 mM inosine.
•7
lx 10 trypanosomes were
incubated at 37°C, for 5
minutes with 1 pM tritiated
adenosine and increasing
concentrations of either inosine
or adenine. Inhibitor
concentrations ranged from
0.1-1000 pM. Uptake of
adenosine was measured and
percentage inhibition
determined, as described in the
text. Each data point
represents an average of at
least 2 experiments.
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Little increases in inhibition were observed with increasing concentrations of inosine
in the presence of adenine (Figure 6.8a). Inhibition progressed slowly and saturation
was reached at 1 mM inosine, similar to the observations in the WT. Duplicate
experiments were, however, not carried out on the WTAX parasites. EC50 value was
0.22 pM.
The effect of varying concentrations of Berenil® on uptake of 1 pM adenosine was
also measured in the T. evansi isolate (WT). Results of inhibition are shown in
Figure 6.9. In the absence of either inosine or adenine little or no inhibition was
• 1 • (K)
observed with Berenil up to 100 pM concentration. Increased inhibition occurred at
500 pM. In the presence of 1 mM adenine there was no increase in inhibition with
(1?)
the addition of increasing concentrations up to 100 pM of Berenil . However in the
presence of 1 mM inosine a dose-dependent increase in inhibition was observed with
Berenil®. Rapid increase in inhibition was observed above 10 pM, and highest
inhibition at 100 pM was 73.5122.6%). There was no saturation at this concentration
of Berenil®. The EC50 value for this inhibition was 13.9 pM. Higher concentrations
of Berenil® could not be used since Berenil®, is known to interfere with cell
membranes of trypanosomes at concentrations above 100 pM (Barrett et al. 1995).
Similar observations on inhibition by Berenil® in the presence of inosine were made
in the culture-adapted drug sensitive (WTAX) parasites.
6.3.3.2. Drug resistant trypanosomes
Results of adenosine uptake inhibition with increasing concentrations of inosine and
adenine in the in vzvo-derived resistant line (CR3) are shown in Figure 6.10a.
Inhibition by increasing concentrations of adenine (in the presence of inosine) was
rather slow, however, a dose-dependent effect was apparent. Little increase in
inhibition occurred at 10 pM adc Tne and saturation was achieved at 50 pM adenine
(97.410.2%). The EC50 value for this process was 4.0 r|M (inhibition by inosine
alone in these parasites was over 75%). A more rapid dose-dependent increase in
inhibition was observed with concentrations of inosine (in the presence of adenine).
At 0.01-1 pM concentration of inosine, inhibition was quite slow (35.8-47.2%).
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(This agreed with the low percentage inhibition by adenine in the drug resistant line
(38.1%, Figure 6.2). However inhibition increased from 10 pM concentration
(61.2+5.9%) and maximum inhibition at 100 pM was 92.1 ±0.4%. Complete
saturation was not attained at 100 pM inosine. The EC50 value for this inhibition was
3.1 pM inosine.
The results of the interaction of Berenil® with the adenine/adenosine transporter in
the CR3 is shown in Figure 6.10b. Relatively h'gh percentage inhibition (up to 90%)
was caused by 1 mM inosine in these parasites. A very slow increase in inhibition
v.t.s observed with increasing concentrations of Berenil® in the presence of inosine
starting from 89.9±0.9% at 0.01 pM to 94.6±0.4% at 100 pM Berenil®. This
increase was much slower compared to the WT parasites. In the CR3 percentage
inhibition remained unchanged at concentrations of Berenil® between 0.01-10 pM, in
the presence of inosine. The EC50 value for this inhibition was 3.5 r|M.
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Figure 6.9: Dose-dependent effect of Berenil® on uptake of 1 p.M adenosine in the
. ... (It)
in v/'vo-maintained drug sensitive Trypanosoma evansi (WT). Inhibition by Berenil
alone (open inverted triangles), Berenil® in the presence of 1 mM inosine (filled
inverted triangles) or Berenil® in the presence of 1 mM adenine (filled squares).
Adenosine uptake assays were carried out and percentage inhibition of uptake
calculated as described in the text. Each data point represents average of at least 3
experiments.
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Figure 6.10: Inhibition
of uptake of 1 pM
adenosine in the in vivo-
derived drug resistant
Trypanosoma evansi
(CR3). a, inhibition by
inosine in the presence
of 1 mM adenine (filled
circles), and adenine in
the presence of 1 mM
inosine (filled squares);
b: inhibition by Berenil
in the presence of 1 mM
inosine. Each data point
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6.4. DISCUSSION
From this study, uptake of 1 pM adenosine was completely inhibited in the presence
of saturating concentrations of both adenine and inosine. This suggests that T. evansi
TREU 1840 possesses two adenosine transport systems, one inhibitable by adenine
and the other by inosine. This observation is in agreement with the observations of
Carter and Fairlamb (1993) who showed that T. brucei possessed two adenosine
transporters, also inhibited by adenine and inosine respectively. Carter and Fairlamb
(1993) named these transporters PI (inhibitable by inosine) and P2 (inhibitable by
adenine). Thus T. evansi also possess the P1/P2 bipartite adenosine transport system.
Also similar to the observations of Carter and Fairlamb, this study showed that in T.
evansi the P1 transporter can be saturated by increasing concentrations of inosine up
to 1 mM and the P2 similarly saturated by increasing concentration of adenine up to
100 pM. Observations of P1/P2 bipartite adenosine transporters have also been
made on T. equiperdum (Barrett et al., 1995). Scott et al. (1997), however, found
that adenosine transport in bloodstream forms of a strain of T. brucei (247) could
only be partially inhibited by both adenine and inosine. He suggested at least four
adenosine transport systems for the T. brucei strain: one transporting adenosine and
inosine, the second adenosine and adenine (including mel Cy and mel Ox), the third
adenosine, adenine and inosine and the fourth adenosine alone.
The existence of two purine nucleoside transporters with non-overlapping substrate
specificities was reported in Leishmania donovani promastigotes (Aronow, et al.,
1987), the first transported inosine, guanosine and their analogues while the second
transported adenosine, analogues of adenosine, and the pyrimidine nucleosides,
uridine, cythidine and thymidine. In the case of T. evansi, as shown in the present
study, the PI and P2 adenosine transporters have overlapping substrate specificities
in that both the PI and the P2 transport adenosine, in addition to either inosine or
adenine. The results on the WT parasites indicate that there may also be some level
of overlap in the substrate specificity for inosine and adenine on either the PI and/or
P2 transporters. This can be appreciated from the observation that both the
percentage inhibitions by inosine (23.2%) and adenine (53.6%) taken individually
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only added up to 76.8%. However, uptake in the presence of inosine (76.8%) and
adenine (46.4%) added was in excess (123.2%) showing that inhibition was not
complete. It is possible that one of the transporters mediates for uptake of both
inosine and adenine. In that case it is not likely that this would be the P2 because
inosine did not inhibit mel Cy lysis, mel Cy being a substrate for the P2. Thus the PI
probably transports adenine to a limited extent.
The existence of two distinct adenosine transporters have been reported in other
members of Trypanosomatidae (James and Born, 1980; Baer et al., 1992).
The present study showed that the PI was a smaller adenosine transport system in T.
evansi compared to the P2. Carter and Fairlamb (1993), found the opposite to be true
in T. brucev. Inosine inhibited 60-70% while uptake via the P2 accounted for only 30-
40% of total adenosine uptake, indicating that the PI was the more elaborate process.
Scott et al. (1997) observed maximum inhibitions of 45% and 50%, respectively,
with saturating concentrations of inosine and adenine, suggesting that the capacities
of the two transporters were fairly similar in that strain of T. brucei. These
differences in activity by the PI and P2 transporters in different species and strains of
trypanosomes further amplify the variations that exists in purine transport functions
within the Trypanosomatidae.
That adenine was a more potent inhibitor of adenosine transport in drug sensitive T.
evansi was also evident from the effects of increasing concentrations of these
inhibitors on uptake. Possible explanations for the differences in the apparent
potency of inhibition between inosine and adenine are two-fold. Either the PI
transporter has lower affinity for inosine and the P2 has a higher affinity for adenine,
or there may be more binding sites or transporter molecules for adenine than there are
for inosine. This remains to be verified.
The lower EC50 value for inosine in the presence of adenine (0.22 pM) compared to
that of adenine in the presence of inosine (0.83 pM) in the WTAX parasites may be
due to higher inhibitions caused by adenine in these parasites and not singularly the
effect of inhibition by inosine alone. Low concentrations giving 50% inhibition of
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transport (IC50) at the P2 by adenine (0.16 pM) have also been reported in T.
equiperdum (Barrett, et al., 1995).
The maximum inhibition of adenosine uptake caused by deoxyadenosine confirm that
the structure recognised by these adenosine transporters is not the carbohydrate but
the purine part of the molecule. It has been suggested that the melaminyl moiety
targets the melaminophenyl arsenicals into drug sensitive trypanosomes via the P2
transporter (Fairlamb et al., 1992b; Carter and Fairlamb, 1993). This means the
melamine ring is recognised similar to the purine ring.
From the present study Berenil® caused inhibition of adenosine uptake in a dose-
dependent manner similar to those caused by inosine and adenine. However high
concentrations of Berenil® were required to produce a dose-dependent inhibition in
• • , # .(R).
the absence of inosine or adenine. Increased inhibition by Berenil in the presence of
inosine in the WT and WTAX parasites confirm that Berenil® interacted with the P2.
Thus Berenil® and possibly other diamidine drugs are taken up into drug sensitive T.
evansi by the P2 adenosine transporter. This was also evident from the lysis data in
which Berenil blocked lysis of trypanosomes by mel Cy similar to adenine and
adenosine , while inosine did not block lysis.
Similar observations on interaction of diamidines with adenosine transporters have
been reported in T. brucei (Scott et al., 1997; Berger et al., 1995; Carter et al., 1996),
T. evansi (Ross and Barns, 1996) and T. equiperdum (Barrett et al., 1995. The
observation of a common mechanism of transport between Berenil® and mel Cy in
this study confirms the basis of cross resistance between the diamidines and some
melaminophenyl arsenicals, but not mel B. An alternative mechanism of uptake not
involving adenosine transport may be responsible for uptake ofmel B.
This study has demonstrated that the P2 transporter is conserved in arsenical resistant
T. evansi.
The two transport systems were maintained in the drug resistant T. evansi although
with modifications in the activity. Up to 10-fold decrease in P2 and 3-fold increase
in the PI were observed, with up to 45% reduction in overall uptake. Alterations in
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P2 transport leading to reduced accumulation of pentamidine has also been reported
by Carter et al. (1996). The events that led to differential decreases in P2 activity in
the different resistant trypanosome lines observed in this study are not well
understood. The reductions in uptake by the P2 are thought to be responsible for the
decrease in overall uptake of adenosine by these parasites. There appears to be some
compensatory increase in percentage uptake at the PI transporter in all the drug
resistant lines. This however, was not enough to bring the total adenosine uptake to
similar levels as the drug sensitive trypanosomes.
The reduction in uptake at the P2 could be a result of mutations leading to
conformational changes in the binding sites on the transporter molecules leading to
reduced affinity for substrate. Alternatively a reduction in the number of transport or
carrier molecules produced in the resistant trypanosomes may be responsible for the
observed resistant phenotype. For this to be established detailed kinetic study of the
P2 transporter is required.
Observations on the conservation of P2 adenosine transporter in Berenil-resistant T.
equiperdum was reported by Barrett et al. (1995). These authors proposed that loss
of affinity for substrate was responsible for the reduced uptake by the P2 transporter
in T. equiperdum. However, the authors were not able to determine the Km and Vmax
values for the P2 transporter of the Berenil®-resistant T. equiperdum. Their
conclusions were based only on reduced uptake of adenosine from inhibition studies,
as well as the expression of limited resistance to drugs using drug assays. If the P2
transport is still present in drug resistant trypanosomes then determination of kinetic
properties of this transporter is required in order to identify the type of mutation
responsible for the reduced capacity for transport.
The finding that the P2 transporter is still present in the drug resistant trypanosomes
could explain our observations on lysis of drug resistant trypanosomes at relatively
low concentrations of mel Cy. (see chapter 5). This confirms that mel Cy resistant
trypanosomes retain some ability to transport melaminophenyl arsenicals. This may
account for their sensitivity to moderately increased concentrations of drug.
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It is not completely clear whether the retention of variable levels of the P2 transporter
is responsible for the differences in stability of resistance following prolonged
withdrawal of drug, (see chapter 4). The instability of resistance in the in vivo-
derived CR3.1 which was found to possess more P2 activity compared to the in vitro-
derived MCR1.1 with less P2 activity suggests this.
There was evidence that Berenil® still interacted with the P2 transporter in the in
vzvo-derived resistant lines, but not in the two in vitro-derived resistant lines. Since
the in v/Yro-selected resistant trypanosomes had least of the P2 activity it suggests
that lack of further inhibition by Berenil® may be a reflection of the extent of
reduction in P2 in these parasites.
Contrary to the observations on the drug sensitive trypanosomes, combination of
Berenil and adenine in the resistant trypanosomes resulted to increased inhibition.
Since Berenil® showed no interaction with the PI in the drug sensitive parasites it is
reasonable to expect that the observed increase in inhibition in the presence of
adenine was not due to an effect on the PI. It is possible that the P2 transporter has
been drastically modified and now interacts with Berenil® in a different way. Further
work needs to be done to elucidate the specific changes occurring at the P2 and any
other transporters that give rise to arsenical resistance in T. evansi.
This study has compared the use of in vitro-derived drug resistant trypanosomes with
the in vzvo-derived resistant lines in the mechanisms of drug resistance. It was
observed that the in vzYro-derived drug resistant lines produced very similar results to
their corresponding in v/vo-derived resistant lines. This substantiates the fact that in
vitro systems can to a great extent be successfully used to replace the use of animal
models in the study of drug resistance.
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CHAPTER SEVEN
KINETICS OF ADENOSINE TRANSPORT AND INHIBITION IN DRUG
SENSITIVE AND DRUG RESISTANT TRYPANOSOMA EVANSI
7.1. INTRODUCTION
Passage of nucleosides across plasma membranes may occur by simple diffusion or
may be carrier-mediated. Simple diffusion has been found to account for a variable
proportion of nucleoside movement across cell membranes. It is recognisable
experimentally as its rate is directly proportional to the nucleoside concentration
gradient and is unaltered by the presence of other substrates or nucleoside transport
inhibitors (Clanachan et al., 1987). Carrier-mediated transport occurs either by
facilitated diffusion or by active transport, each involves specific nucleoside transport
processes (Cass, 1995).
Nucleoside transport processes have been divided into two distinct classes, the
equilibrative and the concentrative transport processes. The equilibrative nucleoside
transport process exhibits the typical features associated with facilitated diffusion. It
is driven by the concentration gradient of the nucleoside being transported. They
function in both uptake and release of nucleosides from cells. The concentrative
nucleoside transport processes are secondary active systems that are driven by
transmembrane Na+ gradients and, in some cases are inwardly directed Na+-
nucleoside cotransporters. Equilibrative nucleoside transport processes are
ubiquitous among mammalian cells and tissues. The concentrative nucleoside
transport processes are limited to specialised cell types such as intestine, kidney,
spleen, lymphocytes, macrophages and choroid (Cass, 1995).
Mammalian cells as well as parasites require the presence of nucleoside transport
proteins in their plasma membranes for the uptake (or release) of physiological
nucleosides. The process by which these purine nucleosides permeate the plasma
membranes independent of intracellular fate such as binding or metabolism is
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described as nucleoside transport (Aronow et al., 1987; Ogbunude and Baer, 1993).
The term uptake, on the other hand, is used to represent both transport across cell
membrane and the accumulation of the substrate and its metabolic products within
the cell (Kidder et al., 1978; Ogbunude and Baer, 1993).
In protozoans uptake of purine nucleosides is generally assumed to occur via
facilitated diffusion (Aronow et al., 1987). Although recently, it was shown
(Ogbunude and Dzimiri, 1993) that in L. donovani promastigotes adenosine is not
only transported by facilitated diffusion but also by a channel-like pathway.
Studies on purine transport in trypanosomes so far have provided evidence for the
presence of two adenosine transporters in drug sensitive trypanosomes. These were
identified as PI (which also transports inosine) and P2 (which also transports
adenine) (Carter and Fairlamb, 1993). Subsequent reports, however, suggest that
there may be more than two adenosine transporters in trypanosomes (Ross and Barns,
1996; Scott et al., 1997).
The P2 transporter has been associated with transport of melaminophenyl arsenicals
into drug sensitive trypanosomes. Loss of this transporter in an arsenical resistant T.
brucei was proposed as a mechanism of resistance to these drugs (Carter and
Fairlamb, 1993).
The present study however, has demonstrated that the P2 transporter is retained in
arsenical resistant T. evansi, although its capacity for uptake of substrate was greatly
decreased.
It is not understood whether the reduced uptake observed at the P2 transporter of the
arsenical resistant T. evansi was due to decreased affinity for substrate or a reduction
in numbers of the transporter molecules. To address this question this study was
undertaken with the following specific objectives.
1. To determine the kinetic properties of both the PI and the P2 adenosine
transporters in drug sensitive T. evansi, as this has not been done before.
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2. To determine how the properties of the PI and P2 adenosine transporters are
altered in drug resistant trypanosomes, selected using a melaminophenyl arsenical
drug, mel Cy.
3. To determine how the changes in kinetic properties of the P2 transporter affect
alternative substrates taken up by this transporter.
An investigation of possible accompanying changes at the P1 transporter may further
elucidate any adaptive mechanisms which enable drug resistant trypanosomes evade
the toxic effects of drugs while at the same time maintaining their normal
physiological functions. These could be exploited for therapeutic purposes.
7.2. MATERIALSAND METHODS
7.2.1. Trypanosomes
The trypanosomes used in this experiments consisted of the mouse-maintained drug
sensitive(WT) parasites, and its in v/'vo-derived drug resistant clone, CR3.1.
7.2.2. Kinetic studies of adenosine transport I: Time course
7.2.2.1. Adenosine transport assays
Transport of 5 pM adenosine was measured at different time points between 10 and
120 seconds, in drug sensitive and drug resistant trypanosomes. Transport activity on
either the PI or P2 transporter was determined by inhibition of one transport process
with a saturating concentration of either adenine or inosine, respectively. Transport
was also measured in the absence of inhibitor.
Trypanosomes separated from mouse blood were washed twice in PSG and
resuspended in transport buffer (CBSS, consisting of 25 mM Hepes/ 120 mM NaCl/
5.4 mM KC1/ 0.55 mM CaCl2/ 0.4 mM MgS04/ 5.6 mM Na2HPC>4/ 11.1 mM
glucose, pH 7.4; Fairlamb et al., 1992a), at a density of 2.5x108 trypanosomes/ml,
and kept on ice. Trypanosome suspensions were prewarmed to 37°C for 5 minutes.
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Aliquots of 80 pi (containing 2xl07 trypanosomes) were added to each of a series of
reaction tubes held at 37°C on a water bath. Inhibitors at 50x final concentration in
assay were added in 2 pi volumes to appropriate tubes. Tritiated adenosine was
prepared at 5 times its final concentration of 5 pM in assay. At zero time 20 pi of [2-
3H]-adenosine (specific activity 185 Bq/mmol or 12.5 mCi/mmol) was added to the
reaction medium using a multiple drop Finn pipette. Experiments were timed
carefully. At the end of incubation 100 pi of Stop solution, consisting of ice-cold 5
mM non-radiolabelled adenosine in PBS, was added to the reaction medium. The
mixture was quickly transferred to an Eppendorf filter unit (SPIN-X, COSTAR)
containing 0.45 pm acetate filter membrane. The filter units were centrifuged at
maximum speed (lOOx g) for 40 seconds in a biofuge. The filters were washed with
0.5 mis of Stop solution and centrifuged at lOOx g for 1 minute. The top of the filter
unit was snipped off using a pair of scissors, the filter holder was removed and the
bottom part containing the filter membrane was cut off using a "micro cutter". The
filter membranes were placed in scintillation vials and dried over night at 50°C (or
for 1.5 hours at 100°C). One ml of scintillation fluid (PACKARD, U.K) was added
to each scintillation vial and incorporated radioactivity counted in a scintillation
counter.
Control incubations (blanks) were performed in the absence of trypanosomes to
correct for non-specific binding of radioactivity. The data was corrected for this
value in each case. Triplicate tubes were used for each assay and each experiment
was repeated 3-4 separate times.
Uptake of adenosine was calculated from counts (counts per minute, CPM) of
incorporated radioactivity, and expressed as pmoles/10 trypanosomes.
Uptake data was analysed using non-linear regression analysis programme, using
MICROCAL ORIGIN computer software. The following exponential association
equation was used to estimate the various uptake parameters as illustrated in Figure
7.1.
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Time (seconds)
Figure 7.1: Illustration of the method of estimation of adenosine uptake rate
parameters in T. evansi by the MICROCAL ORIGIN software.
y = y° + Amaxi (l-e"*771) + AmaX2 (1-exJn)
Where
y = uptake (pmoles/108 trypanosomes), one uptake process was assumed to be zero
x = time (seconds)
T = rate constant = the time (seconds) when 63% of the maximum concentration
(Amax) is attained
Amax = maximum concentration at time infinity (pmoles/108 trypanosomes)
y° = correction if to is not zero
From these plots initial transport rates were calculated from the equation
Ct = cPmax. (1 -e_x/T) =y = Amax ( 1- e"x/r)
Gradient = cPmax/T or AmaJTe'x/T
At time zero gradient = cPmax/T or Amax/T
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Therefore,
AmaJT = Rate of change in concentration of adenosine, hence measures initial uptake
rate.
Attempts were made to separate the individual transport processes (PI and P2) using
this programme from data on the experiments performed in the absence of inhibitor.
Transport data was analysed using two-sample T-test.
7.2.3. Kinetic studies of adenosine transport II: Effects of changes in substrate
concentration on velocity of uptake
7.2.3.1. Uptake assays
Trypanosomes separated from mice blood were washed by centrifugation at lOOx g
for 6 minutes in a biofuge. The trypanosome pellet was resuspended in transport
o
B
buffer at a density of 1.25x10 trypanosomes/ml. Trypanosome suspensions were
prewarmed to 37°C for 5 minutes. Aliquots of 80 pi (containing lxlO7
trypanosomes) were added to each of a series of reaction tubes on a water bath at
37°C. Inhibitors, consisting of 1 mM adenine (to block the P2 and measure the
uptake at PI) or 1 mM inosine (to block the PI and measure the uptake at P2) were
added at 50 times the final concentration in assay, in volumes of 2 pi. Tritiated
adenosine was included in the reaction mixture at the following concentrations 0.1,
0.25, 0.5, 0.75, 1.0, 2.5, 5.0, or 10.0 pM (each at 5 times final concentration).
Experiment was started by the addition of 20 pi of the appropriate concentration of
[2-3H] adenosine. Assay tubes were incubated for 5 minutes at 37°C. The reaction
was stopped by addition of 100 pi of 1 mM unlabelled adenosine in PBS (Stop
solution). The reaction mixture was immediately transferred to an Eppendorf
filtration unit containing 0.45 pm acetate filter (SPIN-X, COSTAR) and centrifuged
at lOOx g for 40 seconds in a biofuge. The filters were washed once with 0.5 ml of
Stop solution and again centrifuged at lOOx g for 1 minute. The top part of the filter
holder was cut off using a micro cutter and the filters were placed in scintillation
vials and dried overnight at 50°C. One ml of scintillation fluid (PACKARD, UK)
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was added to each scintillation vial and incorporated radioactivity counted in a
scintillation counter. Uptake of adenosine was calculated from counts of
decompositions of incorporated radioactivity, and expressed as pmoles/108
trypanosomes.
Control experiments were performed in absence of trypanosomes (blanks) to correct
for any non-specific binding of radioactivity. The data was corrected for this value in
each case. Duplicate tubes were used for each assay. Each experiment was repeated
3-4 separate times.
'Hie uptake data obtained from these experiments was fitted to rectangular hyperbolic
plots and analysed using non-linear regression analysis programme. Kinetic
parameters were determined using Michaelis-Menten equation from MICROCAL
ORIGIN computer software, as shown in Figure 7.2.
Figure 7.2: Illustration of the method of estimation of Michaelis-Menten kinetic
parameters of adenosine uptake in T. evansi by the MICROCAL ORIGIN computer
software.
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Uo = Umax. [A] / ([A] + Km)
where
U0 = initial velocity of uptake (pmoles/108 trypanosomes/5minutes)
Umax = maximum velocity of uptake = value of U0 when [A] = ex (pmoles/108
trypanosomes/5minutes). Umax represents the maximal rate at which a transporter
functions. It is attained when the transporter is saturated with substrate.
[A] = substrate (adenosine) concentration (pM).
Km = dissociation constant (pM) = value of [A] when U0 = 'A Umax The Km value of
a transporter indicates the concentration of substrate at which half the active sites are
filled. It represents the strength with which a transporter binds to its substrate (Cohn
and Gottlieb, 1997).
In this presentation the term Umax has been used instead of the conventional Vmax in
Michaelis-Menten kinetics, since enzymes were not being used.
Plots of the data collected revealed the presence of a non-carrier mediated (passive)
diffusion process (constituting a linear component in the uptake curves). This
became prominent at concentrations above 5 pm adenosine. A modified Michaelis-
Menten equation employing a hyperbolic and a linear component was then adopted
which effectively separated the passive diffusion component from the carrier-
mediated uptake by the PI and P2 transporters, as illustrated in Figure 7.3.
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Figure 7.3: Illustration of the method of correction for adenosine uptake due to
passsive diffusion (linear component) by the MICROCAL ORIGIN software.
U0 = (Umax* [A] /( [A] + Km)) + Kl.[A]
Where,
Kl = rate constant of the linear uptake (passive diffusion)
Data obtained from each experiment was corrected for the passive diffusion
component using the modified Michaelis-Menten equation. The programme
estimated the gradient for the linear component and subtracted it from the rest of the
uptake as shown above.
7.2.4 Kinetics of inhibition of adenosine uptake in Trypanosoma evansi
Kinetics of inhibition of adenosine uptake by inosine, adenine and Berenil® were also
studied in both drug sensitive (WT) and drug resistant (CR3.1) trypanosomes.
Effect of increasing concentration of either inosine, adenine or Berenil® on inhibition
of adenosine uptake was determined by measuring the uptake of 1 pM tritiated
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adenosine by 107 trypanosomes, at 37°C, for 5 minutes. Uptake was measured in the
presence of increasing concentrations of each inhibitor. The effect of inhibition at
the PI or P2 transporters was determined by saturating one transporter with either 1
mM inosine or 1 mM adenine.
Adenosine uptake assays were carried out as described above (section 7.2.4.1.) The
concentrations used for inosine, adenine and Berenil® were 0.01, 0.1, 1, 10, 50, 100
& 1000 pM; 0.01, 0.1, 1, 10, 50 & 100 pM; and, 0.01, 0.1, 1, 10, 50, 100 & 500 pM;
respectively.
The uptake data obtained was plotted and analysed using non linear regression
analysis programme. Inhibition Constants were estimated using the equation below.
U0 = Umax • [S] / ( [S] + Km ( 1 + I/Kj))
= Umax. 1 /(I +Km(l + I/Kj))
= Umax / ( 1 + Km ( 1 + I/Kj))
Where,
o
U0 = initial velocity of uptake of adenosine (pmoles/10 cells/5minutes)
o
Umax = maximum initial velocity of uptake of adenosine (pmoles/10 cells/5 minutes)
[S] = concentration of substrate (adenosine, pM)
Km = dissociation constant for adenosine on the PI or P2 (pM) (= fixed)
I = concentration of inhibitor (pM) (varies from 0.01 - 1000 pM)
K, = dissociation constant for inhibitor (pM)
By substitution,
y = a + b/((l + x/c). d + 1))
Where




Chapter seven: Kinetics ofadenosine transport
X = I
d - Km (fixed as 0.07, 0.74 p.M for PI and P2, respectively in drug sensitive
trypanosomes; and 0.06, 0.1 pM for PI and P2 in drug resistant trypanosomes.
Data was analysed using two-sample T-test.
7.3. RESULTS
7.3.1. Kinetic studies of adenosine transport I: Uptake rates
Transport of 5 pM adenosine via the PI and P2 transporters was measured over a 120
second duration in the presence of saturating concentrations of either adenine or
inosine. The total (overall) uptake represented both processes and was measured in
the absence of inhibitor. Adenosine transport curves for drug-sensitive trypanosomes
are shown in Figures 7.4A-D. Transport in drug resistant parasites is shown in
Figures 7.5A-D.
Similar to results from adenosine uptake inhibition studies there was no transport in
the presence of saturating concentrations of both adenine and inosine in either the
drug sensitive or drug resistant trypanosomes (Figures 7.4D and 7.5D). This
confirms that T. evartsi TREU 1840 possessed two adenosine transport systems.
Kinetic parameters, including maximum concentration at time infinity (Amax), the rate
constant (7) and the initial rates of transport, estimated from exponential plots are
shown in Table 7.1.
The Amax for the total uptake of adenosine (in the absence of inhibitor) in the drug
sensitive (WT) trypanosomes was 140.6±24.0 pmoles/10 trypanosomes. This
represents the total capacity of uptake by the PI and P2 transport processes. The
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rate constant for this uptake was 57.7±10.3 seconds. The initial rate was 2.6710.53
Q
pmoles/second/10 trypanosomes.
In the drug resistant clone there was a slight decrease (not statistically significant: T
= 0.66, P = 0.55, N = 4) in the overall uptake capacity. Amax for the overall uptake
• 8
(in the absence of inhibitor) was 122.6113.0 pmoles/10 trypanosomes. The rate
constant was slightly increased to 72.8+9.2 seconds representing only a slight (not
statistically significant: T= -1.09, P= 0.32, N= 4) reduction in the speed of the overall
transport process. The initial rate of the overall transport in the drug resistant clone
(1.7810.3 pmoles/108trypanosomes) was not significantly different (T= 1.49,P=0.21,
N= 4) compared to the WT trypanosomes. It was not possible from this data to
separate the individual (PI and P2) transport processes using data on overall uptake
in the absence of inhibitor.
In the wild type (WT) the P2 was found to be the larger component of the two
o
transport processes. The Amax for the P2 transporter was 112.5117.8 pmoles/10
trypanosomes. This represent approximately 80% of the total uptake (with no
inhibitor). The rate constant on the P2 transporter was 71.219.7 seconds being
higher than the rate constant for the overall process (57.7 seconds). The initial rate
o
for this transporter was 1.63+0.3 pmoles/sec/10 trypanosomes. The initial rate was
• • • 8
lower than the initial rate (2.6710.5 pmoles/sec/10 trypanosomes) of the overall
uptake in absence of inhibitor.
The Amax of the P2 transporter in the drug resistant trypanosomes was significantly
reduced (T=4.01, P=0.016, N=4) with a mean of 33.618.5 pmoles/108trypanosomes.
This represents only 27.4% of the overall uptake capacity in these trypanosomes, in
contrast to 80% contribution to the total uptake, in the drug-sensitive parasites. The
Rate constant was also reduced in the drug-resistant trypanosomes with a value of
3919.0 seconds, although the difference was not statistically significant (T= 2.44,
P=0.059, N= 4). This rate constant had also reduced compared to the rate constant of
the overall uptake (72.8+9.2 seconds) in the same drug-resistant trypanosomes. This
means the speed of activity of the P2 transporters in the drug-resistant trypanosomes
was increased but the uptake capacity was decreased. The initial rate of transport for
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the P2 transporter in the drug resistant population was 0.81±0.3 pmoles/sec/108
trypanosomes. Although this represents a 2-fold reduction compared to the sensitive
population it was not found to be statistically significant (T=2.21, P=0.078, N=4).
Table 7.1: Kinetic parameters of adenosine transport in drug sensitive and drug
resistant Trypanosoma evansi. I: Uptake rates.






























112.5+17.8 71.2+9.7 1.63+0.3 33.6+8.5 39.0+9.0 0.81+0.3
Legend: Amax = maximum concentration at time infinity
Rate constant = time when 63% of the maximum concentration (Amax) is attained
Each data value is the mean of 3 or 4 experiments ± standard error of the mean.
The Amax for PI transport in the drug sensitive clone was 67.7±9.7 pmoles/108
trypanosomes. This constitutes 48.1% of the total uptake. The rate constant for PI
was 60.4±9.0 seconds and is comparable to the rate constants for the P2 transport
(71.2±9.7 seconds) and the overall uptake process (57.7±10.3 seconds). This means
that the PI and P2 transporter molecules in the drug-sensitive trypanosomes operate
at similar speed. The mean initial rate for PI transport of 1.26±0.2 pmoles/sec/
8 810 trypanosomes was comparable to that of the P2 (1.63±0.3 pmoles/sec/10
trypanosomes) in the same population.
In the drug-resistant clone, the Amax at the PI transporter of 43.9±2.0 pmoles/108
trypanosomes was slightly reduced (1.5-fold) compared to the wild type (T=2.4,
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P=0.14, N=3). However the Amax appears greater than the Amax (33.6±8.5
o
pmoles/10 trypanosomes) at the P2 in the same parasites. The rate constant for the
PI (19.3±5.8 seconds) was significantly reduced (T=3.83, P= 0.03, N= 3) indicating
increased speed of activity. This rate constant was 2-fold lower than that of the P2
transporter (39.9±9.0 seconds) in the same (resistant) trypanosomes. This means that
the transporter molecules of the PI are functioning at a faster speed than those of the
P2 in the resistant trypanosomes. The initial rate for the PI in the resistant clone was
2.68±0.7 pmoles/sec/108 trypanosomes. This was 3.3 times higher than the initial
rate obtained for the P2 transport, 1.5 times higher than that of the overall transport in
the same trypanosomes and 2.1 times higher than the PI of drug-sensitive
trypanosomes. These differences were however, not statistically significant at 95%
confidence level (T=-1.86; P=0.2; N=3.)
A summary illustration of observations on kinetic parameters of adenosine transport
in drug sensitive and drug resistant T. evansi is shown in Figure 7.6.
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Figure 7.6: Summary illustrations of rate kinetic parameters of adenosine
transport on PI and P2 transporters in mel Cy sensitive and mel Cy resistant
T. evansi. Details of experimental procedures are described in the text. The
units of parameters are as follows: Amax (pmole/108 trypanosomes); J
(seconds); Initial Rate (pmole /108 trypanosomes /second). Half arrows
indicate transport.
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7.3.2. Kinetics of adenosine uptake II : Effect of increasing concentration of
substrate on uptake
The effect of increasing concentration of adenosine on velocity of uptake in the drug
sensitive trypanosomes is shown in Figures 7.7A-D. A summary of the kinetic
parameters estimated from these plots is given in Table 7.2.
The maximum velocity of uptake (Umax) for the overall uptake (in the absence of
inhibitor) was 37.4±5.4 pmol/108trypanosomes/5min. The mean Km for this uptake
was 0.38+0.1 pM.
The mean Umax of the PI transport in the WT parasites was 12.4+2.3
pmol/108trypanosomes/5min. A low Km for PI transport (0.07+0.03) pM was
observed.
For the P2 transport the Umax was 28.9+5.1 pmol/108trypanosomes/5min., being over
2-fold higher than Umax for PI. The Km of P2 transporter was 0.74+0.3 pM which is
about 10 times higher than the Km for P1 transport.
Similar plots giving the effects of concentration of substrate on uptake of adenosine
in drug-resistant clone are shown in Figure 7.8A-D. The summary of kinetic
parameters estimated from the plots are included in Table 7.2.
The Umax for the overall uptake in the absence of inhibitor in these trypanosomes was
reduced slightly (T=2.12, P=0.1, N=4) amounting to 22.2+4.7 pmol/108
trypanosomes/5min. The Km for this process was not significantly (T=1.66, P=0.24,
N=4) reduced to 0.14+0.03 pM compared to 0.38+ pM in the drug sensitive
population.
The Umax of PI transport in the drug resistant clone was reduced about 2-fold, to
6.7+1.8 pmol/10 trypanosomes/5min. The difference was, however, not significant
(T=l.98, P=0.12, N=4). The Km for PI of 0.06+0.02 pM was similar (T=0.34,
P=0.77, N=4) to the drug sensitive trypanosomes (0.07+0.03 pM).
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\
The Umax of P2 transport in the drug resistant clone was significantly (T=4.89,
o
P=0.039, N=4) reduced to 3.311.1 pmol/10 trypanosomes/5min. This represents
approximately 9-fold decrease compared to the susceptible clone. The Km of
0.1+0.02 pM also represents 7-fold decrease compared to the wild type parasites.
Statistical comparison did not show a significant difference (T=1.82, P=0.21, N=4).
Table 7.2: Kinetic parameters of adenosine transport in drug sensitive and drug
resistant Trypanosoma evansi. II: Effect of substrate concentration on uptake.
Adenosine
transport function








Total uptake 37.4±5.4 0.38+0.1 22.2+4.7 0.14+0.03
Adenine present
(PI)
12.4±2.3 0.07+0.03 6.7+1.8 0.06+0.02
Inosine present
(P2)
28.9±5.1 0.74+0.3 3.3+1.1 0.1+0.02
Legend: Umax = maximum velocity of uptake. Represents the maximal rate at which
a transporter functions. It is attained when the transporter is saturated with substrate.
Km = dissociation constant. The Km value of a transporter indicates the concentration
of substrate at which half the active sites are filled and represents the strength with
which a transporter binds to its substrate (Cohn and Gottlieb, 1997).
Each data value is the mean of 3 or 4 experiments ± standard error of the mean.
7.3.3. Kinetics of inhibition of adenosine uptake in Trypanosoma evansi
The mean values for the dissociation constant (Kj) for the various inhibitors at the PI
or P2 transporters in the drug sensitive and drug resistant trypanosomes are shown in
Table 7.3.
(r)
Inosine, adenine and BereniL inhibited adenosine uptake on either the PI or P2 with
very low K, values. In the drug sensitive trypanosomes the Kj for inosine and
adenine alone were 0.002± O.OOlpM and 0.28± 0.1 lpM, respectively. Little
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interaction was observed with Berenil® as Kj values remained zero. The Kj for
inosine on the PI was 0.03+0.004 pM. The Kj for adenine and Berenil® on the P2
were 0.3±0.1 pM and 0.01±0.01 pM respectively. There was no interaction with
Berenil® on the PI transporter (Kj = 0.00 pM).
In the drug resistant trypanosomes the Kj for inosine on the PI (0.063±0.03 pM) was
slightly (2-fold) increased compared to the drug sensitive trypanosomes. However at
the P2 the Kj for adenine had increased 6.5-fold (1.94±0.3 pM) compared to the drug
sensitive trypanosomes. There was little or no interaction with Berenil® at the P2 in
these trypanosomes (Kj = 0.00 pM)
The Kj for inosine was lower than that for adenine in both the drug sensitive (10-
fold) and the drug resistant (30-times) trypanosomes.
Table 7.3: Kinetics of inhibition of adenosine transport in drug-sensitive




Drug sensitive Drug resistant
Inosine (PI) 0.03±0.004 0.06310.03
Adenine (P2) 0.3±0.10 1.94010.30
Berenil (P2) 0.01±0.01 0.00
Berenil (PI) 0.00 -
Inosine alone 0.002±0.001 -
Adenine alone 0.28±0.11 -
Berenil alone 0.00 -
Legend: Uptake of 1 pM adenosine by 107 trypanosomes was measured at 37°C, for
5 minutes. Increasing concentrations of inosine, adenine or Berenil were included in
reaction medium. The effect of inhibition at the PI or P2 were determined by
saturation of the alternate transporter with either 1 mM inosine or 1 mM adenine.
The concentrations of inosine used were 0.01, 0.1, 1, 10, 50 100, 1000 pM; adenine
were 0.01, 0.1, 1, 10, 50, 100 pM; and Berenil were 0.01, 0.1, 1, 10, 5, 100 pM.
Experiments were repeated 2-4 times and similar results were obtained.
- = Not done
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A summary of observations on kinetic parameters of adenosine uptake in drug
resistant T. evansi is shown in Figure 7.9.
An overall summary illustrating the main alterations in adenosine uptake in the drug
resistant trypanosomes is shown in Figure 7.10.
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Figure 7.9: Summary illustrations of Michaelis-Menten kinetic parameters
for adenosine uptake on the PI and P2 transporters in mel Cy sensitive and
mel Cy resistant T. evansi. Details of experimental procedures are
described in the text. The units of parameters are as follows: Umax
(pmole/108 trypanosomes/5 minutes); Km (pM), K; (pM). Half arrows
indicate uptake.
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Figure 7.10: Summary illustrations of changes in kinetic parameters of
adenosine transport in mel Cy resistant T. evansi.
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7.4. DISCUSSION
Presence of P1/P2 bipartite adenosine transport system in Trypanosoma evansi:
Transport of 5 pM adenosine was followed between 10 and 120 seconds in a drug-
sensitive T. evansi isolate and its mel Cy-resistant derivative clone, and the various
kinetic parameters measured. The results confirm the observations from inhibition
experiments (Chapter 6) that there are two adenosine transport systems in this strain
of T. evansi (TREU 1840). The finding of bipartite adenosine transport systems in T.
evansi is consistent with previous reports on T. brucei (Carter and Fairlamb, 1993)
and T. equiperdum (Barrett, et al., 1995). Ross and Barns (1996) however, reported
observation of three adenosine transporters in another strain of T. evansi (TREU
1981). It is possible that different strains of T. evansi differ in their adenosine
transport systems. However, the report of Ross and Barns (1996) did not include
investigations on the kinetic properties of these transporters. Conclusions were based
on sequential inhibition of adenosine uptake with inosine, adenine and Berenil " .
This, though indicative, may not have provided sufficient information or conclusive
evidence on the number of transporters present.
Reduced uptake rates at the P2 in drug resistant Trypanosoma evansi.
It was found that the maximum concentration or saturation point (Amax) for the P2
transport was reduced (3.4-fold) in the drug-resistant trypanosomes. On the other
hand, the Rate constant for the same transporter was also reduced, suggesting that
individual transporter molecules were operating at a faster speed. However, the
initial rate of uptake at the P2 was reduced 2-fold. These findings suggest that the
reduced uptake capacity (Amax) together with reduced initial rates of transport are
responsible for the reduced uptake at the P2 transporter in drug-resistant
trypanosomes. Since Amax is the maximum uptake at infinite time, it may be
considered to represent accumulation of substrate in the parasite. Reduced Amax
therefore, represents reduced potential for accumulation of the substrate
intracellularly in drug resistant trypanosomes.
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The lysis as well as adenosine uptake inhibition studies presented here (see Chapters
5 and 6) show that mel Cy competes with adenosine (and adenine) on the P2
transporter in T. evansi. Hence reduced substrate accumulation at the P2 suggests that
resistance to mel Cy is a result of reduced accumulation of the drug. Drug resistance
as a result of reduced accumulation has been reported in trypanosomes with
stilbamidine (Fulton and Grant, 1955), pentamidine (Damper and Patton, 1976;
Carter et al., 1996), and, isometamidium (Sutherland et al., 1991, 1992a). It has also
been shown in multidrug-resistant trypanosomes (Frommel and Balber, 1987); and in
other parasites such as Plasmodium falciparum (Krogstad et al., 1987), and
Entamoeba histolytica (Samuelson et al., 1990).
The uptake capacity (Amax) of a transporter is a function of: i) the number
(concentration) of the transporter molecules available; ii) the speed of operation of
individual transporter molecules (represented by the rate constant); and, iii) the
concentration of substrate. Under the experimental conditions used in this study 5
pM concentration of adenosine was sufficient to provide saturable conditions for
maximum uptake by trypanosomes. Thus variability due to insufficient substrate
concentration was eliminated. Similarly, a lower rate constant obtained for the P2
transporter in the drug resistant trypanosomes is indicative of increased speed. Thus
the reduction in uptake is not a result of slow activity of the individual transporter
molecules. Reduced number of available transporter molecules could only account
for the reduction in Amax and consequently initial rate of transport at the P2.
Non-specific selection effect of mel Cy:
It is generally considered that drugs are not 100% specific for their target molecules
(Martin R.J., personal communication). High concentrations or dose levels may
possibly have some non-specific selective effect for the PI in addition to the P2
transporters. This may account for the slightly reduced Amax at the PI transporter in
the drug resistant trypanosomes. Observations of slight reductions in adenosine
transport by PI transporter have also been reported in T. brucei selected using
sodium melarsen (Carter and Fairlamb, 1993), and T. equiperdum using Berenil
(Barrett et al., 1995). That the rate constant for PI was also reduced in the resistant
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trypanosomes in this study further supports the possibility of non-specific selection
effects by the drug.
It was also observed that the sum of the Amax values for the PI and P2 processes in
the unselected clone was greater than the mean of the overall transport in the absence
of inhibitor. This was however, not the case in the resistant trypanosomes. In the
latter the sum of the Amax of the two individual transporters, PI and P2, was less than
the overall uptake. It is possible that the two transport processes, PI and P2, are not
entirely independent. There may be an overlap in which case the apparent capacity of
one process is a combination of the capacity of that process plus an additional
component which is common between the two. In this situation the sum total of the
two processes measured individually would be more than the overall uptake. In the
mel Cy-resistant trypanosomes, however, one of the two processes (P2) is greatly
deficient. This may have disturbed the balance in the relationship between the two
transporters such that the sum of the two, measured independently, did not amount to
the overall process.
The increased speed of activity of both the P1 and P2 transporter molecules in drug
resistant T. evansi could be a compensatory switch mechanism by the trypanosomes
to make up for the reduced uptake at the P2 transporter.
Effect of substrate concentration on uptake:
Michaelis-Menten kinetics of adenosine uptake were determined in both the drug
sensitive and drug resistant trypanosomes. The results also confirmed the presence
of two adenosine transporters in T. evansi TREU 1840, consistent with reports on
other Trypanosomatidae (James and Bom, 1980; Okochi et al., 1983; Baer et al.,
1992; Carter and Fairlamb, 1993; Barrett et al. 1995).
In the drug-sensitive clone the Umax for P2 transport was over 2 times higher than that
for the PI transport. This compared well with the Rates parameters in the same
Q
parasites. The Umax for PI (12.4 pmol/10 trypanosomes/5min) observed for T. evansi
Q
is comparable to the Vmax (10.6 pmol/10 trypanosomes/sec) reported for T. brucei
o
(Carter and Fairlamb, 1993) and T. equiperdum (8.4 pmol/10 trypanosomes/sec)
(Barrett et al., 1995). The Umax for P2 (28.9 pmol/108trypanosomes/5min.) in T.
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evansi in this study appears higher than reported values for T. brucei (9.5 pmol/108
trypanosomes/sec) and T. equiperdum (6.9 pmol/108trypanosomes/sec). Carter et al.
(1996) also reported transport of pentamidine on the P2 transporter in T. brucei with
a Vmax of 9.35 pmol s"1 (108 cells)"1.
The Km for PI transport (0.07 pM ) obtained for T. evansi was similar to that
reported for the PI in T. brucei (0.15 uM) (Carter and Fairlamb, 1993), although a
relatively higher value (0.60 pM) was observed for T. equiperdum (Barrett et al.,
1995). The Km for P2 (0.74 pM) in T. evansi determined in this study was also very
similar to those reported for T. brucei (0.59 pM) and for T. equiperdum (0.7 pM). A
Km of 0.84 pM was reported for pentamidine on this transporter (Carter et al., 1996).
This study measured uptake at 37°C in contrast to previous observations at 25°C (e.g.
Carter and Fairlamb, 1993; Barrett et al., 1995). A temperature of 37°C
approximates the body temperature and represents the natural environment under
which the T. evansi bloodstream forms live in their host. This provided a more ideal
physiological atmosphere for uptake to take place.
The relatively high Umax for the P2 coupled with higher Amax at the same transporter
supports the observation in this study that P2 transporter is a larger transport process
compared to the PI in drug sensitive T. evansi. In T. brucei and T. equiperdum the
P2 was the smaller component of the two transporters. This confirms the variability
in adenosine transport functions in different species of trypanosomes.
The longer incubation period employed in this study may have enhanced passive
diffusion of adenosine into trypanosomes. This was however, corrected for using the
modified Michaelis-Menten equation as described in the methods. It was not
necessary to correct for passive diffusion component in the data obtained from time
course experiments in view of the short incubation times used. Exponential plots
obtained from this data did not indicate the presence of passive diffusion. Thus the
kinetic parameters presented here are accurate measures of the carrier-mediated
uptake processes at the PI and P2 in T. evansi TREU 1840.
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Alterations observed in the maximum velocity of uptake (Umax) in the drug resistant
clone were similar to those observed in the corresponding Amax in these parasites.
While the PI and P2 adenosine transporters have been previously characterised in
drug sensitive trypanosomes (Carter and Fairlamb, 1993, Barrett et al., 1995) very
little information has been reported on the detailed kinetic changes in the P2 in drug
resistant trypanosomes. Carter and Fairlamb (1993) observed that there was no
detectable rate of transport of 1 pM adenosine on the P2 in a melarsen-resistant T.
brucei clone. On this basis it was concluded that P2 transport was absent in this
clone. Barrett et al. (1995) also determined the Km (0.66 pM) and Vmax (4.15) for the
• (R)
PI transporter in Berenil -resistant T. equiperdum.
This study show that a P2 transport process is still present in mel Cy resistant T.
evansi although markedly reduced. Barrett et al. (1995) also reported the presence of
a P2 component in Berenil®-resistant T. equiperdum. Flowever these authors were
not able to determine detailed kinetic parameters for the P2 transporter in the
resistant clone.
This study has shown for the first time a detailed characterisation of the changes in
kinetic parameters occurring at the P2 adenosine transporter in arsenical resistant
trypanosomes.
Arsenical resistant T. evansi maintained high affinity for substrate on the P2
transporter:
The report of Barrett et al. (1995) suggested that loss of affinity for substrate was
responsible for the reduced uptake by the P2 transporter. This conclusion, however,
was not based on kinetic data but on inhibition studies as well as response to drug.
From the present study the Km of the P2 in mel Cy-resistant trypanosomes was not
increased as expected but rather decreased 7-fold. By definition dissociation constant
(Km) is the reciprocal of affinity of binding between substrate and the transporter. A
decreased Km means that there is increased affinity for substrate at the P2 transporter
in the drug-resistant clone. Thus the reduced uptake at the P2 transporter observed in
this study was not a result of reduced affinity.
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Reduced numbers of transporter molecules is responsible for reduced uptake at the
P2 in arsenical resistant Trypanosoma evansi\
Besides the Michaelis-Menten kinetics this study also measured other kinetic
parameters for the PI and P2 transporters, and the overall uptake. The two
parameters, Amax and the rate constant (7), have not been previously determined for
the PI and P2 adenosine transporters in trypanosomes. These rate parameters
complimented results obtained from Michaelis-Menten kinetics in both the drug
sensitive and resistant trypanosomes.
The rate constant determined for the P2 show that the speed of the P2 transporter
molecules did not decrease. (Indeed the speed of both the PI and P2 transporter
molecules had increased in the drug-resistant trypanosomes). However the initial
rate for the P2 had decreased in this clone. The significant change in Amax at the P2
suggests that the decrease in initial rate of transport was a result of decrease in Amax.
It is concluded that reduced uptake capacity (Amax) at the P2 transporter is
responsible for the reduced initial rate of transport and reduced velocity (Umax). By
definition Amax represents the maximum intracellular concentration (uptake) of
substrate at time infinity. It is considered that in the presence of saturating
concentrations of substrate (and at time infinity) as used in this study then, Amax is
directly a function of the concentration or numbers of transporter molecules
available. Thus reduced Amax signifies reduced concentration or numbers of
transporter molecules. All of these would result to the reduced uptake observed on
this transporter. These factors are also likely to result in reduced overall uptake and
possibly reduced accumulation of substrate in the drug resistant parasites.
The marked change in the Km for the P2 together with changes in Amax and Umax in
the resistant clone suggests that the P2 transporter has mutated to what is now
described as a P2R transporter. The P2R transporter possibly interacts with Berenil®
in a different way. It is also possible that a completely new transporter is being
produced in place of the P2 in the resistant trypanosomes.
It is not known what specific mutations are responsible for the reduction in numbers
of the P2 transporter molecules in arsenical-resistant trypanosomes.
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Kinetics of inhibition of adenosine uptake on the PI and P2 transporters:
Low Kj values for inhibition of adenosine uptake were obtained for both inosine and
adenine from this study. The Kj for adenine on the P2 of 0.3 pM was very similar to
that reported for adenine on the same transporter in T. brucei (Carter and Fairlamb,
1993). Kj values for inhibition by inosine or Berenil® have not been previously
reported, although pentamidine has been shown to strongly inhibit adenosine uptake
on the P2 with Kj of 0.56 pM (Carter et al., 1996).
This study showed a consistently lower Kj for inosine on the PI compared to the Kj
for adenine on the P2. This indicates that in drug sensitive trypanosomes the PI
transporter binds to inosine with greater affinity than does the P2 for adenine. Based
on affinity alone it would be expected that inosine will be a more potent inhibitor of
adenosine uptake than adenine. This is further supported by the observation that
relative to adenosine the Kj for inosine on the PI and adenine on the P2 were equally
lower (approximately 2-fold) than the Km for adenosine on either transporter. That
adenine rather than inosine was a more potent inhibitor of adenosine uptake supports
the present observation that maximum uptake capacity (Amax) accounted for
increased uptake on the P2 in drug sensitive trypanosomes. In the drug resistant
trypanosomes the Amax on the P2 had greatly reduced resulting to decreased uptake.
A different picture was found in drug resistant trypanosomes. The Kj for inosine on
PI remained similar to that observed in the drug sensitive trypanosomes. (Similarly
the Km for adenosine on this transporter was not changed in these trypanosomes.)
However the Kj for adenine on P2 increased 6.5-fold, indicating a marked decrease in
affinity for adenine. The Km for adenosine on this transporter had however,
decreased 7-fold compared to drug sensitive trypanosomes.
Presence of a new adenosine transporter, P3, in arsenical resistant Trypanosoma
evansi:
The major changes in Kj for adenine, Km for adenosine, together with the changes in
Amax, rate constant, Umax and the initial rate, on the P2, provide sufficient evidence
that the transporter in the resistant trypanosomes is completely different from the P2
in the drug sensitive trypanosomes.
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It is concluded that a new transporter, which is termed here P3, is present in arsenical
resistant T. evansi. The P3 may have been selected during induction of resistance to
mel Cy or may be a replacement for the P2 by the trypanosomes. It is logical to
expect that a remnant of the P2 and the new, P3 transporter, may coexist in arsenical
resistant trypanosomes.
The presence of a third transporter explains the apparently high overall uptake in the
drug resistant clone inspite of the marked decrease in P2 activity. This switch to P3
represents another important adaptive mechanism by which drug resistant
trypanosomes maintain their purine needs in the face of interferences with already
existing pathways.
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CHAPTER EIGHT
GENERAL DISCUSSION AND CONCLUSIONS
Aims and experimental design:
The aim of this study was to investigate the biochemical basis for the development of
resistance to arsenical drugs in T. evansi, and to determine if the mode of resistance
development in vitro was similar to that developed in animals. The experimental
design involved production and, characterisation of cloned lines of T. evansi in vivo
and in vitro with varying degrees of sensitivity to mel Cy.
The resistance induced using mel Cy was characterised with respect to stability of
resistance and cross resistance to other trypanocides. The mode of uptake of
melaminophenyl arsenicals represented by mel Cy and mel B into T. evansi was
investigated using an in vitro lysis assay. A detailed investigation, including a kinetic
study of purine (adenosine) transport pathways of both drug sensitive and drug
resistant trypanosomes was undertaken. Alterations in transport associated with the
expression of the resistant phenotype were determined from these studies.
Influence of host immunity on resistance development:
The results showed that high levels of drug resistance can be easily produced in
immunosuppressed hosts as well as in in vitro systems, but not in immunocompetent
hosts. This observation highlights the prominent role of the host environment,
specifically host immunity in determining the efficacy of trypanocidal drugs and the
development of drug resistance. This phenomenon has also been observed in the
chemotherapy of other parasitic infections (Doenhoff et al., 1991).
The importance of the involvement of host immunity in chemotherapy of
trypanosomosis is best appreciated when it is considered that animals that come
under natural challenge with trypanosomes in endemic areas are constantly prone to
various disease or stress conditions which impose a state of immunosuppression on
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these animals. This study showed that such animals would provide a medium for the
selection of drug resistant trypanosomes. This could be an important factor
contributing to the widespread occurrence of resistance to trypanocides on the field.
It is suggested that in attempting to control trypanosomosis efforts should be directed
not only at the trypanosome parasite alone but also on other concurrent parasitic
infections prevalent in affected animals within that locality. This calls for integrated
approach to the control of trypanosomiasis requiring complete herd health
programmes rather than individual disease control. This thought is recently being
shared by other workers (see Holmes, 1997).
The fact that drug resistant trypanosomes produced in this study maintained their
natural characteristics, including infectivity in the host, is important in the
maintenance of resistant parasites under field conditions. This increases the risk of a
wide scale spread of resistance once induced. Furthermore, a reduction in virulence
of drug resistant trypanosomes such as observed in this study means a host
harbouring resistant trypanosomes is likely to live longer than one with drug sensitive
parasites (assuming no mixed resistant/sensitive infections occurred). This shows a
trend towards adaptation between the resistant parasite and the host which favours
the survival of the parasite and consequently maintenance of resistance in nature. On
the other hand in a situation of mixed drug sensitive/ resistant infections, if reduced
virulence was a factor of reduced growth rate of the drug resistant trypanosomes as
has been suggested (Mutugi et al., 1996), it might be expected that with time the drug
sensitive populations may outgrow the resistant one. The resistant population may
then decline after several generations of transmission from hosts to host. Detailed
study of the dynamics of transmission and maintenance of drug resistant parasites is
needed.
Absence of naturally resistant sub-populations of Trypanosoma evansi isolate:
The development of resistance to mel Cy in T. evansi populations was a result of
induced mutation and subsequent selection of resistant mutants. Experiments failed
to demonstrate the existence of high level resistant mutants either in vivo or in vitro.
However, this does not rule out completely the possibility of occurrence of some
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mutants with very low resistance prior to induction. These probably, could not
survive the selective effect of the drug at the concentrations tested.
Cross resistance between mel Cy and other trypanocides:
Resistance induced against mel Cy conferred a high degree of cross-resistance to mel
B, another melaminophenyl arsenical drug, and to Berenil®, a diamidine. In
circumstances where widespread resistance to a drug occurs there is usually a need to
introduce an alternative drug to which trypanosomes respond. In such a situation this
study suggests that introduction ofmel Cy would alleviate the problem of resistance
to suramin and to a lesser extent quinapyramine. Both of these are drugs that have
been commonly used in the control of trypanosomosis caused by T. evcinsi.
Mel Cy has been reported to be effective against diminazene aceturate-resistant T.
brucei (Zweygarth and Kaminsky, 1990). Field isolates of T. evansi and T.
equiperdum that were resistant to Berenil®, suramin, quinapyramine or
isometamidium were also reported to have remained fully sensitive to mel Cy. This
led to the suggestion that mel Cy might be an effective trypanocide for controlling
veterinary trypanosomosis (Zhang et ah, 1992). It has however, been shown (Zhang
et al., 1993) that trypanosomes selected for resistance using Berenil® exhibited two
mechanisms of resistance - one expressing cross resistance to mel Cy and the other
showing no cross resistance to mel Cy. In the light of this report and the cross
resistance between mel Cy and Berenil® observed in the present work, it is envisaged
that mel Cy can only be used to a limited extent as a substitute in situations where
Berenil® resistance occurs. A switch to Berenil® may also not be useful where mel
Cy resistant trypanosomes are prevalent. Similarly, these results underscore the
(R)
potential problems that might arise in any attempts to use mel Cy and Berenil"
concurrently in an endemic area to control trypanosomosis as this will only increase
the chances of development of resistance to both drugs.
Differences in uptake mechanisms between melaminophenyl arsenical drugs:
Mel Cy and mel B, both trivalent melaminophenyl arsenicals caused in vitro lysis of
T. evansi in a manner that indicated that specific transport mechanisms were involved
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in the uptake of these drugs into trypanosomes. However, attempts at inhibition of
lysis by these drugs using purine compounds revealed that there were differences in
the mode of uptake of the two arsenicals. The study showed that mel Cy was taken
up by an adenine/adenosine transporter, similar to T. brucei (Carter and Fairlamb,
1993). Mel B was not recognised by either of the two adenosine transporters. The
blocking of both mel Cy and mel B lysis by Berenil® further raises questions on the
specific mechanisms of uptake of mel B and the diamidines. The basis for the cross
resistance between mel Cy and mel B observed in this and previous studies also
warrants further investigation.
A bipartite adenosine transport system maintained in arsenical resistant Trypanosoma
evansi:
Studies on adenosine uptake in T. evansi showed that these parasites possess a P1/P2
bipartite adenosine transport system similar to T. brucei (Carter and Fairlamb, 1993)
and T. equiperdum (Barrett et al., 1995), and mel Cy interacted with the P2
transporter.
The P2 transporter was maintained in arsenical resistant T. evansi. However the
activity of the P2 transporter was modified resulting to reduced uptake at the
transporter, and a reduction in total adenosine uptake by the parasite. Observations
of reduction in activity of the P2 transporter were previously reported in T.
equiperdum (Barrett et al. (1995). However, in contrast to suggestions by Barrett et
al (1995) this study showed that reduced uptake at the P2 in arsenical resistant T.
evansi was not due to reduced affinity for substrate. The drug resistant trypanosomes
actually showed increased affinity for substrate indicated by a 7-fold decrease in Km
at the P2 compared to drug sensitive parasites.
Reduced numbers of transporter molecules is responsible for reduced uptake at the
P2 transporter:
A detailed kinetic study of the PI and P2 transporters showed that reduced uptake at
the P2 was a result of reduced maximum capacity (Amax) of the transporter, reduced
initial transport iate, and reduced initial velocity of uptake. The results also showed
increases in speed of activity of both the P1 and P2 transporter molecules in drug
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resistant trypanosomes. From the kinetic parameters determined it was found that
reduced Amax was the major factor that possibly gave rise to other changes observed
at the P2. Amax was shown to be an index of the numbers or concentrations of
transporter molecules available. Hence reduction in Amax at the P2 represents a
reduction in the concentration of transporter molecules. This is likely to have
resulted in reduced initial transport rates and reduced initial velocity of uptake
observed. Consequently, these may have resulted in decreased uptake and finally
decreased intracellular accumulation of substrate in drug resistant trypanosomes.
if the P2 transporter is still present, but not capable of concentrating substrate as
rapidly as in the drug sensitive trypanosomes it means that it would require only a
longer time (and probably higher concentrations) for toxic substrates such as mel Cy
to be accumulated at concentrations high enough to cause cytotoxicity in drug
resistant trypanosomes. However beyond that time or concentration level the
resistant organisms would become susceptible to the effect of the drug. This may
explain the pattern of the in vitro lysis by mel Cy observed in the drug resistant
trypanosomes. These were partially lysed by relatively low concentrations (10-50
pM) but at the same time were resistant to the dose (1 pM) that caused rapid lysis of
drug sensitive parasites. It is logical to expect that the more the decrease in P2
activity the higher the dose required to cause lysis of the resistant trypanosomes,
which is what was observed in this study. It is considered that under in vivo
conditions, and in drugs which are rapidly excreted from the body such as mel Cy
(Raynaud et al, 1989b) decreased intracellular accumulation as a result of decreased
uptake could provide a double advantage to the drug resistant trypanosomes.
Cross resistance between mel Cy and Berenil is a result of common mechanism of
uptake:
This study showed that Berenil® interacted with the P2 transporter, in similar manner
to mel Cy, in drug sensitive T. evansi. This provides evidence that the cross
resistance observed between mel Cy and Berenil® is due to a common mechanism of
uptake. However, the fact that mel Cy and mel B have been shown in this study to
have different modes of uptake and that lysis by both drugs was blocked by Berenil®
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invites speculation on other possible mechanisms involved in transport of
melaminophenyl arsenicals and the diamidines. Obviously the proposition of the
existence of one transporter that mediates for all melaminophenyl arsenicals and the
diamidines, based on the findings of this study, is not tenable. Alternative modes of
(g)
entry for arsenicals such as mel B, and possibly Berenil may exist which have not
yet been identified.
Alterations in P2 transporter of drug resistant Trypanosoma evansi:
The marked change in the Km of the P2 transporter, besides other changes such as
Amax, Umax and initial transport rates, in drug resistant trypanosomes provides strong
evidence that the P2 transporter has mutated and possibly functions as a different
transporter. We termed this transporter P2R in this study. This was evident from the
changes in the interaction with Berenil® both in the presence of inosine and adenine
in these trypanosomes.
Kinetics of inhibition of adenosine uptake:
The kinetics of inhibition of adenosine uptake showed that inosine, adenine and
Berenil® inhibited uptake on either the PI or P2 transporters with very low Kj values.
There was no interaction with Berenil® on the PI. In the drug resistant line the Kj for
inosine on PI was similar to that of the drug sensitive line. However, a 7-fold
increase in K, for adenine was observed on the P2.
A new adenosine transporter, P3, is present in arsenical resistant Trypanosoma
evansi:
Based on changes in all the kinetic parameters of what should be the P2 it was
concluded that a new transporter (P3) was present in the arsenical resistant
trypanosomes. This P3 transporter may have been selected for during the induction of
resistance to mel Cy, or may be an adaptation by the resistant trypanosomes
following gross reductions in activity of the P2 transporter.
In conclusion this study has shown that the dynamics of interaction of substrate with
the adenosine transporters in trypanosomes is very complex and may not be fully
explained on the basis of competitive inhibitions and kinetic data alone. Molecular
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studies involving isolation and cloning of the P2 and P3 transporters may fully
elucidate the specific mutations responsible for arsenical resistance in these
trypanosomes. It is also of interest to study the interaction of the P3 transporter with
other alternative substrates, including toxic adenosine analogues. This may provide
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In Vivo And In Vitro Selection Of Drug
Resistant Trypanosoma evansi Isolates And
A Comparison OfTheir Drug Resistance
Profiles
E.A. Suswam,** C.A. Ross and A.G. Luckins.
Centre for Tropical Veterinary Medicine, University of
Edinburgh, Easter Bush, Roslin, Midlothian EH25 9RG.
Trypanosoma evansi bloodstream forms resistant to
the arsenical trypanocide Melarsamine
hydrochloride (Mel Cy, Cymelarsan) were derived
from a drug sensitive isolate after induction in
irradiated or cyclophosphamide-treated mice. The
isolate was also adapted to axenic growth in vitro
and drug resistant parasites were obtained by
cultivation in the continuous presence of increasing
concentrations ofMel Cy. Attempts were made to
induce resistance in immunocompetent (normal)
mice. Drug resistant trypanosomes were tested for
their sensitivity in vivo to Mel Cy and compared
with wild type parasites. Mice infected with wild
type parasites were cured with 1.0 mg/kg Mel Cy. In
contrast, all drug resistant parasite populations were
not cured by 40.0 mg/kg, which is the highest
tolerated dose in these animals. In vitro assays were
also carried out to determine the sensitivity of the
different trypanosome populations to Mel Cy and to
other trypanocides. Cloned trypanosomes, derived
after the induction of resistance to Mel Cy in
cyclophosphamide-treated mice, exhibited greater
tolerance to the drug than the uncloned parent
populations. Cross resistance to other trypanocides
was detected.
